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P R E F A C E 
It is generally agreed that although dramatic regressions may 
sometimes be achieved by hormonal therapy for disseminated breast 
cancer, only about one in three patients responds to such measures and 
no satisfactory system of selection is available, despite many attempts 
to devise one. The research to be described, which was carried out at 
the Westminster Hospital, London, between March, 1972 and July, 1973, 
constitutes a fresh approach to the problem. 
The method which has been developed includes a number of innovations 
and has been designed with the primary aim of clinical applicability 
in mind. Its basis is a twenty-four hour organ culture system for 
human breast cancer slices which maintains the tissue close to its 
original state in the patient and is not intended for proliferation. 
Among its other advantages are its rapidity, the use of a fully-
synthetic, chemically-defined medium and the avoidance of single-
cell suspension techniques. 
In addition to appropriate controls, the tumours have been 
cultured with 17-beta-oestradiol and testosterone, which have been 
known for many years to influence some breast cancers, and also 
with prolactin. The introductory section of this thesis reviews 
modern research linking prolactin to animal and human breast cancer. 
The existence of prolactin as a separate hormone in Man has only 
recently been established. 
Assessment of the results of the culture has been based on 
histology and on a very sensitive multi-phase histochemical estim-
ation of the total dehydrogenase activity of the pentose shunt pathway, 
which is an excellent marker of neoplastic activity. 
The technique has been standardised and is being routinely 
performed with a high degree of reliability and reproducibility. 
It requires no elaborate apparatus and could be established in 
any laboratory. One hundred and fifty breast cancer patients have 
now been studied and 53% of the tumours exhibited hormone dependence 
according to the criteria used. Analysis of the results showed a 
meaningful relationship to the menstrual status and to the treatment 
the patient had received prior to testing. 
Perhaps the most striking single feature of the project has 
been the demonstration that 50 of the 150 tumours were dependent 
on prolactin in vitro. Although a good deal of investigation has 
been carried out on the role of prolactin in rat mammary tumours, 
this is to the best of our knowledge the first large-scale study 
of the effects of prolactin on human breast cancer. 
Another important new concept has emerged from the project. A 
number of tumours were found to be testosterone-dependent in vitro 
and clinical observations on these patients tended to support this 
result. This concept may help explain several apparent paradoxes 
in the hormonal treatment of the disease. 
The clinical course of all the 150 patients was closely followed, 
although it is emphasised that this project was not a controlled 
clinical trial. However, where it has been possible to compare the 
results of the test with the response of the patient to hormonal 
therapy, there has been an extremely encouraging correlation of the 
order of 90%. It is gratifying that these early results have 
prompted the establishment of a formal trial at the Westminster 
Hospital to determine unequivocally whether the test does represent 
a significant improvement over the present unsatisfactory selection 
of patients for hormonal treatment. 
Apart from its specific applications in the present study, the 
technique offers a very useful laboratory tool for the study of 
breast cancer generally and for a number of other tumours and 
pharmacological agents as well. 
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I N T R O D U C T I O N A N D R E V I E W 
In this introductory section I propose to summarise the main 
evidence, in a historical context, that led to the belief that breast 
cancer was at least in a proportion of cases not entirely autonomous, 
and that its behaviour could to some extent be controlled by endogenous 
and exogenous hormonal manipulations. Charles Huggins, one of the 
great pioneers in the field of hormones and cancer, has stated that 
"Cancer is not necessarily autonomous and intrinsically self-perpetuating. 
Its growth can be sustained and propagated by hormonal function in the 
host which is not unusual in kind or exaggerated in rate but which is 
operating at normal or even subnormal levels." (1972). The validity 
of this remark is well-known to everyone concerned with breast cancer, 
while the accuracy of his final words in particular will often be 
manifested as we examine the subject in depth in the following pages. 
Despite now overwhelming evidence linking sex hormones and prolactin 
with the growth of breast cancer, attempts to demonstrate a simple 
quantitative relationship between circulating blood levels of these 
hormones and the natural history of the disease have consistently 
failed. 
It is also appropriate to state at the outset that there is a 
large measure of agreement that hormones themselves do not initiate 
the transformation of benign into malignant breast cells (Bulbrook, 1972). 
A mammary tumour virus may well be the initiating agent, with the 
hormones acting as modifiers of viral action, although in this role 
they may be so powerful that the effects of the initiating agent may 
be virtually abolished (Furth, 1965). Recent work has shown that 
some human milk contains particles identical to mouse mammary tumour 
virus (Moore et al., 1971) and Schlom et al. (1971) have shown that 
these particles are RNA virions and that they are found in the 
majority of human breast tumours. It still remains to be proved that 
these particles are in fact the initiators of the malignant change, 
which - once accomplished - is then powerfully influenced and modified 
by hormones. 
After a review of the classical evidence linking the steroid sex 
hormones with breast cancer, recent work on the physiology of prolactin 
and its role in breast cancer will follow, while this introductory 
section will conclude with an account of the main attempts to predict 
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response to hormonal treatment. 
HISTORICAL OBSERVATIONS LINKING HORMONES TO BREAST CANCER 
The observation by Sir George Beatson in 1896 that oophorectomy 
had a beneficial effect on two women with breast cancer is usually 
taken as the first documented evidence of the hormonally-controlled 
nature of the disease. Like many important discoveries, the significance 
of this one was overlooked for many years and the next development was 
only in 1932, when Lacassagne succeeded in initiating mammary cancers 
in specially bred male mice by injection of oestrones. Interestingly 
enough, the next piece of evidence again came from male breast cancers, 
namely the observation by Farrow and Adair in 1942 that bilateral 
orchidectomy may benefit certain cases of human male breast cancer. 
From this point onwards evidence of hormonal influences began 
accumulating more rapidly, and may be considered in three main groups. 
The first illustrated the beneficial effects of certain endocrine-
ablative procedures; the second demonstrated varying effects of 
administering certain exogenous hormones in humans with the disease; 
and the third developed mammary cancer models in animals, especially 
rats and mice. 
The earliest reports of bilateral oophorectomy and orchidectomy 
have already been mentioned. The next endocrine-ablation to be employed 
in advanced mammary cancer was bilateral adrenalectomy. In 1952 
Huggins and Bergenstal reported the use of the operation in a group of 
patients with advanced prostatic and mammary cancers and also a 
11 miscellaneous 11 group of tumours. There was some evidence of remission 
in the prostatic cancers, while of the seven breast cancer patients one 
died post-operatively, one was unaffected by the procedure, one appeared 
to be aggravated and four were objectively improved. No specific 
mechanism to explain the regression was postulated, but Huggins and 
Bergenstal felt that 11 it is most reasonable to assume that the 
regressions are due at least in part to elimination of critical amounts 
of sex hormones. 11 The success of the operation was later popularly 
ascribed to removal of residual oestrogen secretion {after ovarian 
ablation or the menopause) by the adrenal cortex, (Huggins and Dao, 
1953; Bulbrook and Greenwood, 1957) but we shall see in due course 
that it is by no means certain that adrenalectomy always acts by 
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affecting oestrogen secretion, and that there is indeed considerable 
doubt that the adrenal cortex is the major site of oestrogen secretion 
in the postmenopausal woman at all (Grodin et al., 1973). Also in 
1952 Luft, Olivecrona and Sjogren achieved remission of advanced 
breast cancer by hypophysectomy, the mechanism of action being ascribed 
to removal of pituitary gonadotrophins with a resultant drop in 
gonadal and adrenal steroid hormone production. These three operations, 
then, oophorectomy, adrenalectomy and hypophysectomy, became and have 
remained the principal forms of indirect surgical relief for disseminated 
breast cancer. Like hormonal therapy in general, as will be discussed 
in detail later, they produced remission rates of the order of only 
30 - 40%. 
At the same time as some successful remissions were being obtained 
by ablative procedures, successes were being achieved in other cases 
by additive hormonal treatment. In 1944 Haddow et al. described the use 
of phenolic oestrogens and in 1947 Adair reported success following ad-
ministration of the male sex hormone, testosterone, to women with ad-
vanced breast cancer. 
DEVELOPMENT OF EXPERIMENTAL ANIMAL MODELS 
Meanwhile, methods of initiating mammary cancers in animals were 
being discovered and in particular the rat was shown to develop the 
tumour readily after exposure both to certain aromatic hydrocarbons 
and to ionising irradiation. Maisin and Coolen (1936) succeeded in 
producing mammary as well as skin cancers by painting the skin of mice 
with 3-methylcholanthrene and Shay et al. (1949) produced mammary 
tumours in rats by the same method even more easily. Finally Huggins, 
Grand and Brillantes (1969) refined the animal model still in the most 
widespread use when they succeeded in evoking manmary cancers in all 
female Sprague-Dawley rats that were given one feed of 7,12-dimethyl-
benzanthracene (DMBA). Huggins, Morii and Grand (1961) further 
found that intravenous injection of the lipid emulsion of DMBA was even 
more effective. Mammary cancers induced in male rats in this way were 
not influenced by orchidectomy or hypophysectomy, but in female rats 
the tumours, (whether induced by radiation or by aromatic compounds), 
were susceptible to various hormonal influences. For example, 
pregnancy and progestogens accelerated their growth (Huggins, Moon 
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and Morii, 1962) while ablative procedures, notably hypophysectomy, 
caused most of them to disappear. At the time it was considered that 
the effect of hypophysectomy was mediated via the gonadotrophins of 
the anterior pituitary and the steroid hormones of the target organs, 
but we shall see later how the DMBA tumour and hypophysectomy relate 
to the concept of prolactin dependence. 
RELATIONSHIP OF TUMOUR TO MENSTRUAL STATUS 
By this stage it was clear that addition or removal of both male 
and female steroid hormones could under certain circumstances produce 
a remission in breast cancer. Though it quickly became apparent that 
it was impossible to apply hard-and-fast rules, clinical experience 
showed that patients could be considered broadly in two groups, 
separated by the menopause, with the proviso that there was a period 
of a few years immediately preceding and after the menopause, when 
the response of the tumour was even less predictable than usual. It 
appeared that in the premenopausal patient the tumour was likely to 
be stimulated by oestrogens, (Haddow et al., 1944; Nathanson, 1947) 
although there had never been any conclusive evidence, (and this 
remains true today), that high oestrogen levels might play a part in 
its induction, as it seems to do in rodents. The issue was further 
complicated by the influence of absorbed oestrogens and the fact that 
breast cancer tissue itself could aromatise testosterone to oestriol, 
(Adams and Wong, 1968). However, in general it seemed that ovarian 
ablation by surgery or irradiation was the likeliest hormonal 
manoeuvre to succeed in the premenopausal patient. There was also 
some measure of agreement that although prophylactic ovarian ablation 
as an adjunct to primary surgical treatment might possibly delay the 
appearance of metastases slightly, it did not materially alter the 
long-term life-expectancy or natural history of the disease. 
The situation was even more complicated in the postmenopausal 
woman. It appeared as if oestrogen secretion by the adrenal cortex 
began to rise, (Huggins and Dao, 1953; Bulbrook and Greenwood, 1957) 
hence the postulated mechanism for successful adrenalectomy. 
However, this is a paradox when one considers that oestrogen ad-
ministration can also induce a remission in a certain number of 
postmenopausal women, particularly the older ones, (as it does in a 
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small number of premenopausal women, for that matter). The prevail-
ing theories became less credible as it became evident that no con-
sistent relationship was observed between either the pre- or post-
operative excretion of oestrogens and the clinical response to 
oophorectomy, adrenalectomy or hypophysectomy. Forrest (1971) 
concluded that "the view that the remission of advanced breast cancer 
induced by endocrine surgery resulted from changes in total circulating 
oestrogens was no longer tenable. 11 
Atkins et al. (1960) and Hayward et al. (1970) showed that 
transfrontal hypophysectomy gave a significantly better remission rate 
than bilateral adrenalectomy plus odphorectomy, and although the 
rationale was thought to be based on a gonadotrophic and adrenocortico-
trophic effect (i.e. the steroid hormones), I think that in the light 
of recent data, including those from the experimental work to be 
described, it is reasonable to infer that the success of hypophysectomy 
has been due to specific removal of an additional pituitary factor as 
well as the gonadotrophin effect, and this factor is almost certainly 
prolactin. 
In addition to the already-mentioned shortcomings of the simple 
division of breast cancer patients into the pre- and postmenopausal 
groups, with the therapeutically-difficult group straddling the 
menopause, a few more complicating factors need to be mentioned. 
Androgen therapy has been found to be useful in a certain number of 
patients in both age-groups and - like all hormones - it may act 
either directly on the tumour cells, or via an oestrogen-blocking 
effect on the tumour cell, or via a feedback mechanism on any or 
all of the ovaries, adrenals and especially the pituitary. The 
observation of a remission in the same tumour to oestrogen and 
androgen used successively and the rebound response after cessation 
of androgen administration (Delarue et al., 1955) further cloud 
the picture. Progestogens are known to cause a worth-while remission 
in certain cases of breast cancer, often after oestrogen therapy 
has failed, but the physiology of the progestogens' effects on 
breast cancer remains relatively obscure even to date, (Hayward, 
1970) and again it may operate both directly and via pituitary or 
other feedbacks. 
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THE EFFECTS OF CORTICOSTEROIDS 
The response of some breast tumours to the corticosteroids 
completes this review of the role of the main steroid hormones 
in this disease. Apart from the well-known non-specific effects 
of the corticosteroids, including induction of euphoria, relief 
of hypercalcaemia, relief of cerebral oedema in the presence of 
cerebral metastases and the important local anti-inflammatory 
action, the corticosteroids probably work on a negative feedback 
system, lowering the secretion of ACTH and possibly gonadotrophins 
and thereby the production of both androgens and oestrogens from 
the ovaries and adrenal cortex. They may in fact have considerably 
wider feedback effects on the pituitary, resulting in suppression 
of prolactin secretion as well. Administration of corticosteroids 
has sometimes been referred to as a 11 medical adrenalectomy 11 but 
Ker (1970) has pointed out that it is clearly not as effective as 
a surgical adrenalectomy, and furthermore several non-responders 
to corticosteroids achieved an excellent remission after surgical 
adrenalectomy. The incidence of side-effects of the drugs also has 
to be taken into account. 
It will already be clear at this stage, before we examine attempts 
at prediction of response to hormonal therapy, that the need for 
such prediction is very great, and that furthermore an ideal method 
should indicate specifically which hormonal manipulation is 
likeliest to succeed. Despite all the important studies towards 
this end, and the increased understanding of the pathophysiology 
of the disease that they have given us, it is agreed that a 
satisfactory system has not yet been found. This sets the 
background for the experimental work which I will describe after 
discussing the advent of prolactin on the breast cancer scene. 
EVIDENCE FOR THE ROLE OF PROLACTIN IN BREAST CANCER 
The period 1937-1950 saw a great deal of interest in the 
stimulatory effects of hypophyseal isografts on the breasts of mice, 
leading in certain strains, (at the time only those strains 
carrying the Mouse Tumour Virus), to breast tumours. The investigators, 
chief among them Loeb, (Loeb et al. 1937; Loeb and Kurtz, 1939) 
assumed without further question that the effects were due to 
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stimulation of ovarian oestrogen production. In 1951 these 
experiments were re-performed on a large scale at the Netherlands 
Cancer Institute in Amsterdam to determine whether the same results 
occurred in Mouse Tumour Virus (MTV)-free animals and to analyse the 
hormonal situation more clearly. In their first publication on this 
work Muhlbock and Boot (1959) showed that the hypophyseal isografts 
did in fact produce a high tumour incidence in MTV-free mice and 
raised the possibility that prolactin was involved in the process, 
as the isografts produced prolactin continuously throughout the life-
span of the recipients. Boot has discussed these findings fully 
in a more recent review (1970). In 1957 Hadfield described a 
11 mammotropic agent, 11 which he thought was probably prolactin, in 
the urine of women with breast cancer, and showed that it disappeared 
when there was a favourable response to hypophysectomy. Also in 
1957 Pearson noticed that administering ovine prolactin to breast 
cancer patients after hypophysectomy could induce exacerbation of 
their disease. In 1959 Pearson and Ray went on to show that 
oestrogen administration after hypophysectomy produced no observable 
effect on breast cancer, even in patients with previously hormone-
sensitive tumours, (as judged by previous response to hormonal 
treatment), and they suggested that oestrogens required an intact 
pituitary gland to act. 
On the experimental front Furth and Clifton (1958) described 
a mammotrophic pituitary tumour in rats and also claimed that the 
secretion of prolactin by the anterior pituitary is normally 
stimulated by physiological levels of oestrogens in the blood. 
Ablation of circulating oestrogens, for example by oophorectomy, 
would therefore decrease secretion of prolactin. Although this 
concept is still accepted today, in 1963 Kim et al. showed, 
paradoxically, that administration of very high doses of oestrogens 
may also lower prolactin secretion in rats, and this was adduced 
as one of the possible factors in the response of certain breast 
tumours to high dose oestrogen therapy. However, the vagaries of 
prolactin secretion are still far from understood, (as w~ll be 
elaborated in the Discussion), and it is still not known, for 
example, whether high doses of oestrogen act mainly on the tumour 
cells directly, or by blocking prolactin uptake and utilisation by 
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the tumour cells, or via a feedback-effect on pituitary prolactin 
secretion. In 1962 McCalister and Welbourn strengthened the case 
for prolactin still further by showing that injection of ovine 
prolactin which caused an exacerbation in certain breast cancer 
patients, predicted a high likelihood of response to subsequent 
hypophysectomy. 
In 1969, in a classic paper, further evidence of prolactin's 
role came from Pearson and his colleagues, who showed that the 
Huggins 7,12-DMBA-induced breast tumour in Sprague-Dawley rats was 
definitely a prolactin-dependent tumour, and in 1970 Nagasawa and 
Yanai in Tokyo, using similar techniques of appropriate endocrine-
organ ablations followed by exogenous administration of the hormones, 
settled another long-debated point by showing that it was indeed 
prolactin and not growth hormone that maintained and stimulated 
these tumours. At the time these experiments were carried out, 
at the end of the 1960 1 s, there was still no conclusive laboratory 
proof that prolactin existed as a pure entity separate from growth 
hormone in humans, although the implications these studies might have 
for breast cancer in women were obvious. 
CONTROL OF PROLACTIN SECRETION AT PITUITARY AND HYPOTHALAMIC LEVEL 
From this point onwards a considerable awakening of interest 
in prolactin took place, particularly in regard to the investigation 
of agents that could increase or diminish its secretion. Cassell, 
Meites and Welsch, (1971), found that certain ergot alkaloids 
inhibited secretion of prolactin, both by pituitary suppression and 
also via hypothalamic control. It had been shown as far back as 1956 
by Polishuk and Kulesan that phenothiazine tranquillisers and also 
reserpine were able to stimulate breast growth and lactation in 
patients. It now appeared that of the group of "releasing factors" 
of the hypothalamus for the anterior pituitary, that for prolactin 
was inhibitory, and this has been called Prolactin Inhibiting 
Factor (PIF). Soon it transpired that a wide range of drugs which 
suppressed the pituitary, and particularly the phenothiazines, were 
thus able to switch off PIF production and secretion down the 
hypothalamo-pituitary axis, thereby allowing prolactin secretion to 
proceed at a higher level. 
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Hwang et al (1971) observed that levodopa markedly lowered 
prolactin secretion, while it raised GH and FSH levels. This is 
believed to operate via transformation of levodopa, a 
dihydroxyphenylalanine isomer, to dopamine in the brain, and this 
catecholamine is thought in turn to stimulate production of the 
various hypothalamic "releasing factors," which in the case of 
prolactin is - as mentioned above - an inhibitor. Stoll (1972) 
suggested that the hypothalamic centres might show a diminishing 
sensitivity with age, reflecting depletion of dopamine, (precisely 
as parkinsonism reflects a similar deficiency in the striato-
nigral system). Since the hypothalamic centres are partly regulated 
by circulating steroid hormone levels, (the"long feedback" mechanism), 
he postulated that in order for levodopa to effect a lowering of 
prolactin secretion in certain older post-menopausal patients with 
a sub-threshold circulating oestrogen level, priming might be 
needed by giving oestrogens as well as levodopa. He showed that none 
of seven patients over two years past the menopause regressed on 
either levodopa or oestrogen therapy alone, but three of them showed 
some objective regression of tumour bulk with the two drugs together. 
He suggested that in younger patients levodopa alone might trigger 
the hypothalamic response without added oestrogen. No prolactin 
levels were measured in any of these patients. Minton and Dickey 
(1972) later showed in two patients that clinical remission did 
correlate with some lowering of the prolactin levels by levodopa, 
whereas in a third patient there was no clinical remission and the 
prolactin levels did not drop. 
Although it appears at present highly unlikely that the 
progression of human breast cancer can be equated so simply and 
directly with the plasma prolactin levels, (as will be elaborated 
upon in the Discussion), and although the levels are usually within 
the normal range in these patients, clinicians are naturally wary 
of possible exacerbations being produced by administering pheno-
thiazine tranquillisers and similar PIF suppressors. As this new 
experimental work is becoming more widely known, more and more 
clinicians are avoiding these drugs in breast cancer patients, at 
least until the whole matter has been more thoroughly elucidated. 
In late 1972 and in 1973 results from our laboratory were 
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published (Salih, Flax, Brander and Hobbs, 1972; Flax, 1972; Flax, 
1973; Flax and Salih, 1973) showing unequivocally that prolactin 
enhanced the survival of breast culture slices in vitro clearly 
above the controls in 30% of the cases studied. These results will 
be discussed in detail later on, but at this stage it may be said 
that they provided the first clear evidence that prolactin was 
stimulatory to a number of human breast cancers in vitro. Secondly, 
they showed that such stimulation took place at physiological 
concentrations of prolactin in the culture system employed, which 
supported the idea that this hormone probably promotes human breast 
cancer within the normal range of plasma concentrations. 
PROOF OF THE EXISTENCE OF PROLACTIN AS A SEPARATE ENTITY IN MAN 
Since it is literally only within the past two years that 
satisfactory proof of prolactin's separateness from growth hormone 
in humans has become available, it is relevant to summarise some 
of the laboratory and physiological evidence of the story. Ovine 
prolactin was prepared in a pure form free from growth hormone in 
the late 1930 1 s, but it took until the 1970 1 s to purify human 
prolactin, due to its considerable chemical, physiological and 
biological similarity to human growth hormone. When the latter 
was first isolated in the 1950 1 s it was found to have a substantial 
amount of prolactin activity, which distinguished it from other 
previously purified mammalian growth hormones where prolactin was 
completely separate. Li and his colleagues (1969) were sufficiently 
convinced to conclude that human growth hormone and human prolactin 
were identical. However, Pasteels and his colleagues had noticed that 
cultures of human adult and foetal pituitary glands continued secreting 
prolactin or at least a prolactin-like substance into the culture medium 
over a long period, (measured by the classical bioassay of the pigeon 
crop sac effect), whereas growth hormone production declined. This 
suggested that two separate hormones might be involved (Pasteels et al., 
1972). Addition of a hypothalamic extract to the culture reversed the 
pattern of secretion, thus confirming what is now the current concept, 
namely that the hypothalamus produces an inhibitory factor for prolactin 
release and a releasing factor for growth hormone. Pasteels (1972a) 
has reviewed his findings in detail. 
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Other lines of evidence suggesting that the two hormones were 
different included the production of different human "growth hormone" 
preparations of differing ratios of growth hormone: prolactin 
activities (Wilhelmi, 1961); the presence of cells in the human 
anterior pituitary with staining properties similar to those of 
prolactin-producing cells in other species, (Pasteels, 1963); the 
failure to find elevated growth hormone levels in the plasma of 
nursing mothers or of galactorrhoea patients, or to find any measurable 
growth hormone at all in certain lactating dwarfs (Geschwind, 1972); 
and the finding by Peake et al. (1969) of human pituitary adenomata 
rich in specifically prolactin-like activity. 
The crucial requirement was now actually to differentiate the 
two hormones in the laboratory, and the key to the problem was that 
in its immunological properties human prolactin is related to ovine 
prolactin and not to human growth hormone (HGH), though it is 
chemically very similar to HGH (Forsyth and Edwards, 1972). Hwang, 
Guyda and Friesen (1971) and Friesen et al. (1972) studied the 
independent synthesis of prolactin and growth hormone by monkey and 
human pituitaries in short-term incubation, using the property, shown 
by Herbert and Hayashida (1970) that extracts of pituitaries of 
pregnant and lactating rhesus monkeys gave lines of partial identity 
with ovine prolactin when reacted on agar diffusion plates against 
an antiserum to ovine prolactin prepared in guinea-pigs. Ultimately 
they were able to produce primate prolactin of sufficient purity to 
use in a radio-immunoassay. In a more conventional technique Lewis 
et al. (1971a and b) found that prolactin was less readily extracted 
from fresh-frozen human pituitaries than growth hormone, possibly 
because of tighter binding within the cell, and were thus able to 
obtain a prolactin-rich fraction which could be further purified with 
a sephadex column. 
These studies led to the development of several other radio-
immunoassay systems, for example those of L'Hermite (1972) and 
Malarkey (1971), both using heterologous systems with anti-ovine 
prolactin antiserum. The classical pigeon crop assay method, as 
improved by Nicoll (1969) is still widely used and other bioassay 
methods are also available. As yet there are no definitive published 
comparisons between measurements made by the two types of assay. 
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Other problems include the fact that as yet highly-purified 
human prolactin is only available in very small amounts, though 
its existence is now established beyond doubt, and it is fair to 
state that at the present time all available assay methods are 
but steps towards the perfection of a homologous radio-immunoassay 
system for human prolactin. 
PHYSIOLOGY OF PROLACTIN 
The origin of prolactin in the human pituitary appears to be 
in certain cells of the acidophil group in the anterior lobe. 
Pasteels (1972b), the principal worker in this field, has clearly 
demonstrated that prolactin and growth hormone are secreted by 
different types of acidophil in both monkey and human pituitaries. 
He accomplished this using specific antisera against human 
growth hormone and against ovine prolactin and here again one sees 
another example of the use of the immunological cross-specificity 
between ovine and human prolactin. On light microscopy the prolactin cells 
stain orange-yellm1 with Orange G. On electron microscopy they are dis-
tinguished by large, varied and irregular secretory granules. These 
cells are rare in normal adult pituitaries but increase in number 
during pregnancy, becoming sufficiently abundant by term to have been 
recognised as "pregnancy cells" by Erdheim and Stumme as long ago as 
1909 (cited by Forsyth and Edwards, 1972). Goluboff and Ezrin (1969) 
estimated that in late pregnancy and lactation more than 50% of all 
acidophils are prolactin-secreting. 
Prolactin is phylogenetically the oldest of the polypeptide 
hormones secreted by the pituitary gland (Turkington, 1972). It 
has a molecular weight of 20-25,000, with 180-200 amino-acids 
and two or three disulphide bridges (Forsyth and Edwards, 1972). 
Its functions are numerous. Nicoll and Bern (1972) have described 
over 80 different actions in vertebrates, which may be considered 
in the following groups. Just how many of these are important in 
Man remains to be proved. 
(a) It plays a major role in mammary growth and lactation in 
humans and animals, though the precise nature of the 
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interaction in the breast between prolactin and other 
pituitary and steroid hormones needs to be elucidated. 
(b) It appears to play some part in maintaining the structure 
and function of the corpus luteum. How far this applies 
in humans is uncertain. 
(c) It has some role in the development of accessory 
reproductive organs in male rodents, and very recent 
work on prolactin and prostatic carcinoma in Man has 
raised the suspicion, (though so far no definite proof), 
that it may be involved in that disease too (Farnsworth, 
1972). Its role in the human male under normal physio-
logical conditions is however still unknown. 
(d) In certain animals, and probably also in Man, prolactin 
may reduce water, sodium and potassium excretion, thereby 
raising plasma osmolality, by acting directly on the 
proximal kidney tubule. 
(e) Just as growth-hormone does have a certain small amount 
of intrinsic prolactin-like activity, prolactin has been 
found to have slight GH-like activity in various animals 
and in Man. 
Like many other hormones, prolactin has a circadian rhythm of 
secretion, (Nokin et al., 1972) with a peak at l a.m. to 5 a.m. 
This time, being in the sleeping hours, would of course correlate 
with diminished hypothalamic activity, less PIF production and 
therefore greater prolactin secretion. 
When we come to the question of stating normal prolactin levels, 
there are still considerable problems in that several different assay 
methods are in use, with different standards, and even the units differ 
greatly. The Brussels group uses a milli-unit system, the Cardiff 
group a milli-ampoule system, while the Montreal and St. Bartholemew's 
groups, who have at present probably the most reliable radio-immuno-
assays for prolactin, use a nanogram/ml system. The latter will 
certainly become the substantive units. In normal adults, male and 
female, Friesen et al. (1972) have found a range of 0-28 ng/ml with 
a mean value of 10. As far as the ovarian cycle is concerned, there 
is an ovulatory peak in the rat, but apparently none in humans. 
During pregnancy there is a progressive rise, with a very high level 
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(mean of 200 ng/ml) at term, which falls rapidly in 2 - 3 weeks in 
non-nursing mothers. In lactating mothers the mean is about 100 ng/ml 
and doubles 30 minutes from the onset of suckling. The levels in 
24 hour neonates are 40 - 400 ng/ml (mean 192) but in infants from the 
age of 6 weeks and older children they do not differ significantly 
from adult levels. 
Not enough significant data is available yet to show whether 
prolactin secretion alters in post-menopausal women. Present indications 
are that it does not, although in rats it is known that ageing reduces 
hypothalamic activity, which would free the anterior pituitary from 
PIF and promote more prolactin secretion. If this were valid for 
women, it would correlate well with Stoll 1s "ageing hypothalamus" 
concept for breast cancer. In breast cancer patients there is so 
far no evidence that levels of prolactin are raised, even if the 
tumour is thought to be prolactin-dependent. 
The different physiological, pathological and pharmacological 
influences on prolactin secretion and blood levels will be discussed 
in greater detail in later chapters. 
Early research suggests the presence of receptor-like binding 
activity in normal mouse mammary gland cells, but the nature of 
these molecules has not yet been chemically identified (Turkington 
and Frantz, 1972). It is considered likely that some sort of 
prolactin receptor must be present in normal and possibly neoplastic 
human breast cells, but its nature is at the present time completely 
unknown. 
ATTEMPTS TO PREDICT RESPONSE TO HORMONAL TREATMENT 
It has been stated (Sellwood et al., 1968) that about 30% 
of breast cancer patients show significant regression of their 
tumours after endocrine environment changes. In spite of the multi-
plicity of trials and reports of each modality of endocrine 
treatment, there is a large measure of agreement on this figure. It 
is not surprising, therefore, considering the value of the remission 
if one is indeed attained, that there is a great need to select 
those patients who would be likely to benefit from hormonal treatment. 
There is an equal need to select and spare from fruitless treatment 
the two out of three patients who would not respond. This applies 
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particularly to the major endocrine organ ablations, attended as they 
are by a certain morbidity and mortality and the need to remain on 
permanent replacement medication. 
Clinical Guidelines 
Of the many attempts to select these patients, clinical guidelines 
have remained the most useful, though with a success rate no better 
than one in three. The menstrual status has been the main clinical 
feature considered, and although practice varies to some extent from 
one centre to another, most therapists have advised castration for 
premenopausal women with advanced or recurrent breast cancer, performed 
either by radiation or by surgery, (the main difference being that 
radiation takes 4 - 6 weeks for its effect to be complete). In the 
patient who is less than 5 years post-menopausal some authorities 
have also advised castration just as in the pre-menopausal group, while 
others have administered androgens as a form of anti-oestrogenic 
treatment, sometimes followed with castration if this has been successful. 
It is the patient over 5 years past the menopause who really enters the 
therapeutic maze. Adrenalectomy and hypophysectomy are the major 
ablative procedures in this group, while oestrogens have been the 
commonest exogenously administered hormone, especially in the older 
age-group. However, apart from the likelihood that a patient who 
has obtained a remission from a previous hormonal treatment, 
particularly castration, is more likely to benefit from a further 
endocrinal procedure, most clinicians would agree that there are quite 
simply no hard-and-fast rules at all. Preferences and indications for 
each form of treatment vary from clinician to clinician, as well as from 
centre to centre, and even the mode of performance of each treatment, 
(whether by surgery, irradiation, isotope implantation or drug 
administration), is hotly debated. 
Apart from menstrual status, the second clinical guideline, namely 
the response to previous hormonal treatment, has already been mentioned. 
Even this is controversial. Dao et al. (1967) claim to have shown 
unequivocally that non-response to previous castration or other hormonal 
therapy does not diminish the chances of a response to adrenalectomy. 
The next important guide to response is the disease-free interval, 
that is the period between removal of the primary tumour and the appearance 
of metastases. Atkins et al. (1968), in their review of 10 years of 
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experience, confirmed the findings of several previous workers that 
the longer the free period, the greater the likelihood of a response 
to endocrine ablation. A period of 2 years appeared to be fairly 
critical; the chance of responding to adrenalectomy or hypophysectomy 
if the free period was less than that became very small. 
Some attempt has also been made to select hormonal treatment on 
the basis of the predominant set of metastases, that is visceral, soft 
tissue or osseous. For example, corticosteroids are said to yield 
relatively good results with brain, lung and liver metastases, whereas 
adrenalectomy is commonly thought to be ineffective for metastases in 
these sites yet very useful for bony metastases. However, every 
clinician knows that this type of differentiation is fraught with 
exceptions to the rule and does not offer a rational selection from the 
therapeutic lottery for the individual patient. 
A very general working rule that is accepted by a majority of 
therapists is that it is reasonable to try first simple hormonal 
measures, that is administration of hormones, for the less urgently 
ill patients, whereas it is more logical to use surgical ablation first 
in patients who are in danger of rapidly losing condition or whose 
metastases are in dangerous sites. 
Urinary Steroid Excretion Patterns 
Clearly a prediction system was badly needed. With the advent of 
relatively better methods to determine urinary oestrogens than had 
been previously available, (Brown, 1955; Aitken and Preedy, 1956) 
several investigators tried to estimate these in the hope that a 
simple test to predict response to endocrine-ablative surgery would 
evolve. This hope failed to materialise because no consistent patterns 
of excretion were observed in these patients both before and after the 
various operations (Forrest, 1965). This finding also strengthened 
the conviction that the natural history of breast cancer was not simply 
determined by fluctuations in the total circulating oestrogens. 
During the past decade, the Discriminant Function of Bulbrook, 
based on urinary steroid excretion, attracted the most attention. 
Bulbrook, Greenwood and Hayward (1960) measured the 24 hour excretion 
of aetiocholanolone and 17-hydroxYcorticosteroids (17-0HCS). Applying 
the formula [so - 80(17-0HCS in mg/24 hours) + aetiocholanolone in 
micrograms/24 hours], they claimed that those patients who had a 
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positive value for the "discriminant function" were far likelier to 
respond to adrenalectomy or hypophysectomy than those with a negative 
value. In view of the difficult laboratory techniques for measuring 
aetiocholanolone, several other investigators showed that alternative 
measurements were available which correlated well with the discriminant 
function and which were easier to perform. The "Alternative 
Discriminating Function" or "Miller Ratio" as described by Miller et al. 
(1967) was the most popular such alternative. It measured excretion of 
total 17-hydroxycorticosteroids and ll-deoxy-17-oxosteroids and derived 
a ratio of 0.11, above which the results corresponded to a positive 
Bulbrook discriminant and below which to a negative one. Juret at al. 
(1968) developed a similar prognostic approach by finding that objective 
remission was commoner in patients who excreted the greatest amount of 
androsterone and aetiocholanolone. 
The cause of a negative discriminant is not known. All the 
approaches, in summary, suggest that an abnormally low androgen 
metabolite excretion in relation to 17-hydroxycorticosteroid excretion 
predicts a poor response to endocrine-ablative surgery. This may well 
be a genetically-transmitted enzymic or other metabolic defect and a 
very interesting prospective study was set up in Guernsey in 1961 by 
the Guy's group (Bulbrook et al., 1971 ), to test whether low androgen 
excretion might identify a group of women who would develop breast 
cancer in later life. However, interesting though these investigations 
are, the marked limitations of the discriminant function approach and 
the increasing realisation that there were multiple endocrine pathways 
involved in the disease, as opposed to a purely steroid hormone 
hypothesis, have unfortunately shown that this is not a satisfactory 
prediction system for the individual patient either. 
Firstly, all investigators found small groups of patients who 
responded exactly contrary to the predictions. Secondly, it was clear 
that in patients over 50 years of age the number of negative discriminants 
rose steadily, such that over the age of about 60 the discriminant 
function had little predictive value at all. In addition, not all 
workers found the same proportion of negative discriminants in early 
breast cancer cases as Bulbrook. Further complicating factors were 
the knowledge that thyroid abnormality,, general illness, stress (such 
as a surgical operation or the prospect of one), and the steroid 
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metabolism of the tumour itself were all able to affect the discriminant 
function. The investigations of Wade et al. (1969), Ahlquist et al. 
(1968) and Fotherby et al (1970) showed quite clearly that the accuracy 
of prediction was not as good as the encouraging early reports had 
indicated. 
Some workers have used a form of discriminant function combined 
with the disease-free interval in order to predict response, for example 
Wilson and Moore used a discriminant based on the response of adrenal 
steroid production to ACTH infusion coupled with the disease-free 
interval (1968). This appeared to improve the accuracy of prediction, 
but the disease-free interval seemed more significant than the bio-
chemical measurements, and the value of the trial was somewhat diminished 
in that a number of the patients received 5-fluoro-uracil as well as 
adrenalectomy. 
Oestrogen Uptake and Receptors 
The next group of experiments aiming at a prediction system are 
those concerning oestrogen uptake and oestrogen receptors. In this 
context it should be remembered from the earlier discussion that it is 
by no means certain that oestrogen is the only or even the main hormone 
involved in promoting breast cancer. Radio-active studies with labelled 
oestrogen in vivo showed as long ago as 1951 that certain breast cancers 
showed selectively higher uptake of oestradiol than others (Lewison et 
al., 1951; Fol ca et al., 1961 ). This led to in vitro investigations of 
oestrogen receptors in target cells, and Jensen - a pioneer in this 
field - after originally showing that there were cytoplasmic receptors 
for 17-beta-oestradiol in the cells of the immature rat uterus, (Jensen 
et al., 1966) went on to confirm, as have several other workers, that 
oestrogen-binding sites are present in some human breast cancer tissues 
(Jensen et al., 1971 ). He also showed that there was some correlation 
between the presence of these receptors and the endocrine-responsiveness 
of the tumour. The cytoplasmic receptor is thought to be an 8S protein, 
(composed of two 4S fractions), which takes the oestradiol into the cell 
and transports it to the nucleus. 
In 1973 Braunsberg, James et al. reported on an in vivo study of 
35 patients whose oestradiol-uptake in vivo was correlated with clinical 
response. They found that patients with a low uptake tended not to 
respond favourably to endocrine ablation or to androgen therapy, but that 
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the converse was not true and that high oestradiol uptake was found 
in several patients who did not respond to treatment. As with all 
the oestrogen-uptake studies to date, both in vivo and in vitro, they 
were left with the conclusion that a good deal of further study was 
needed before its possible usefulness could be assessed. 
Application of Culture Techniques to Mammary Cancer 
Cammeron and Chambers (1937) were the first to culture breast 
cancer cells successfully using the coverslip technique, but extensive 
application of organ culture techniques to the mammary gland began 
in the 1950 1 s (Fell, 1964). Once the technical problems of culture 
began to be overcome, an investigation of hormone effects in culture 
systems in vitro soon followed, again with the paramount aim of 
providing a prediction system for response to endocrine treatment. A 
number of different parameters were used to assess the response of the 
tissues, and these fell into four main groups: biochemical, histo-
chemical, histological and radio-active. Hollander et al. (1959) 
found that 17-beta-oestradiol stimulated isocitric dehydrogenase and 
alpha-ketoglutarate production in homogenates of some breast tumours 
and that a few of these patients had remissions after oophorectomy. 
Rienits (1959) reported effects of oestrone and testosterone on the 
respiration of tumour slices, using the Warburg method, but was not 
able to correlate any of the results with histology or the progress 
of the disease. Heuson and Legros (1963) reported that testosterone 
and 17-beta-oestradiol decreased 14c-leucine incorporation by tumour 
cells, no clinical correlation being given. 
In 1971 Burstein et al. described a cell culture technique in 
which they investigated the effects of cortisol, oestradiol, 
progesterone, testosterone and human chorionic gonadotrophin on 20 
tumours. Response was assessed by 3H-thymidine uptake. Ten of the 
20 showed some alteration of uptake with various hormones, with some 
of these being increased by oestradiol and testosterone and some 
decreased. In the 6 patients in whom there was an opportunity to 
correlate the clinical course, there was some evidence that it 
accorded with the in vitro findings. 
Ceriani and his colleagues (1972), assessing response on histology 
alone, showed that normal breast tissue could survive in a hormone-
free medium for a short time, that insulin allowed complete maintenance, 
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and that addition of oestradiol and ovine prolactin to the insulin-
containing medium showed some of tumour survival. 
In 1968 Mioduszewska and her colleagues from Poland reported the 
effects of ovine prolactin, human growth hormone, 17-beta-oestradiol, 
progesterone, testosterone and cortisol on cell culture and organ 
culture systems of human breast cancer. The effects in trypsinised 
cell cultures and in the fragments of tissue in organ culture did 
not tally precisely and the number of patients studied, (34 in all), 
was too small to permit any conclusions about clinical correlation, 
but the authors felt that lack of response to prolactin and stimulation 
of growth by cortisol were probably associated with a poor response to 
hormonal treatment, while the converse was associated with a good 
prognosis. The validity of any conclusions drawn from this culture 
system is open to question as the media for both cell and organ 
cultures contained 20% human serum. The same objection applies to 
any culture experiments in which the media contain human or animal sera 
of unknown hormonal composition. Esber et al. (1973) have investigated 
this problem and have found that such sera, in which they measured 
oestrone, insulin, oestradiol, progesterone and testosterone, vary by 
up to 23 times in the concentrations of these hormones and there are 
in addition marked variations of ratio to each other. It was in order 
to obviate precisely this problem that the work to be described was 
based on a chemically-defined medium. 
Using the coverslip technique, Barker and Richmond (1971) 
cultured breast tumours from 14 patients with stilboestrol, ovine 
prolactin and hydrocortisone. The response was assessed by glucose 
utilisation and lactic acid production. Unlike Mioduszewska they 
were unable to demonstrate any effect at all of prolactin and 
hydrocortisone, while in two cases stilboestrol appeared to decrease 
the activity of the tumour, a finding in agreement with Rienits (1959). 
The follow-up period was too short to evaluate any clinical correlation. 
In 1970 Chayen et al. reported organ culture experiments in 16 
breast cancers. It appeared as if they could be divided by a short-
term culture system into a group that survived well without oestradiol 
added to the medium and a group that needed oestradiol in the medium. 
No clinical correlation was available. Assessment of response was based 
on a histochemical reaction which estimated the total production by the 
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pentose shunt of the co-enzyme dihydronicotinamide adenine di-
nucleotide phosphate (NADPH). 
This work leads us to a description of the experimental method 
and results on which this dissertation is based. At this stage we 
may state, in general, that the emphasis in hormonal studies has 
shifted from urinary excretion patterns to the tumour itself, both 
in vivo and in vitro, but that no method hitherto developed has 
proved consistently reliable in the laboratory and acceptably accurate 
to apply clinically. Furthermore, we may state that the past two 
years have seen the whole subject become considerably more complex. 
There is now overwhelming evidence that - in addition to the 
steroid hormones - the anterior pituitary and the hypothalamo-
pituitary axis play an important role, especially in regard to 
prolactin. 
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D E S I G N A N D M E T H O D 0 F 
T H E E X P E R I M E N T 
FUNDAMENTAL PRINCIPLES 
It was decided to study human breast cancer tissue by an organ 
culture method both in the presence of various hormones and with 
appropriate controls. The following two fundamental principles were 
observed in the design of the experiment: 
(l) The condition of the tumour was to remain as near physiological 
as possible. For this reason fresh, thin slices of tumour were 
used without any homogenisation, trypsinisation, centrifugation, 
fragmentation or other mechanical or chemical treatment. Other 
workers have also asserted that organ culture systems are closer 
to the in vivo situation than monolayer cell culture (Tchao et 
al., 1968; Roller et al., 1966). For the same reason the 
experiment was designed as a maintenance rather than a 
proliferative system, thereby avoiding substantial alterations 
in the biology of the tumour with successive generations of cells. 
The incubation period was therefore kept as short as was consistent 
with obtaining meaningful results; after appropriate trials a 
period of 24 hours was found to be optimal. 
(2) A fully-defined chemical medium was used in order to obviate the 
host of unknown factors that must necessarily be involved in 
culture systems whose media include biological additives such 
as bovine or human serum. Esber et al. (1973) have confirmed 
the gross variability of hormone concentrations (up to 23 times) 
that exists in commerically-available animal sera. 
THE PATIENTS 
The data refer to biopsies of 150 patients taken between February, 
1972 and late May, 1973. These were all females with various stages of 
breast cancer, most of whom were under the care of surgeons and radio-
therapists at the Westminister Hospital, London, S.W.l., although a few 
patients were accepted from nearby hospitals provided that the biopsies 
could be properly collected and brought to our laboratory within an 
hour of removal. Six of these 150 patients had a second biopsy on which 
we were able to perform a repeat experiment during the period under 
review. Apart from being examined histologically in our own laboratory, 
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all these tumours had been histologically confirmed as part of the 
routine clinical management of the patients. 
HISTOLOGICAL TYPING 
All tumours in this series had been independently confirmed 
histologically by a pathologist, in addition to the routine histo-
logical assessment made in our laboratory as part of the project. 
However, several different pathologists in different hospitals had 
reported on these tumours originally. In addition, the appearances 
of a metastatic deposit more often than not fail to reproduce the 
particular histological variant of the primary lesion, so that no 
attempt was made in this project to relate any results to specific 
histological types of breast cancer. In 83 of the 150 biopsies 
the pathologist's report was specific enough to classify the tumour 
into sub-groups, and the distribution - according to the World 
Health Organisation "Histological Typing of Breast Tumours" (Scarff 
and Torloni, 1968) - was as follows: 
Type I (Intraduct and Intralobular Non-Infiltrating Carcinoma) 3% 
Type II (Infiltrating Carcinoma) 87% 
Type III (Special Histological Variants) 
Medull ary 3% 
Papillary, Intracystic and Intraductal 3% 
Mucous 3% 
Squamous 1 % 
THE BIOPSIES 
All biopsies of primary and metastatic tumours were taken under 
strictly aseptic conditions, either under general anaesthesia or under 
local analgesia with 1% plain lignocaine, depending on the clinical 
circumstances of the particular patient and her treatment. A block 
of tumour tissue 1 cm in each dimension was more than ample for the test 
and it was usually possible to manage with half that amount. The block 
was preferably taken from as representative an area of the tumour as 
possible. It was immediately transferred to Trowell 's T8 medium in a 
sterile container, which had been previously warmed to 37°C. The 
specimen was then taken to the laboratory. If a patient was to receive 
radiotherapy to a lesion, the biopsy was performed before irradiation 
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commenced. The only two significant problems in the technique of 
the entire experiment were related to the taking of the biopsy; one 
consisted of the taking of a biopsy with little or no tumour tissue 
in it and the other was due to contamination arising either from an 
initially infected lesion or from a lengthy delay before the specimen 
reached the laboratory. All such doubtful cases were discarded. The 
recognition of unsatisfactory biopsies and the numbers rejected will 
be mentioned in detail in the sections on Results and Discussion. 
SELECTION OF HORMONES TO BE TESTED 
I have indicated in the introductory chapter the close relationship 
between the steroid hormones and breast cancer, and clinical experience 
has shown how addition or removal of these may affect the disease 
adversely or favourably. There was also a great deal of evidence, much 
of it in animals, however, suggesting that prolactin was also involved 
in the growth of some breast cancers. Hardly any data had been reported 
on prolactin's role in human breast cancer. Such data as was available, 
for example that of Mioduszewska (1968), was not conclusive because of 
the small numbers involved and particularly because the culture media 
had contained as much as 20% of serum of unknown hormonal composition. 
Progestational hormones have been used with some success in the manage-
ment of some patients with advanced breast cancer, but even to date their 
precise mode of action is ill-understood. They may operate directly on 
the tumour cell but a feedback mechanism through the pituitary is more 
probable. Furthermore, some progestogen metabolites have androgenic and 
others oestrogenic effects at target cell level. It therefore seemed 
reasonable to concentrate attention on the main human oestrogen - 17-
beta-oestradiol, the main human androgen - testosterone, and prolactin. 
The first two are readily available but at the start of the project 
human prolactin was not easily obtainable in the United Kingdom in any 
satisfactory amount. 
STANDARDISATION OF HORMONE CONCENTRATIONS 
It is clearly impossible in an in vitro system to reproduce the 
in vivo conditions exactly, where a continuous and widely varying secretion 
of many hormones reach the tumour via the circulation. Furthermore, the 
extent of trapping and concentration of particular hormones by the tumour 
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is unknown, nor is it feasible to mimic this in vitro. Finally, in 
the culture system to be described the tumour slice does not lie 
permanently immersed in the hormone-containing medium, but relies on 
absorption up the lens paper covering the grid on which the slice 
rests. The concentrations used by other workers were of course avail-
able but it was decided, in view of the above reasons, not simply to 
follow those nor to attempt to imitate the physiological levels of 
these hormones in the blood. Instead, the concentrations to be used 
were determined by a series of trial experiments. 
Ovine Prolactin 
Ovine prolactin is known to behave very similarly to human 
prolactin and to be closely related to it (Forsyth and Edwards, 1972). 
This was the type of prolactin used in almost all the experimental 
work described in the introductory section. In 1953 the World Health 
Organisation Expert Committee on Biological Standardisation asked the 
National Institute for Medical Research, London, to prepare a Second 
International Standard for Prolactin, since stocks of the First 
International Standard were running low. This task was in due course 
completed using a freeze-dried powder prepared from sheep pituitary 
glands. At the time it was of course still not known whether human 
prolactin even existed as a separate entity. After an international 
collaborative assay the Second International Standard for Prolactin 
was eventually established, with a defined potency of 22 International 
Units per mg of powder. The International Unit Prolactin is defined 
as the activity contained in 0.04545mg of the Second International 
Standard. This material, which has been fully described by Bangham et 
al. (1963) was made available for this project by the courtesy of the 
Medical Research Council 1 s Division of Biological Standards, London. 
It was provided in ampoules containing 10 mg of powder with an activity 
of 22 I.U. per mg. 
Ovine and Human Prolactin Equivalence 
I have previously alluded to the unsatisfactory state of affairs 
that existed between different laboratories with regard to the reference 
units and assay of prolactin. At the present time this is gradually 
being rectified and standardised and a system of nanograms per ml is 
universally emerging pari passu with refinement of the radio-immuno-
assay and purification techniques. Dr. A. S. McNeilly, of the 
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Department of Chemical Pathology, St. Bartholomew 1 s Hospital, developed 
a radio-immunoassay system for prolactin at the time that this project 
was in progress and kindly investigated our ovine prolactin solutions. 
Using his radio-immunoassay and an ovine prolactin preparation of known 
strength for comparison, he found that in a sheep system our solution 
of 0.22 I.U. per ml was equivalent to 130 ng/ml and our solution of 
0.022 I.U. per ml to 13 ng/ml. Now it has been generally agreed that 
sheep prolactin has roughly half the activity of human prolactin in a 
human system, so it seemed likely that the solutions used in our human 
breast system were equivalent to 65 and 6.5 ng/ml of human prolactin 
respectively. In other words, they were of a similar order of magnitude 
to the physiological range of concentrations in the plasma (0-30 ng/ml ). 
This finding was substantiated later in the project when a small 
amount of highly-purified (90%) human prolactin was obtained by 
courtesy of Dr. Henry Friesen of Montreal. A series of experiments was 
commenced using the highly-purified human prolactin in parallel with the 
ovine prolactin in our breast cancer culture system. Ten experiments 
have been completed to date and these have provided two important 
confirmatory findings. Firstly, it has been gratifying to note that there 
were no anomalous results; all tumours that were dependent on ovine 
prolactin were also dependent on human prolactin and vice versa. Secondly, 
dose-response curves comparing the pure Friesen preparation with con-
centrations of 0.22, 0.11, 0.022 and 0.011 I.U. per ml of ovine prolactin 
have confirmed that the potency of the human prolactin is about twice that 
of ovine prolactin. Our solutions of 0.22 and 0.022 I.Li. per ml therefore 
do correspond to approximately 65 and 6.5 ng/ml of human prolactin 
respectively, as calculated previously. 
Prolactin Concentrations 
In selecting the concentrations of prolactin to be used, few 
precedents were available as this was the first large-scale invest-
igation of human breast cancer tissue and prolactin in vitro, to the 
best of our knowledge. In the small series of Mioduszewska et al. (1968) 
it was stated that a concentration of 100 micrograms per ml of ovine 
prolactin was used, but no specific details of the preparation were 
given, and besides the culture medium consisted of 20% human adult 
serum. 47 experiments were accordingly conducted with 4 concentrations 
of the ovine prolactin used in this study; 0.22, 0.11, 0.022 and 0.011 
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per ml. As demonstrated above, these corresponded roughly to human 
concentrations of 65, 32.5, 6.5 and 3.25 nanograms per ml respectively. 
In the 47 experiments only one tumour showed better survival and 
higher activity at 0.011 I.U. per ml than at the higher concentrations. 
It was found that 0.022 and 0.022 I.U. per ml bracketed all the other 
dependent tumours and these were accordingly the concentrations chosen 
for the study. These concentrations are all of a similar order of 
magnitude to the normal plasma prolactin levels, which Dr. Friesen 
had found to be from O up to about 30 ng/ml. Prolactin dependence 
in our system is thus being demonstrated at concentrations approximating 
to physiological levels. 
Oestradiol Concentrations 
Twenty five experiments were conducted using 3 concentrations 
of 17-beta-oestradiol, namely ,o-5, ,o-6 and ,o-7 Molar. Not a single 
one showed better survival and higher activity at l0- 7M than at either 
,o- 5 or l0- 6M. The last two were accordingly chosen as the two 
standard concentrations of oestradiol for this study. A higher 
concentration such as ,o-4M was found to be toxic to the cells 
and few or none survived. The two concentrations used are equivalent 
to 2.72 and 0.272 micrograms/ml respectively. In fact, on comparing 
these concentrations with those used by some other workers in breast 
culture systems, they are similar to those of Altmann and Chayen 
(1967) - l0- 5M and Heusen and Legros (1963) - 7 micrograms/ml. On 
the other hand, they are greater than those used by Mioduszewska et al. 
(1968) - 0.0015 micrograms/ml and Burstein et al. (1971) - 0.0015 
micrograms/ml. Blood levels of oestradiol are of the order of 0.02 to 
0.07 micrograms per 100 ml (Van de Wiele et al., 1970), with a rise 
around ovulation up to as high as 0.1 micrograms per 100 ml. These 
concentrations are of the order of 10- 7 to l0- 8M. 
Testosterone Concentrations 
Twenty five experiments were conducted using 4 concentrations 
of testosterone; ,o-5, ,o-6 , ,o- 7 and ,o-8 Molar. Of these, only 3 
showed better survival and higher activity at either ,o-7 or 10-BM 
than at 10- 5 or l0- 6M. The last two were again chosen as the most 
suitable concentrations for use in this study, although it is 
conceded that a small number of cases might exhibit dependence on 
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testosterone only at these very low levels of ,o-7 or l0-8M. Testosterone 
has a molecular weight of 288.4 and the two concentrations used are 
therefore equivalent to 2.884 and 0.2884 micrograms per ml respectively. 
Here again these are similar to or substantially lower than those used 
by other workers, for example Burstein et al. (1971) - 5 micrograms 
per ml; Mioduszewska et al. (1968) - 5 micrograms per ml and Heuson 
and Legros (1963) - 11 and 33 micrograms per ml. Blood levels of 
testosterone are in the range of 0.03 to 0.10 micrograms per 100 ml 
in normal women (Gandy and Peterson, 1968), with Pearson Murphy (1969) 
finding a similar range though with a slightly higher mean (0.18 micro-
grams per 100 ml) in premenopausal women than in postmenopausal ones 
(0.09 micrograms per 100 ml). Once again these concentrations are of 
the order of ,o- 7 to ,o-8M. 
Thus for the two steroid hormones experimental findings suggested 
that concentrations of ,o-5 and ,o-6M bracketed the vast majority of 
the dependent cases and these were chosen for the study. They also 
turned out to be of the same order of magnitude as the concentrations 
used by many other workers. With respect to the blood levels of these 
hormones, it is impossible to mimic in vivo conditions precisely and 
in any case only two single hormone levels (oestradiol and testosterone) 
are being considered; under physiological conditions the blood contains 
several other active oestrogens (notably oestrone and oestriol) and active 
androgens (notably dehydroepiandrosterone and androstenedione). The 
total androgenic or oestrogenic activity in the blood is therefore 
considerably higher. Furthermore, the absolute blood levels of these 
hormones are not in themselves of prime importance, (as has been 
emphasised repeatedly), in view of the known ability of breast cancers 
to concentrate hormones selectively up to several-fold. Lewison et al. 
(1951 ), Folca et al. (1961) and Braunsberg et al. (1973) have amply 
demonstrated the ability of a proportion of breast cancers to exhibit 
a high oestradiol uptake, and Deshpande et al. (1963 and 1966) and 
Braunsberg et al. (1967a and b) have shown that a smaller proportion 
of these tumours can do the same for testosterone. Results from this 
study, as will be seen later, confirm that a certain percentage of 
breast cancers show enhanced activity specifically in the presence of 
testosterone and not of the other two hormones tested. 
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SETTING UP THE CULTURES 
Slicing the Tumour 
As soon as the biopsy arrived from the theatre it was placed in 
the Trowell 1 s medium (Difeo) in a 60xl5 mm sterile disposable culture 
dish (Falcon Plastics). The whole setting up of the culture took 
place in a special sterile cabinet with positive pressure ventilation 
and an ultra-violet attachment to permit convenient sterilisation of 
the cabinet and its contents between experiments (Slee Laminar Flow 
Bench, HLF/H). Surrounding normal tissue and fat, if any, were then 
trimmed away and serial adjacent slices of the tumour were cut by 
hand, using a number 22 disposable scalpel (Gillette). The specimen 
was held by sterile dissecting forceps during the cutting, taking care 
not to traumatise it and avoiding taking a slice where the forceps 
might have crushed the tissue. The slices were as thin as could 
conveniently be cut by hand and about 2 - 3 mm in diameter. 
Culture Method and Medium 
It had been decided to use a maintenance culture system broadly 
similar to that described by Trowell (1959). His method enabled slices 
of normal organs and tissues to be kept alive in a chemically-defined, 
fully-synthetic medium for up to one week without either proliferation 
or de-differentiation. This proved to be a landmark in culture systems 
and has been used with minor modifications by a number of investigators. 
The details of his chemically defined medium, known as Trowell 1 s T8 
Medium, are given in the Appendix. It is entirely protein and hormone-
free apart from 5 mg/100 ml insulin, (equivalent to approximately 
l0-5M), the significance of which will be discussed later. 
Trowell 1 s method met the criteria which I outlined earlier in that 
(a) the tissues were permitted to remain very close to their physio-
logical state in the body, without any proliferation, (b) no homogenisation 
techniques were used and (c) the medium was chemically-defined. 
Differences from Trowell 1 s method included the fact that this study used 
malignant and not benign tissues and that they were maintained for only 
24 hours instead of a week. Trowell found his medium to be perfectly 
adequate for a range of benign tissues but Chayen et al. (1970), in the 
breast cancer study to which I have already referred, found that the 
addition of glutathione and ascorbic acid, to concentrations of l0-4M, 
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greatly improved the state of the stroma ir. short-term maintenance 
cultures. These were accordingly added to the T8 medium in this 
study. 
The medium was measured into sterile plastic universal containers 
(Sterilin) in 10 ml amounts and glutathione and ascorbic acid were 
added from stock solutions to give the required l0- 4M concentrations. 
No further additions were made to the Medium Control container. The 
others all received appropriate amounts of 17-beta-oestradiol, 
testosterone and prolactin from stock solutions to give the required 
final concentrations. The steroid hormone and prolactin solutions 
had been prepared from the respective dry powders by dissolving them 
in 99.8% ethyl alcohol. 
Sterility 
Complete sterility was essential for setting up and incubating 
the cultures. I have already mentioned the special flow cabinet, the 
working surface of which could be sterilised by ultra-violet light 
and which was fitted with a positive pressure fan system. All plastic 
materials used in the experiments, including the culture dishes, the 
various containers and the syringes for making up solutions, were 
disposable and never re-used. Metallic apparatus such as dissecting 
forceps and the stainless-steel grids, were thoroughly washed after 
use, allowed to soak in Decon 90 detergent, and were than re-washed 
in water and autoclaved immediately prior to use. Disposable sterile 
scalpels were used for cutting the tumour slices. 
Procedure 
After appropriate labelling of a series of plastic culture 
dishes in the flow cabinet, (Fig.l) they were then dealt with as 
follows: a 25 x 25 mm stainless steel wire grid, with legs 2 mm high, 
was placed in each dish. This was more robust and cheaper than the 
tantalum used by Trowell in his earlier work. A piece of lens paper 
(Green's Lens Tissue No. Cl05) sufficiently large to cover the grid 
and the base of the dish was then placed over it. 5 ml of the 
prepared media were than poured carefully into each dish at the side 
of the grid. The lens paper rapidly became completely moist but the 
top of the grid, covered by the lens paper, remained above the surface 
of the fluid in the dish. The set of culture dishes consisted of: 
(i) a Medium Control (MC) containing Trowell 1 s T8 medium plus 10-4 
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Figure 1: The set of culture dishes and prepared media in the flow 
cabinet. The tube for gassing the cultures is also seen. 
Figure 2: Examples of culture dishes with the tumour slices mounted 
on the lens paper on the grid. 
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glutathione and ascorbic acid, but without any added hormones; 
(ii) Medium as above in 6 further culture dishes containing 




.22 I.U./ml ovine prolactin 
.022 I.U./ml ovine prolactin. 
A slice of the tumour was then carefully dipped into the medium 
and placed on the lens paper covering the grid in each dish (Fig.2). 
Care was taken to handle the tissue gently with fine dissecting 
forceps and not to transfer droplets of different media into each 
other. 
The dishes were then covered with their lids and stacked in wire 
frames which were then placed in modified Kilner Jars (Fig.3). The 
jar lids had two vents leading out into soft plastic tubing controlled 
by a gate-clip for gassing. After closing the jars tightly they were 
gassed with a mixture of 95% oxygen and 5% carbon dioxide (British 
Oxygen). The gassing was controlled in such a way when closing the 
clips that all the air in the jars was replaced by the gas mixture 
but the pressure was not allowed to rise above atmospheric pressure. 
The jars were then placed in a Griffin Incubator at 37°C and the time 
noted. At the same time as the dishes were incubated, the final slice 
of tumour was placed in a small screw-cap plastic specimen ampoule 
(Sterilin) for liquid nitrogen storage. This ampoule was placed in an 
ampoule rack (Arnold's Veterinary Products) which was then stored 
(Fig.4) in a liquid nitrogen refrigerator (Union Carbide). This 
specimen, stored with no added medium, hormones or fluid of any sort 
was called the Initial Control (IC). At the beginning of the project 
trials were conducted to see whether there was any difference between 
cooling the tissue in liquid nitrogen immediately as described and 
cooling it down gradually as is usually done for single cell suspension 
storage. A G.V. Planer Cooling Unit (Type R200), cooling at 2°c a 
minute, was employed. No difference in the subsequent histochemical 
and histological assessments of the slices was noticed and accordingly 
they were routinely cooled immediately and not by the gradual method. 
Repeat gassings were carried out in exactly the same manner as 8 
33 
Figure 3: The culture dishes are stacked in frames in the modified 
Kilner jars. One jar is being gassed. 
Figure 4: Storage of tumour slices in ampoules in the liquid nitrogen 
refrigerator. 
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and 16 hours respectively and at 24 hours the incubation was ended. 
The tissues were then rapidly transferred from their dishes into 
labelled screw-top ampoules and these were immediately placed in 
racks in the liquid nitrogen refrigerator. 
As far as the length of the incubation period was concerned, 
preliminary studies were again carried out. Chayen et al. (1970) 
had used varying periods up to 24 hours for their tumours in their small 
pilot study but it was clearly necessary to arrive at a standard period 
in order to make comparisons. After assessing survivals in the various 
hormones at periods of 6, 12, 18, 24, 30 and 36 hours it was considered 
that optimal differentiation of survival in the controls and the 
various media was evident at 24 hours. The differentiation was no better 
at 36 hours than 24 and in view of the clinical advantage of getting 
a result earlier a standard 24 hour incubation period was adopted. 
ASSESSMENT OF SURVIVAL AND THE EFFECTS OF THE HORMONES 
A suitable method was required to evaluate how the tumour had 
survived in the controls and the different hormones and whether in 
fact it had been enhanced by any of them. 
Importance of Histology 
Histological examination was clearly essential. Fell (1964) 
and Forsyth (1971) have both emphasised the importance of including 
histology side by side with biochemical studies, both as an aid to 
determine the response to substances administered, (in this case 
the hormones), but also to confirm that conclusions are based on 
satisfactory cultures and sections. One would hardly expect histological 
evidence of enhancement or proliferation in such a short-term maint-
enance system, but in fact it was easy to see when a tumour had 
deteriorated in a particular hormone or hormones or in the medium control. 
Vesiculation and vacuolation of the cytoplasm, pyknotic and deformed 
nuclei and areas of necrosis were readily apparent when present. Other 
slices had survived very well and appeared histologically just as intact 
as the fresh-frozen initial control (IC) which would approximate almost 
exactly to the state of the tumour as it was in the patient just prior 
to taking the biopsy. Chayen et al. came to similar conclusions 
with their histological assessments. In the present study there was in fact 
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excellent correlation between the histological and histochemical 
assessments, (the former being checked by an independent histo-
pathologist). (Salih, Flax, Brander and Hobbs, 1972). However, 
histology was not nearly as sensitive as histochemistry in detecting 
minor differences in survival, nor so easy to read. Nevertheless, 
histology continued to be performed on all experiments both as a 
rough check against the 'histochemical results, and also for a more 
important reason; it was essential to confirm that each section did 
in fact contain tumour. Occasional biopsies, especially small ones 
from skin and subcutaneous metastases, were often far from homogeneous 
and consisted largely of collagen with very few malignant cells scattered 
through the specimen. If the histological check did not confirm that 
there was representative tumour tissue in any of the sections, and 
most particularly in the controls, then comparisons of activity and 
survival had to be considered invalid and that experiment discarded. 
Selection of a Histochemical Technique 
For the histochemical assessment a method based on measurement 
of the total dehydrogenase activity of the pentose shunt pathway 
was chosen. In 1953 Glock and McLean emphasised the importance of 
the recently discovered pentose shunt pathway in animal tissues. 
This - together with the classical Embden-Meyerhof glycolytic 
pathway - was one of the two prinicipal routes of carbohydrate 
metabolism (Fig. 5). As it was important in many situations to measure 
the relative importance and activity of these two pathways, they 
developed a method for assaying the two dehydrogenases of the pentose 
shunt, namely glucose-6-phosphate dehydrogenase (G-6-PD) and 
6-phosphogluconate dehydrogenase (6-PGD). These enzymes catalyse 
reactions, as shown in the diagram, which produce large amounts of 
NADPH, which in turn provides energy for a variety of important cell-
ular activities. One of the most elegant features of Glock 1 s and 
McLean's method was that by using glucose-6-phosphate alone as a 
substrate, and working at a pH of 7.6, one was able demonstrate 
and measure the summation of both the G-6-P and the 6-PG dehydrogenases. 
Other workers explored the role of the pentose shunt pathway in 
benign and malignant tissues. In 1956 Kit showed that the total 
dehydrogenase activity of the pentose shunt was 2 to 5 times greater 
in certain animal tumours than in a range of benign tissues tested, 
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I steroids) folate GLUCOSE-6-PHOSPHATE / Biosynthesis (fats, 
'1,t dehydrogenase~ reductase 
6-PHOSPHOGLUCONATE NADPH~ Mitochondrial I ~ ~ transhydrogenation 
~ dehydrogenase ~ ~ 
RIBULOSE-5-PHOSPHATE Diaphorase system 
l 
NUCLEIC-ACID SYNTHESIS Glutathione/ascorbic 
acid system 
Figure 5: Simplified diagram of the pentose shunt pathway showing 
the routes which the NADPH, produced during the two 
dehydrogenations, can take. 
(From: Altmann, F. P. and Chayen, J., 1967) 
37 
although activity was still relatively high in actively proliferating 
benign cells such as those of the reticulo-endothelial system. In 
1962 Chayen et al. confirmed that 6-PGD was markedly elevated in 
rapidly proliferating cells, benign or malignant; it was very high 
indeed in tumours from several sites in humans and animals and 
strikingly higher than normal tissues from those sites. Considering 
normal tissues independently, the level was related to the degree of 
proliferative activity, for example it was fairly high in regenerating 
liver. 
Following on these studies, a new test for gynaecological cancers 
was devised, (Bonham and Gibbs, 1962) measuring the 6-PGD in vaginal 
fluid. The authors claimed that this was easier to perform and more 
accurate than exfoliative cytology. Cameron and Husain (1965) con-
firmed the validity of the test in invasive genital cancer, but 
found that it had a serious limitation as a screening test in that 
many of the patients with carcinoma-in-situ did not exhibit a raised 
enzyme level. 
Altmann and Chayen (1967), recognising the possibility of 
studying malignant tumours by these techniques of multi-phase 
biochemistry, as they were known, investigated the influence of 
17-beta-oestradiol and also drostanolone (an androgen) in maintenance 
cultures of breast tumours and in 1970 published the short communication 
to which I have already referred. They suggested that certain tumours 
required oestradiol for complete or even enhanced survival while others 
did not. Altmann and Chayen emphasised the advantages of this type 
of approach over the conventional biochemical analyses, which involve 
the homogenisation and differential centrifugation of tissues. The 
hormones appeared to act by increasing the pentose shunt activity and 
their effects could then be measured directly or indirectly by 
appropriate techniques using one of the reactions illustrated in Figure 
5 as a parameter. They themselves measured total NADPH using the 
diaphorase pathway which is actually a "wasteful" or unprofitable 
oxidative pathway for the cell in that it is not linked to any known 
mechanism of oxidative phosphorylation. Early work in the present 
project (Salih, Flax and Hobbs, 1972), confirmed that certain breast 
cancers required oestradiol for survival and even enhancement while 
others did not. In a small series of 14 cases it also appeared as if 
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this provided useful prognostic information for hormonal therapy. 
In our studies, as already mentioned, we decided - after testing both 
approaches - to use a direct technique, namely measuring the total 
dehydrogenase activity, rather than an indirect one such as the 
diaphorase pathway. 
After our preliminary investigations of these multi-phase 
biochemical techniques, we then introduced a significant addition 
in that we began to study prolactin in this system as well as 
17-beta-oestradiol and testosterone. As it turned out, in a substantial 
and highly significant proportion of the tumours prolactin was in fact 
demonstrated to enhance the dehydrogenase activity and the activity of 
the cells profoundly, and the technique proved to be a very convenient 
model to study the effects of the 3 hormones tested, (oestradiol, 
testosterone and prolactin). It was equally useful to study a number 
of other tumours and hormones. 
Cutting the Sections 
In order to ensure that no thawing, metabolic activity and 
consequent loss of enzymes occurred during mounting the blocks, a 
meticulous technique was observed. The block holder (No. 4035/S Slee), 
was placed in a small plastic well containing liquid nitrogen, surrounded 
by polystyrene insulation, and enough water was pipetted on to the top 
of the block holder to cover it. Only as the water began visibly 
freezing was the slice of tissue removed from its ampoule and rapidly 
mounted (Fig.6). Freezing was complete within 5 - 10 seconds after 
mounting the tissue and the block holder was then placed in the cryostat 
chamber. 
Once all the slices, including the initial control (IC), were 
mounted and in the cryostat chamber, eight micron sections were cut 
in quadruplicate from each slice. The cryostat used was the Slee 
Retracting Microtome, Type HR, operating between -25°and-35°c. As 
each section was mounted on its appropriately-labelled slide, it was 
placed in a steel slide rack in the cryostat chamber, where it remained 
until the histochemical or histological reactions were performed. 
On cutting each slice of tissue, care was taken that a sufficient 
depth in the tissue was reached and rapid preliminary methylene blue 
stains were performed to ensure that representative tumour tissue was 
indeed being cut before the definitive sections were taken. 
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Figure 6: After removal from liquid nitrogen, each slice is rapidly 
mounted on a block holder for cutting cryostat sections. 
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Of the four sections taken of each slice, two were set aside for 
histology and two for histochemistry. 
Histology 
On the one set of slides conventional haematoxylin and eosin 
staining was then carried out. I have already indicated that the 
prime aim of histology was to ensure the presence of satisfactory 
tumour tissue in each section, while it was also useful as a rough 
parallel with histochemical assessment of activity. Routine 
mounting under a coverslip with Canada Balsam was then followed 
by microscopic examination. 
Histochemistry 
A volume of 7 ml of the reagent mixture was found to be adequate 
for the number of sections to be treated. Accordingly, the following 
weights of reagents were prepared in flat-based plastic ampoules using 
an Instanton Electric Balance (Unimatic CL4D). (The concentrations 
are given in parentheses). Sources of the chemicals used are given 
in the Appendix. 
0.021 grams Neotetrazolium Chloride (3 mg/ml): This served as 
the final electron acceptor, being reduced to highly-coloured insoluble 
formazan, which is the material seen under the microscope. 
0.0105 grams Glucose-6-Phosphate (1 .5 mg/ml): This is the substrate 
for the reaction and as mentioned previously, at pH 7.6 the use of this 
substrate alone permits measurement of the total dehydrogenase activity 
of both G-6-PD and 6-PGD. 
0.007 grams Phenazine Methosulphate (0.1 mg/ml): This is the first 
electron acceptor from the reaction of the dehydrogenases on G-6-P; it 
then transfers the electrons to the neotetrazolium chloride. 
0.014 grams NADPH (2 mg/ml): This serves as the co-enzyme for 
both stages of the electron transfer. 
1.4 grams Polyvinyl Alcohol ("polyviol II or PVA) (25% w/v): Over 
the period of one hour's incubation it is obviously undesirable for 
the enzymes to diffuse widely from the cells. Altmann and Chayen (1965) 
showed that one of the problems of enzyme histochemistry is that if the 
tissue is not fixed, in order to avoid denaturation, then enzymes may 
dissolve out of the section into the incubation medium. On the other 
hand, if it is fixed to stop such a loss of soluble enzymes then activity 
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is inhibited and denaturation occurs. This applies strongly to 
dehydrogenase enzymes. They then showed that by using PVA, 
cytochemically a very inert substance, at a 20% w/v concentration, 
it was very effective in preventing loss of any nitrogenous matter 
out of tissue sections, and in particular it permitted soluble 
enzymes to be retained during enzyme histochemical reactions, 
without the use of any chemical fixative which would inactivate or 
denature the enzymes. In this study 25% w/v was found to be even 
more effective. 
O.lM glycylglycine buffer was used to keep the mixture at a 
pH of 7.6, and for the number of sections studied it was convenient 
to use a volume of 7 ml. 
Procedure 
Five of the 7 ml of glycylglycine buffer, kept at 37°C in the 
incubator, were used to dissolve the polyviol, stirring with a glass 
rod. The G-6-P, NADP and neotetrazolium chloride were then poured 
into the dissolved polyviol. At this stage the sections were removed 
from the cryostat chamber and left at room temperature. The remaining 
2 ml of buffer were added to the reagent mixture and the phenazine 
methosulphate, after being dissolved in .7 ml of distilled water, was 
also added to the buffered mixture. After thorough stirring the mixture 
was then ready for adding to the sections. 
The slides were first placed in the incubator and a circular 
plastic ring half an inch in diameter was placed over each section. 
The mixture was then poured from the small 25 ml beaker in which it 
had been prepared into each small ring, about 3 - 4 drops being found 
to be sufficient to cover each section completely (Fig.7). The mixture 
was of a syrupy consistency, due to the polyviol, and this enabled it 
to remain confined to the area enclosed by the ring and not to leak 
away under it, thereby obviating the need for any form of sealing. 
Incubation at 37°C was then carried out for exactly one hour, after 
which time the slides were washed in distilled water for 10 minutes in 
a dark cupboard. Coverslips were then mounted over the sections using 
Farrant 1s medium. Time course studies at 15, 30, 45 and 60 minutes 
had been carried out initially. These had shown that incubation for 
one hour gave optimal results. 
All the above chemicals were kept in the ordinary refrigerator 
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Figure 7: Pouring the histochemical reagent mixture into the ring 
chamber over the sections. 
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when not in use, apart from the glycylglycine buffer which remained 
in the incubator and which was regularly checked to ensure that its 
pH remained at 7.6 (pH Meter PHM 28, Radiometer, Copenhagen). One 
particular precaution to be observed was that the phenazine metho-
sulphate, a chemical that is very sensitive to light, had to be kept 
in a dark place during storage and had to be exposed to light for as 
short a period as possible during weighing. Similarly, it had to be 
dissolved quickly on addition to the reagent mixture, which was then 
poured on to the sections in the incubator without delay. 
Evaluation of the histology and histochemistry and of the overall 
results will be described in detail in the next chapter. 
PATIENT FOLLOW-UP 
I have indicated previously that this study was initially 
concerned with the development of a technique and not a clinical 
trial, but it was of course highly desirable to watch the clinical 
progress of each patient whose tumour had been tested. No attempt 
was made to conform to any method of patient selection or treatment 
protocol, although the results of the hormone-dependence studies were 
available to the clinician as an extra aid to selection of therapy if 
he so wished. 
Documentation 
As soon as a specimen was received by the laboratory a trained 
nursing sister employed by the Tumour Biology Group interviewed the 
patient and studied the clinical notes. A standard proforma was 
completed for each patient, embodying all the relevant personal data 
as well as the specific details of the breast lump. On an attached 
sheet the whole of the clinical history was summarised, including 
all the management to date and all histological reports. These 
clinical notes were then brought up to date by the nursing sister or 
myself each time the patient attended a clinic. 
In the case of patients who had not yet suffered recurrence of 
early breast cancer and who were under routine follow-up surveillance 
by the various consultant surgeons, arrangements were made for me to 
see the notes after each visit. 
However, all those with advanced or recurrent breast carcinoma 
were seen by me personally, with the exception of a few private patients 
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and patients who had gone abroad subsequent to treatment. A special 
Breast Clinic was held every Wednesday afternoon where each patient 
was seen jointly by Dr K. Newton, Consultant Radiotherapist, Mr K. 
Robinson, Consultant Surgeon, and myself. 
Response to Treatment 
In the Results section data concerning the menstrual status, 
biopsy site and stage of the disease will be presented in relation 
to the hormone dependence studies. At the time of writing most of 
the Stage I and II patients tested have not yet required anything 
further than their primary treatment. Many of the others have either 
received non-hormonal treatment, or else hormonal plus other treatment. 
However, in a number of cases it has been possible to assess the 
correlation of the in vitro testing with the response to hormonal 
treatment. Illustrative examples of these will be given in the 
Discussion and an attempt will be made to evaluate the accuracy of 
prediction. 
In assessing the response to hormonal treatment, I have insisted 
on objective improvement of all visible, palpable and radiological 
lesions before accepting it as a regression. Symptomatic relief alone 
has not been counted as regression, nor has mere arrest in the 
development of-the lesions . Furthermore, the objective improvement 
has had to be maintained for at least three months. For the purposes 
of this study I have not included any intermediate partial regression 
group; situations such as the regression of some lesions and not of 
others will be specifically mentioned where relevant. 
At the time of writing this thesis, it is gratifying to note that 
these early clinical correlations have proved sufficiently encouraging 
to warrant the institution of a formal prospective trial at the 
Westminster Hospital to test whether this prediction technique does 
indeed offer the patient a better chance of successful treatment 
than the 30% she is confronted with at present. 
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R E S U L T S 
SURVIVAL SCORING ON A HISTOLOGICAL BASIS 
After examination of each section by ordinary light microscopy 
under low and high-power objectives, it was given a score based on 
the absence or extent - if any - of degenerative and destructive 
changes in the tissue and cells, such as cytoplasmic vacuolation, 
pyknosis of the nuclei and frank necrosis. Perfect survival was 
assigned a maximum score written as++++, while lesser degrees of 
survival received fewer plus symbols down to complete death of the 
tissue, which was assigned a minus symbol. A half was designated 
by a plus symbol in brackets. 
SURVIVAL SCORING ON A HISTOCHEMICAL BASIS 
The visible end-product of the histochemical reaction was a 
highly-coloured red-black dot of formazan, as seen by ordinary low 
and high-power light microscopy. The more active the tumour, (and 
therefore the total dehydrogenase activity of the pentose shunt), 
the denser the aggregations of formazan dots. It is possible to 
assess this density semi-quantitatively and at the start of the 
project a few experiments were thus assessed using the Quantimet 70 
machine, which computed and compared the densities of the dots in a 
series of fields, but in nearly all cases direct visual assessment 
proved to be simple. If the method or some modification of it does 
eventually become widely-used, however, the availability of a means 
of automatic assessment might prove an attractive advantage. 
Density of formazan was also scored with a system of+,(+) 
and - symbols,++++ being the maximum. Total absence of any histo-
chemical activity was assigned a minus symbol. 
"DEPENDENCE" AND "INDEPENDENCE" 
Generally speaking, the fresh-frozen initial control(IC) was 
relatively very active, the medium control (MC) was usually (but not 
always) much less active, often showing frank death of the tumour 
and zero activity histochemically, while the slices in the different 
hormones showed varying degrees of activity. There was good correlation 
between histological and histochemical evidence of survival and 
degeneration (Salih, Flax, Brander and Hobbs, 1972), but when it 
came to detecting subtle differences or activity that was enhanced 
over that of the controls, histochemistry proved the main yardstick. 
In over half the 150 cases, the activity of the tumour in one and 
sometimes two of the hormones was clearly greater than that of both 
controls, (IC and MC), and these cases were defined as 11 Dependent. 11 
Examples are given in Figures 8, 9 and 10. The remaining cases, 
which had not shown enhanced activity compared with both controls, 
were defined as 11 Independent 11 (Figure 11), though they had often 
(although not always) fared better than the medium control, suggesting 
that these tumours were certainly not always unresponsive to the 
effects of these hormones in vitro. 
Spectrum of Activity in the Independent Group 
In this Independent group, then, there was a whole spectrum of 
activity; a particular tumour might have shown moderate activity in 
the IC yet poor survival in the MC and equally poor survival in all 
the hormones tested, suggesting that at least in vitro this tumour 
did not appear to be influenced by hormones. Another tumour might 
have been much more active than the MC in one or two of the hormones, 
(e.g. prolactin and testosterone), but if it was no more active than 
the IC it was deemed independent by our criteria. The same tumour might 
have fared so badly in oestradiol as to show signs of complete death of 
the tissue. It is thus important to bear in mind throughout the 
Results and Discussion that 11 independence 11 of a tumour does not 
necessarily imply that it is totally influenced by any of the three 
hormones tested. On the contrary, where a particular hormone causes 
striking tumour inhibition in vitro, its administration to the patient 
often met with a favourable response. 
Hormonal Profile Concept 
In view of the spectrum of response, the test could be regarded 
as giving a hormonal profile of the tumour rather than a rigid classi-
fication into 11 Dependent" or "Independent, 11 which are not entirely 
satisfactory words for use in this disease, despite having been 
hallowed by long usage. They were only used in this study because it 
was realised that the results of the test might be taken into consider-
ation when endocrine-ablative surgery, (a much more radical step than 
47 
(a) (b) (c) (d) 
Figure 8: Composite histological and histochemical photomicrographs* 
showing a tumour that was dependent on 17-beta-oestradiol 
at l0-5M. 
(a) Initial Control (b) Medium Control (c) ,o-5M 17-beta-
oestradiol (d) ,o-6M 17-beta-oestradiol 
*All photomicrographs were taken at a magnification of 375x. In the 
composite pictures the upper line illustrates the histochemical results 
and the lower one the histology. 
(a) (b) (c) (d) 
Figure 9: Histology and histochemistry clearly demonstrate that this 
tumour is prolactin-dependent at both concentrations. 
(a) Initial Control (b) Medium Control (c) 0.022 I.U. 
per ml ovine prolactin (d) 0.022 I.U. per ml ovine prolactin 
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Figure 10: A black and white enlargement of a prolactin-dependent example 
to show detail of the formazan deposition, which is always 
related to the tumour cells only. 
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(a) ( b) ( C) ( d) 
Figure 11: This is an example of an independent tumour. For the sake of 
compactness only the survivals in the two concentrations of 
oestradiol are illustrated . The tumour survived equally badly 
in the other two hormones and the appearances were identical. 
(a) Initial Control (b) Medium Control (c) ,o-5M 
17-beta-oestradiol (d) ,o-6M 17-beta-oestradiol 
50 
simple hormone administration), was being contemplated. It was thus 
desirable to have a strict, clear-cut definition so that one could be 
sure, (or at least as sure as possible within the limitations of an in 
vitro experiment), that the 11 dependent 11 cases stood a high chance of 
responding to such surgery. 11 Dependence 11 was accordingly defined as 
enhanced activity compared with both controls; the tumour not only 
had to be more active after culture in a particular hormone than after 
culture in medium alone, but it also had to be unequivocally more 
active than its state when freshly-removed from the patient. 
It is therefore readily conceded that after long-term prospective 
evaluation of the test and its clinical correlation, it may be appropriate 
to draw a different dividing line or even to assess the results in a 
completely different way, for example, a hormonal profile instead of 
hormonal dependence. The fact that other as yet untested hormones, 
such as progestogens and growth hormone, may also have to be taken into 
account, could complicate the interpretation of results still further. 
For the present study however, it was deemed best to retain the clear-
cut criterion of in vitro dependence described. 
OVERALL IN VITRO HORMONE DEPENDENCE OF 150 FEMALE BREAST CANCERS 
Dependent on Prolactin only 24 (16%) 
Dependent on Oestradiol only 15 (10%) 
Dependent on Testosterone only 14 ( 9%) 
Dependent on both Prolactin and Oestradiol 16 (11%) 
Dependent on both Prolactin and Testosterone 10 ( 7%) 
Total Prolactin Dependent Tumours 50 (33%) 
Total Oestradiol Dependent Tumours 31 (21%) 
Total Testosterone Dependent Tumours 24 (16%) 
Total Dependent Tumours 79 (53%) 
Total Independent Tumours 71 (47%) 
The table shows that 53% of the 150 tumours studied were able 
to thrive in one or two hormones to the extent that they were more 
active than both controls. The most dramatic finding is the high 
incidence of prolactin dependence. Thus 24 of the 150 tumours (16%) 
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were dependent on prolactin alone while a total of 50 (33%) were 
dependent either on prolactin alone or on prolactin as well as one 
of the steroid hormones. As indicated previously, the independent 
group covered a whole spectrum of hormonal responses in vitro, but 
no case in this group showed higher activity than both controls. 
ANALYSIS ACCORDING TO MENSTRUAL STATUS 
The patients have been considered in 3 groups; premenopausal, 
less than 5 years postmenopausal and over 5 years postmenopausal. 
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Considering the 150 as a whole, it is found that in the premeno-
pausal group there were more dependent than independent tumours in the 
ratio of about 2:1. In the less than 5 years postmenopausal group more 
were independent than dependent, in the ratio of about 4:3. There was 
some increase in dependence again in the over 5 years postmenopausal 
52 
group, the proportions being approximately equal. Comparing these ratios 
in the 3 groups one finds that there is a tendency for dependence to be 
least common in the less than 5 years postmenopausal group, although the 
numbers are not highly significant (chi-square= 3.72 with 2 degrees of 
freedom; p = 0.16). This tendency is interesting in that it supports 
the well-known clinical experience that hormonal therapy is least likely 
to be successful in the period at and immediately following the menopause. 
If we extract from the above table the total number of prolactin, 
oestradiol and testosterone-dependent results in each of the three groups, 
they may be compared overall and in pairs. 
Premenopausal Less Than 5 Years Over 5 Years 
Postmenopausal Postmenopausal 
Prolactin 12 10 28 
Oestradiol 9 7 15 
Testosterone 1 3 20 
Comparing the three overall to see whether there are any differ-
ences between the groups of dependent subjects, there is a significant 
probability that there are; chi-square= 8.19 (4 degrees of freedom), 
p = 0.08. This indicates that it is worth comparing them in more detail 
to see where the difference lies. 
Comparing the premenopausal group with the less than 5 years post-
menopausal group, there is no significant difference (p = 0.51). 
Similarly, there is no significant difference between the two post-
menopausal groups (p = 0.31). However, if we compare the premenopausal group 
with the over 5 years postmenopausal group, there is a highly significant 
difference in the dependence ratios; chi-square= 6.93 (2 degrees of 
freedom), p = 0.03. 
It can be seen at a glance that this difference in dependence ratios 
is due to (a) a greater incidence of prolactin dependence in the pre-
menopausal group; (b) a greater incidence of oestradiol dependence in the 
premenopausal group, and (c) a considerably greater incidence of testo-
sterone dependence in the over 5 years postmenopausal group (20 out of 
63 as compared with 1 out of 22 in the premenopausal group). This 
difference is even more striktng in that the 1 testosterone-dependent 
patient in the premenopausal group had had androgen therapy with durabolin 
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for several months before testing. 
There would thus appear to be a very real trend of alteration in 
the distribution of in vitro hormone dependence of breast cancers from 
the premenopausal patients to those over 5 years postmenopausal. The 
group less than 5 years postmenopausal lies in a transitional zone in 
which all hormone dependence seems to be less common and in which 
profound re-adjustments are taking place. When the definitive post-
menopausal pattern stabilises and the incidence of hormone dependence 
again begins to rise, the ratios of dependence have altered consider-
ably from the premenopausal situation. The whole question of a 
tumour's capacity to adapt dynamically to an altered hormonal milieu 
will be discussed in a later Section. 
EFFECT OF ENDOCRINE-ABLATION PRIOR TO TESTING 
Thirty four of the patients had had an endocrine-ablative procedure 
at some stage (months or years) before tumour culture was carried out. 
Only l of the 34 had had an ablation (bilateral oophorectomy) for 
gynaecological reasons before breast cancer became apparent. The others 
had all had the procedures for breast cancer. The details are shown 
below: 
Radiation Menopause 11 
Bilateral Oophorectomy 14 
Bilateral Adrenalectomy 
and Oophorectomy 5 
Bilateral Adrenalectomy 
alone 2 
Hypophysectomy alone l 
Bilateral Oophorectomy 
and subsequent Hypophysectomy l 
The table on the following page shows the dependences of the 
post-ablation group. Considering this group in terms of the number 
of years after the procedure, (i.e. after they stopped menstruating), 
the subgroups are too small for comparisons to be significant 
(p = 0.58), but it is interesting that we again see the same trend 
as in the series of 150 as a whole, namely that dependence appears 
to be less common in the 5 years after ceasing menstruation than 
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afterwards. 
DEPENDENCES IN THE POST-ABLATION GROUP 
Overall Less than 5 years Over 5 years 
After Procedure ;l\;fter Procedure 
Dependent on 
Prolactin only 6 3 3 
Dependent on 
Oestradiol only 2 1 1 
Dependent on 
Testosterone only 2 1 1 
Dependent on both 
Prolactin and Oestradiol 3 2 1 
Dependent on both 
Prolactin and Testosterone 2 0 2 
Tota 1 Pro 1 actrn 
Dependent Tumours 11 5 6 
Total Oestradiol 
Dependent Tumours 5 3 2 
Total Testosterone 
Dependent Tumours 4 1 3 
Total Dependent Tumours 15 7 8 
Total Independent Tumours 19 14 5 
By breaking down the post-ablation group further in terms of the 
three main specific procedures, as illustrated in the following table, the 
sub-groups become even smaller and less significant, but it is interesting 
that the patients who had had only ovarian function ablated, (either 
surgically or by radiation), nonetheless had a spread of dependences, 
including oestradiol, prolactin and testosterone. This might logically 
be expected since adrenocortical function would maintain at least a small 
amount of circulating steroid hormones. Of the 5 patients who had had 
both the ovaries and the adrenals removed, however, (i.e the bulk of the 
steroid-secreting tissues in the body), 4 were independent and 1 was 
dependent on prolactin, the secretion of which had not been interrupted, 
(although it could have been affected by feedback mechanisms). Following 
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the ablation the prolactin dependent case had originally had an excellent 
objective regression, while of the 4 independent cases 2 had regressed 
and 2 had not. 
Two further postmenopausal patients had had bilateral adrenalectomy 
alone and their tumours were also independent, as was the tumour of 1 
patient who had had a hypophysectomy a long time prior to tumour culture. 
Curiously enough, the recurrent tumour of a patient who had had a bi-
lateral o6phorectomy and subsequently a hypophysectomy, both with good 
regressions, turned out to be testosterone-dependent and was in fact kept 
under control by oestradiol administration. In the context of this last 
case, it is interesting that Jantet et al. (1963) measured the degree of 
adrenocortical atrophy after hypophysectomy and found that it bore no 
relation to the efficacy of hypophysectomy in producing a regression. This 
is relevant in that if adrenocortical function persists to some extent 
after hypophysectomy, it could produce steroid hormones which might still 
sustain the tumour. 
Radiation Bilateral Bilateral Adrenalectomy 
Menopause Oophorectomy and Otiehorectomy 
Dependent on 
Prolactin only 1 4 1 
Dependent on 
Oestradiol only 1 1 0 
Dependent on 
Testosterone only 0 1 0 
Dependent on both 
Prolactin and Oestradiol 1 2 0 
Dependent on both 
Prolactin and Testosterone 1 1 0 
Total Prolactin 
Dependent Tumours 3 7 1 
Total Oestradiol 
Dependent Tumours 2 3 0 
Total Testosterone 
Dependent Tumours l 2 0 
Total Dependent Tumours 4 9 l 
Total Independent Tumours 7 5 4 
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INFLUENCE OF CLINICAL STAGE AT THE TIME OF BIOPSY 
All patients were routinely assigned a clinical stage prior to 
biopsy. The widely-used convention was followed whereby Stage I re-
ferred to an uncomplicated mobile breast lump alone, less than 5 cm 
in its greatest diameter; Stage II implied mobile homolateral axillary 
nodes in addition to the breast lump; Stage III included any local, 
axillary or supraclavicular extension of the disease beyond Stages I 
and II, but without distant dissemination, and Stage IV referred to 
distant dissemination of the disease, regardless of the condition of 
the primary. The same convention was followed in cases of recurrence. 
The in vitro dependences were as follows: 
I 
Dependent on 
Prolactin only 3 
Dependent on 
Oestradiol only 1 
Dependent on 
Testosterone only 2 
Dependent on both 
Prolactin and Oestradiol 2 
Dependent on both 
Prolactin and Testosterone 4 
Total Prolactin 
Dependent Tumours 9 
Total Oestradiol 
Dependent Tumours 3 
Total Testosterone 
Dependent Tumours 6 
Total Dependent Tumours 12 
































The above table indicates that there does not seem to be any 
significant difference in the ratios of dependence in any of the 
clinical stages and this is borne out by statistical analysis (p = 0.54). 
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INFLUENCE OF THE SITE OF BIOPSY 
Biopsies were taken from primary and metastatic tumour sites, 
the latter including lymph nodes, skin and subcutaneous deposits and 
also a few visceral metastases. These were classified in the two 
groups and the results were as follows: 
Primary Metastatic 
Dependent on 
Prolactin only 9 15 
Dependent on 
Oestradiol only 8 7 
Dependent on 
Testosterone only 4 10 
Dependent on both 
Prolactin and Oestradiol 9 7 
Dependent on both 
Prolactin and Testosterone 7 3 
Tota 1 Pro 1 acti n 
Dependent Tumours 25 25 
Total Oestradiol 
Dependent Tumours 17 14 
Total Testosterone 
Dependent Tumours 11 13 
Total Dependent Tumours 37 42 
Total Independent Tumours 33 38 
The table indicates that the site of biopsy did not affect the 
dependence ratios and statistical analysis confirms the lack of any 
significant association (p = 0.69). The dependences have been further 
analysed according to the specific origin of the biopsies, (i.e. skin, 
subcutaneous tissue or lymph nodes,) but this also revealed no 
differences. It should be noted that apart from a few experimental 
cultures, which have not been included in this series, this technique 
has not yet been evaluated for bony metastases. 
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D I S C U S S I O N 
I propose to commence the Discussion with an assessment of the 
value and advantages of the technique itself. 
(a) It is a relatively simple procedure that requires no 
elaborate apparatus and could be established in any conventionally 
equipped hospital laboratory. 
(b) The time taken for the whole experiment consists of 24 hours 
of incubation of the culture plus about 2 hours for the various 
technical steps. The fact that a useful answer as to hormonal-
dependence of an individual patient's tumour can be provided as soon 
as 26 hours after taking the biopsy is of great value to the clinician 
in a situation where he is anxious to start treatment for advancing 
disease. Equally, it would be very useful where one is considering 
employing adjuvant hormonal manoeuvres after primary surgical treatment 
of the early operable tumour. 
(c) The tumour remains as close as possible to its natural 
condition in the patient. Since this is only a short-term culture 
with no proliferation and therefore no alteration of characteristics 
that daughter generations of cells might have, it enhances the value 
of conclusions drawn from these studies as compared with others lasting 
several days. 
(d) The absence of any form of mechanical or physico-chemical 
preparation of the tumour before culture, as is the case with single-
cell suspensions and other cell culture methods, is an obvious 
advantage tending to create more physiological conditions. 
(e) A very important asset of this technique is that the histo-
chemical reaction enables assessment of the carcinoma cells alone. 
Using techniques preparing single cell suspensions, one is unable to 
obtain a 100% survival of all the tumour cells and in addition it is 
impossible to be certain which of the surviving cells are malignant 
and which are from normal breast epithelium or the connective tissue 
element in the tumour. In this technique one can be absolutely 
certain that the formazan deposition is in relation to the cancer cells. 
Other assays in relation to a given mass of tumour are subject to errors 
arising from the varying content of stroma, oedema fluid and the 
allowances made for dry and wet weight. 
59 
(f) Parallel assessment of duplicate histological sections 
ensures that conclusions are based only on representative tumour. 
(g) Oestrogen-binding to breast cancer lasts for only 5 hours 
(Deshpande, 1972), and therefore the present test allows time for 
the oestradiol level in the culture fluid to over-ride any pre-
existing steroid bound in vivo at the time of the biopsy. Prolactin 
may bind for longer periods, (about 8 hours, personal communication 
from Dr. H. Friesen, 1973) but again it would seem that the culture 
fluid level can dominate by 24 hours. The test therefore offers the 
chance to see the true effect of chemically-defined medium upon the 
breast cancer tissue. 
(h) Tumour culture methods in general offer one notable 
advantage over other hormonal prediction systems based on urinary 
or blood levels of hormones in that they measure, directly and 
unequivocally, the effect of a given hormone on the target tumour 
cells. In vivo the situation is considerably more complicated 
because of the multiplicity of hormones, feed-back mechanisms and 
fluctuations in secretions and levels. This is of course to some 
extent counter-balanced by the extreme caution with which one tries 
to extrapolate in vitro findings to the in vivo situation, the validity 
of which can in the final analysis only be established by carefully-
controlled forward clinical trials. 
(i) The technique has been extremely reliable. Pentose shunt 
dehydrogenase activity has accorded very well with the survival of 
the tumour and seems to be an important marker of neoplastic capacity. 
I have already discussed the two important technical problems, namely 
an inadequate biopsy and contamination, and these are both related to 
taking of the biopsy. As far as the technique itself is concerned, 
one can confidently state that given a good, sterile specimen a short 
time after biopsy, the experiment will reliably and reproducibly 11 work 11 • 
(j) Last but by no means least, this technique has made possible 
the first major study of the effects of prolactin on human_breast 
cancer, and it has revealed, for the first time, that over 30% of 
human breast cancers are enhanced in vitro by prolactin. 
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REJECTED EXPERIMENTS 
In addition to a number of experiments on other tumours, which 
will be mentioned later, and on breast biopsies that turned out to 
be benign or even secondaries from other primary tumours, 21 primary 
or metastatic breast cancer biopsies were rejected for technical 
reasons. Two tumours were non-viable on arrival, having been delayed 
2~ and 4! hours respectively after biopsy. They showed no histo-
chemical activity on completion of the culture and marked deterioration 
histologically. 
A further specimen that had been delayed a little over an hour 
before reaching the laboratory revealed a number of bacterial 
colonies on microscopy after culture and this experiment was accordingly 
rejected, although the enzyme reaction had worked. One other biopsy 
reached the laboratory in less than an hour and was taken from a clean-
looking lesion, but this also showed some bacterial contamination after 
culture and was therefore rejected. 
Of the remaining 17 biopsies, 11 were discarded because (a) there 
was no tumour discernable at all on histology, (b) there were so few 
tumour cells scattered sparsely within an abundant collagenous stroma 
(usually in skin or subcutaneous metastases) that it was impossible to 
compare the slices, or (c) the specimen was simply too small to permit 
the cutting of enough slices to carry out the complete experiment. 
The final 6 were discarded because the biopsy came from a frankly 
infected or even ulcerating lesion, or from very near it. These specimens 
showed varying degrees of survival after culture but it was impossible 
to draw any valid conclusions from them. 
On several occasions, after a first biopsy had proved unsatisfactory 
because of too little tumour in the specimen, a subsequent biopsy from 
a more representative lesion, or after a period of adequate dressings 
and topical or systemic antibiotic treatment, was successful. 
In general, it was very easy to decide which experiments should 
be rejected. Histological examination permitted inmediate rejection of 
any experiment in which each slice did not contain adequate tumour 
tissue. The same applied to any experiment where any of the sections 
revealed colonies of bacteria. Very often the decision could be made 
before the stage of microscopy by finding that the medium had changed 
colour after incubation from the normal bright-red to a pale yellow-brown. 
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This was because the phenol red indicator had changed due to a drop 
in the pH from the usual 7.6 to a more acidic level, as a result of 
bacterial activity. This gross change was usually associated with 
biopsies that were known to have been taken from infected lesions. 
The technique thus has built-in safeguards, notably histological 
examination and the pH indicator, to prevent acceptance of any results 
based on unsatisfactory experiments. 
SURVIVAL OF THE MEDIUM CONTROL 
Although in the majority of cases the medium control showed 
markedly lower dehydrogenase activity than the initial control, and 
corresponding evidence of deterioration histologically, in 22 of the 
150 cases it actually showed enhanced enzymic activity and no 
deterioration on histology compared with the initial control. There 
is reason to attribute the good survival in these cases to the insulin 
in the medium. Trowell 1 s T8 medium contains 5 mg/100 ml insulin, 
(5 microgram/ml), and several workers have demonstrated the effect of 
insulin in mammary gland cultures. In mouse mammary glands insulin 
is absolutely necessary in vitro for the survival and maintenance of 
the cultures, and biochemically it has been shown to have a stimulatory 
effect on DNA and RNA synthesis, quite independent of its effect on 
glucose transport. (Forsyth, 1971). It also stimulates both 
glucose-6-phosphate dehydrogenase (G-6-PD) and 6-phosphogluconate 
dehydrogenase (6-PGD) in the pentose shunt pathway (Leader and Barry, 
1969), which are precisely the enzymes being measured in the present 
technique. Barker, Fanger and Farnes (1964) showed that normal adult 
human breast tissue slices could be kept alive in simple media for a 
period of up to about 5 days, without addition of serum or any hormones. 
However, addition of insulin produced striking proliferative changes 
in the morphology. Ceriani, Contessa and Nataf (1972) confirmed that 
for human breast cancer cultures as well as those of animal and normal 
human breast, insulin allowed more complete maintenance of the tissue 
and even some enhancement, which was more marked when oestradiol or 
ovine prolactin were added to the insulin-containing cultures. 
In the 22 cases mentioned, therefore, it seems highly likely that 
these are examples of insulin alone providing a powerful stimulus to 
growth and metabolic activity, manifesting in this particular system 
62 
by increased dehydrogenase activity of the pentose shunt and by no 
evidence of deterioration after culture in the medium only. It is 
interesting that two of the patients among these 22 had repeat 
biopsies several months later and these again showed higher activity 
in the medium control than the initial control, thus supporting the 
reliability of the technique. 
These examples of insulin enhancement of the medium control 
underline the need to compare the cultures in the 3 hormones under 
investigation with both the medium as well as the initial control 
before evaluating their effects. 
PROLACTIN DEPENDENCE 
Perhaps the most striking single result of the whole project has 
been the remarkably high incidence of in vitro dependence on prolactin. 
This has potentially sweeping clinical implications. It immediately 
offers some explanation, if prolactin dependence is indeed a valid 
concept in vivo, as to why a substantial percentage of patients fail 
to respond to hormonal measures involving oestrogen or androgen addition 
or subtraction only. It may also help to explain the clear demonstration 
by the Guy's Group (Atkins et al., 1960; Hayward et al., 1970), that 
transfrontal hyophysectomy gave the best remission rate of all ablative 
procedures; the difference may well be accounted for by complete 
removal of prolactin secretion in prolactin-dependent cases. Further 
indirect supporting evidence comes from the well-known clinical 
observation that some patients who have escaped from remissions induced 
by oophorectomy or adrenalectomy may have a further remission following 
hyophysectomy. The experimental finding, in this relatively large series 
of cases, that prolactin, (both ovine and human), can enhance the 
activity of breast cancer cells above their control level in the fresh-
frozen biopsy immediately after removal from the patient, provides 
powerful support for its role in human breast cancer. 
Plasma Prolactin Levels 
There is still a good deal of uncertainty about the plasma levels 
of prolactin. At present there is no clear evidence at all that human 
breast cancer patients have higher plasma prolactin levels than matched 
controls. The Cardiff group (Forrest, 1972), found no significant 
differences in prolactin levels in 48 patients of whom 6 had benign breast 
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disease, 10 primary breast cancer and 32 advanced breast cancer. 
There was also no significant difference in this series between 
pre- and postmenopausal patients. Although there is abundant 
evidence by now that increased prolactin secretion accelerates the 
growth of induced breast cancers (Meites et al., 1972), there is also 
evidence that in spite of the progressive growth of the DMBA-induced 
prolactin-dependent tumours in these animals, the plasma prolactin levels 
remained within the normal range and did not change significantly 
from month to month (Nagasawa et al., 1973). At this stage it appears 
highly likely that most human breast cancers whose growth is dependent 
on prolactin will be so at physiological levels. In one group of 
patients who are known to have grossly elevated prolactin levels, namely 
those with non-puerperal galactorrhoea, no increased incidence of 
breast cancer has yet been reported. Thus in Man we are as yet unaware 
of any evidence indicating a predisposition to breast cancer in patients 
with a high plasma prolactin level, although Meites et al. (1972) have shown 
that this is the case in rats. Whether prolactin may possibly play 
a part in the development of the rare but dreaded breast cancer of 
pregnancy or the puerperium, (when levels are high), is still not 
known. 
However, evidence is steadily accumulating to show that prolactin 
is a powerful growth-promoter in a number of existing breast cancers. 
In the present study, as the results indicate, as many as 50 of the 
150 tumours studied were dependent on prolactin in vitro. Of these, no 
fewer than 27 were dependent on the lower concentration used, (0.022 
I.U. per ml, approximately 6.5 ng/ml), and 16 of the 27 were dependent 
at the lower concentration only. If the growth of these tumours is 
dependent on prolactin at physiological plasma levels, and indeed low 
physiological levels, then the problem of how to counter prolactin 
arises. The possibilities include suppression of its secretion at 
hypothalamic or pituitary level by surgical or pharmacological means 
and interference with its peripheral action at target cell level. 
The search for a peripheral prolactin blocker is now being 
actively pursued, both by the pharmaceutical companies and by academic 
researchers, but to the best of our knowledge none has yet been reported. 
A good deal of attention has however been focussed on pharmacological 
and surgical attempts to suppress prolactin secretion. The pendulum 
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of opinion has also begun to swing away from explaining the beneficial 
effects of hypophysectomy in terms of adrenocorticotrophic and 
gonadotrophic hormones to attributing them to removal of prolactin. 
For example Ray (1972), in reviewing the experience of hypophysectomy 
for disseminated breast cancer at Cornell and the New York Hospital, 
emphasises the importance of prolactin above the trophic hormones. 
Ray goes as far as to give prolactin abolition quite unequivocally 
as the rationale for the success of the operation. He also mentions 
the importance of a complete ablation of the gland, as leaving even 
a small fragment of the anterior lobe could compromise the result. 
Jantet et al. (1963) actually showed that even when hypophysectomy 
was performed by the transfrontal route, 16 out of 22 subjects had 
residual anterior pituitary tissue at autopsy. 
Hypophysectomy as a Suppressor of Prolactin Secretion 
There are only very scanty data in the literature correlating 
the response of anti-prolactin measures of any sort with plasma 
prolactin levels. In three cases Dickey and Minton (1972) showed 
that some lowering of the prolactin level by levodopa was associated 
with a clinical response. We have so far had the opportunity of 
studying the plasma prolactins of 6 breast cancer patients and the 
results are of some interest. The first two sets of estimations 
were performed by Dr. Boyns and Mr. Cole, of the Tenovus Institute, 
Cardiff, who assayed human growth hormone (HGH) in the plasma samples 
as well. Their prolactin units are in 11 milli-ampoules/ml 11 and 
growth hormone is measured in the conventional micro-units/ml. Three 
further sets of prolactins were assayed by Ors. Friesen and Del Pozo, 
of McGill University, Montreal and the sixth set by Dr. McNeilly of 
St. Bartholomew's Hospital. 
Patient 48, 65 years of age, had originally been treated by 
radiotherapy in April 1969 for a Stage III carcinoma of the left 
breast. Local recurrence developed in 1970 and she had subsequently 
been treated with norethisterone, oestradiol, cytotoxic chemotherapy 
and finally, in June 1971, the oestrogen antagonist ICI 46474 
(
1 Tamoxifen 1 ). The latter produced some degree of regression in the 
local disease but bony metastases developed a few months later. In 
June 1972 biopsy and in vitro testing of the breast lesion showed 
clear-cut prolactin dependence, at both concentrations. On 7th July, 1972 
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a trans-ethmoidal hypophysectomy was performed. Plasma prolactin 
levels were monitored and these showed a transient fall (Fig.12) 
soon followed by a climb back to pre-operative levels. Parallel growth 
hormone assays remained low, suggesting that even a near-complete 
ablation may not be enough to stop prolactin-secreting cells from 
maintaining a normal plasma prolactin level. The patient obtained no 
remission of her disease and despite chemotherapy died in November, 1972. 
Patient 70, who presented in July, 1970 at the age of 42 years with 
a right breast destroyed by tumour, a pleural effusion and a lung 
metastasis, illustrates the opposite picture. She initially had a 
good regression from a radiation menopause, but by April, 1971 there 
was again active disease in the right breast and skeletal metastases 
were present. Norethisterone was administered without success. By 
June, 1972 the patient was rapidly losing condition in the face of 
progressing local and bony disease. Biopsy and testing of the breast 
lesion at this time showed it to be independent but with good survival 
in prolactin and marked inhibition by oestradiol. The latter was 
accordingly administered with definite regression of the breast disease 
but no effect on the bony metastases. A repeat breast biopsy and 
culture were performed on 27th August, 1972, at which stage the patient 
was in unrelieved agony and bedridden because of pelvic and vertebral 
bony metastases. Local radiotherapy to several of the bony deposits 
had not alleviated the pain at all. The new culture revealed oestradiol 
inhibition just as before, but this time the tumour had survived so 
well in prolactin as to be classified as dependent on it. In the face of 
a hopeless clinical situation it was decided to resort to hypophysectomy, 
which was performed by the trans-frontal route on October 25th, 1972. 
This produced a remarkable result; the patient rapidly lost all her 
pain, regained normal mobility and was in due course able to return to 
her work as a music teacher. The local breast disease resolved 
completely and to date, some 8 months post-operatively, she remains well 
and symptom-free, with no signs of active disease on clinical 
examination. The bony metastases are showing early signs of re-calcifi-
cation on X-ray. Figure 13 shows that her plasma prolactin was at a 
level undetectable by the Cardiff assay both pre- and post-operatively, 
but the HGH level did drop immediately post-operatively to very low 









































Figure 12: Plasma prolactin and growth hormone levels of Patient 48 








































Figure 13: Plasma prolactin and growth hormone levels of Patient 70 
following trans-fronta 1 hypophysectomy. The very high 
prolactin peak is in a specimen taken under general 
anaesthetic, which is known to produce such elevation. 
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complete and went hand in hand with an excellent regression. 
Mrs. E. S., 48 years of age, had not had in vitro testing of 
her tumour since she had no soft-tissue lesion that could be biopsied, 
but her history and response to hypophysectomy are relevant to the 
present study. In January, 1972 she had been treated by simple 
mastectomy and radiotherapy for a right breast carcinoma. Six months 
later vertebral deposits appeared. In January, 1973 she was seen at 
the Westminster Hospital with multiple bony metastases, including 
ominous deposits in the first and second cervical vertebrae. These 
were treated with local radiotherapy and a collar to try to prevent 
cervical subluxation. She was also given levodopa (500 mg six-hourly) 
in addition to the cytotoxic chemotherapy she was already receiving 
and which was not controlling the pain or the lesions. The levodopa 
did seem to produce some purely subjective improvement in her bone 
pain and as it is known that levodopa does lower prolactin secretion 
and has been suggested as a possible predictive test for pituitary 
ablation (Minton and Dickey, 1972; Stoll, 1972), trans-frontal 
hypophysectomy was recommended. This was performed on March 23rd, 
1973, with an outstanding result. In addition to rapid symptomatic 
relief, X-rays taken less than two months later showed clear evidence 
of healing and re-calcification of vertebral, rib and pelvic metastases, 
(Figs.15 and 16) which is in fact unusually early to detect radiological 
signs of regression of bony metastases. Figure 14 shows that her plasma 
prolactin levels dropped down to 4 ng/ml post-operatively and stayed 
down. Dr. Del Pozo (1973) has recently informed me that the lower limit 
of sensitivity of the McGill prolactin assay is presently about 
4 - 5 ng/ml and that they are rarely finding levels below this. This 
patient 1s hypophysectomy would then appear to have been virtually 
complete, and about 4 months post-operatively her excellent regression 
is being maintained. 
Patient 183, 36 years of age, had had a left modified radical 
mastectomy abroad in November 1970, followed by an oophorectomy. In 
January 1973 she came to the Westminster Hospital with Stage IV disease, 
(scar recurrence and bony metastases). Biopsy and testing of the scar 
recurrence revealed prolactin dependence and on 13th April trans-
ethmoidal hypophysectomy was performed. Figure 17 shows that her plasma 



















Figure 14: Plasma prolactin levels of Mrs. E.S. following 
trans-frontal hypophysectomy. 
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Figure 15: Mrs. E. S. Chest X-ray on 4th January, 1973 shows rib 
metastases. 
Figure 16: On the 21st May, 1973, 2 months after trans-frontal 
hypophysectomy, re-calcification is clearly occurring. A 
later radiograph taken in early July shows even more impressive 
bone healing . 
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has had objective regression of her disease, with radiological 
resolution of the metastases and a return of alkaline phosphatase 
levels to normal. 
Patient 69, 51 years of age, had been treated by radiotherapy 
for a left breast carcinoma in February 1968. Local recurrence in 
September, 1969 was treated by a radiation menopause. After initial 
regression the disease advanced and by July 1972 she had been 
successively treated with cyclophosphamide, norethisterone, combination 
chemotherapy and durabolin, none of these having achieved a regression. 
Biopsy and testing in July, 1972 showed independence with equally poor 
survival in all hormones. She was maintained on prednisone and 5-fluoro-
uracil but by this time had progressing vertebral metastases. A repeat 
biopsy of the breast lesion was taken in April, 1973 and this time it 
showed prolactin dependence. All other forms of treatment had been 
exhausted and on 11th May, 1973 a trans-frontal hypophysectomy was 
performed. After an initial symptomatic improvement which only lasted 
a few days, it soon became clear that the progress of the disease had 
not been arrested. It will be seen from Figure 18 that her plasma 
prolactins failed at any stage to reach a sufficiently low level and 
oscillated right up to pre-operative levels. It is very significant 
that the operation had been complicated in this patient by the finding 
of an internal carotid aneurysm and thus in spite of it having been 
performed by the trans-frontal route, there was some doubt about the 
completeness of ablation. 
Pharmacological Attempts to Suppress Prolactin Secretion 
Mention has been made earlier of the finding of Cassell et al. 
(1971) that ergocornine and ergocryptine inhibited the growth of 
7,12-DMBA-induced tumours in Sprague-Dawley rats, this effect being 
due to suppression of pituitary prolactin secretion, mediated both 
via hypothalamic PIF and a direct anterior pituitary effect of the 
drugs. In 1971 Lutterbeck et al. described the use of the ergot 
alkaloid 2-brom-alpha-ergocryptine (CB 154) to terminate galactorrhoea 
in 3 non-puerperal women and in 1972 Varga et al. showed that it also 
inhibited puerperal lactation. No prolactin levels were measured in 
the blood of these patients but the drug was believed to act by 
specifically suppressing prolactin secretion. Later in 1972 Besser et al. 
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Figure 18: Plasma prolactin levels of Patient 69 following 
trans-frontal hypophysectomy 
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amenorrhoea in women could be successfully treated with CB154. 
Plasma prolactin levels were measured in these patients and were 
often greater than 1,500 ng/ml, which is over 500 times normal. 
They fell dramatically in response to treatment although it is not 
known how near zero they reached because the assay in use at the time 
had a lower limit of sensitivity of 22 ng/ml of prolactin, which is 
near the upper limit of the physiological range. Besser et al. found 
that the response to treatment, that is the cessation of galactorrhoea 
and the return of normal gonadal function, suggested that there was 
an inverse relationship between prolactin secretion and gonadotrophin 
secretion in Man. This is precisely what we would expect in view of 
the previously-discussed evidence that the hypothalamic "releasing 
factors" are indeed "releasers" for GH and the trophic hormones, 
whereas for prolactin the effect is inhibitory (PIF). Del Pozo et 
al. (1972) showed that levodopa could transiently depress prolactin 
levels further than CB154, but this could not be sustained for more 
than 4 hours, even on regularly-spaced medication. Boyd et al. (1970) 
had shown that levodopa increases GH secretion, and Sherman et al. 
(1971) showed that·chlorpromazine, which increases prolactin secretion, 
reduces GH release. Thus all these drugs would appear to be acting 
non-specifically on the hypothalamus, either stimulating or depressing 
the secretion of the "releasing" factors down the hypothalamo-
pituitary axis, the net effect on the gonadotrophins, ACTH and growth 
hormone being inverse to that on prolactin. However, there is good 
evidence that the ergot alkaloids act directly at pituitary level as 
well, (FlUckiger, 1972) and at the present time the whole complex 
subject of the primary site of action of all these drugs remains 
controversial. 
Cyclicimide, (CG603), a thalidomide derivative and also an 
inhibitor of prolactin secretion in the rat, produced a clinical 
remission in only one of 23 patients in whom it was tried in a 
European trial, (Heuson, 1972), the dose being the maximum tolerable 
one of 2 gm daily. However, the drug is toxic, produces weight loss, 
which itself can produce mammary tumour regression (Heuson, 1972), and 
is to our knowledge not being further tried in humans. 
Is Human Breast Cancer Simply Related to Prolactin Levels? 
In considering the treatment of breast cancer by lowering prolactin 
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secretion, the situation in humans would thus appear to be considerably 
more complex than in the rat, in whom tumour regression may be obtained 
by any of the methods that lower prolactin secretion, though not 
necessarily to complete shut-off. In 1972 the European Breast Cancer 
Trial published its results on treatment of 19 patients with CB154 at 
the recommended dosage of 2.5 mg three times daily; not a single 
remission was obtained (Heuson et al., 1972). No plasma prolactins 
were measured in their study and it is thus not known how effectively 
the levels were lowered. 
One patient in this present study, number 52, a lady of 62 years, 
presented in November 1970 with a Stage III right breast carcinoma that 
was treated by radiotherapy. This regressed but did not disappear. In 
March, 1972 it re-activated and she was treated first with norethisterone 
and then with ICI 46474, with no effect. In January, 1973 a biopsy 
revealed prolactin dependence, at high and low concentrations, and she 
was given a course of CB154, 2.5 mg three times a day. No objective 
signs of regression were seen and after 6 weeks the treatment was 
stopped and chemotherapy instituted. (The latter has also not 
succeeded in controlling the diseaseJ Figure 19 shows that her plasma 
prolactin levels were certainly lowered, though by no means abolished. 
This does not reflect an inability to register low levels on the part 
of the assay method, which Dr. McNeilly believes to be accurate down 
to l - 2 ng/ml. 
We have now seen that there appears to be some correlation 
between the success of hypophysectomy and the sustained depression of 
plasma prolactin levels post-operatively. At the same time, there is 
the problem of completeness of the operation by either route and of the 
extent of prolactin secretion by the residual fragments. CB154, which 
does produce a sustained depression of prolactin levels, although never 
below 3 ng/ml (Del Pozo et al., 1972), has not yet been shown to produce 
any objective regressions in breast cancer, whereas levodopa, which 
usually does drop prolactin levels to below 3 ng/ml, but always 
transiently, has achieved temporary regressions in a few patients 
(Minton and Dickey, 1972). It may well be, as the present study suggests, 
that a substantial proportion of these prolactin-dependent tumours are 
able to thrive in a very low concentration of the hormone, presumably 



































Figure 19: Plasma prolactin levels of Patient 52 after administration 
of CB154. 
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manoeuvres, in the present state of knowledge, may simply not be 
depressing prolactin secretion and levels sufficiently or for long 
enough. 
It is now known that intravenous administration of synthetic 
thyrotrophin-releasing hormone (TRH) in Man is able to stimulate 
prolactin as well as thyrotrophin secretion (Bowers et al., 1971; 
Jacobs et al., 1971). Whether under physiological conditions there 
is a hypothalamic releasing mechanism for prolactin as well as an 
inhibitory one is unknown. Even if there were it is not known whether 
this would be a function of TRH or of some hitherto undiscovered 
hormone. 
Another aspect of the complexity of the problem is the knowledge 
that pituitary stalk section, which could be expected and in some 
cases has been confirmed to raise plasma prolactin levels, (by 
interrupting PIF secretion down the hypothalamo-pituitary axis,) 
(Turkington et al., 1971), nonetheless results in a number of remissions 
in disseminated breast cancer. One possibility is that stalk-section 
may operate by interrupting the releasing factors for the trophic 
hormones, which may result in switching off ovarian and adrenocortical 
steroid production in cases that are steroid hormone and not prolactin-
dependent. Another suggested rationale has been that stalk-section 
may result in virtual abolition of function of the anterior pituitary 
by some mechanical or vascular derangement. The paradox still remains 
difficult to explain and is yet another facet of the intricate 
relationship between the growth of human breast cancer and plasma 
prolactin levels. 
Treatment of Prolactin Dependent Cases by Inhibitory Hormones 
The prolactin-dependent cases did not necessarily need to receive 
anti-prolactin measures in order to gain a remission. In several 
instances excellent remissions were obtained by adminstering the 
hormone which appeared to be strikingly inhibitory to the tumour in 
culture. For example, patient 46, 62 years of age, was treated by 
radiotherapy for a right breast carcinoma in 1969. In 1970 local 
recurrence developed and she was treated successively with norethi-
sterone and then a combination of durabolin and prednisone. By August 
1971 chemotherapy with 5-fluoro-uracil had to be started. In May, 1972 
it was decided to biopsy and culture the local recurrence in view of 
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failure to control it with chemotherapy. The biopsy turned out to be 
prolactin dependent but was also inhibited markedly by oestradiol. 
Ethinyl oestradiol was then administered and good objective regression 
ensued. 
INFLUENCE OF OESTROGENS ON PROLACTIN SECRETION 
Meites (1972), one of the principal workers in this field, has 
clearly shown that apart from the "short-loop feedback" whereby high 
circulating prolactin or implantation of prolactin in the median 
eminence of a rat reduces prolactin secretion by the in situ pituitary, 
several other hormones, including oestrogen , thyroxine (T4) and 
tri-iodo-thyronine (T3) all have a positive "long-feedback" influence 
on prolactin secretion. Oestrogens seem to increase prolactin secretion 
both by hypothalamic and direct anterior pituitary effects, while 
thyroxine apparently acts only at pituitary level. Other workers have 
confirmed that oestrogen administration raises prolactin levels in 
humans as well as in animals, (L'Hermite et al., 1972 b). Pasteels et 
al. (1972 ) demonstrated in humans that the number of "prolactin cells" 
in the pituitary were increased as a side-effect of administration of 
various hormones like oestrogens and androgens, (including to breast 
cancer patients,) and in conditions like hepatic cirrhosis where 
androgens and oestrogens are not catabolised properly. In a small series 
of patients Forrest (1972) has shown that oestrogenic therapy may 
enhance and anti-oestrogenic therapy may depress prolactin secretion. 
Anti-Oestrogenic Therapy in Prolactin-Dependent Cases 
Certain of the prolactin-dependent cases in this study were given 
anti-oestrogenic treatment by the clinicians concerned and underwent a good 
remission. Patient 38, 69 years of age, had radiotherapy to a left breast 
carcinoma in 1953 followed in 1954 by a toilet mastectomy and bilateral 
oophorectomy. In 1963 she received local radiotherapy to recurrent 
supraclavicular disease. In April 1968 she developed hepatomegaly and 
progressive supraclavicular disease. Durabolin and norethisterone failed 
to control the disease and 5-fluoro-uracil, cyclophosphamide and finally 
combined chemotherapy were tried. In May, 1972, the disease still not 
under control, a biopsy of the supraclavicular mass was cultured and 
showed dependence on both oestradiol and prolactin. The patient was started 




Figure 20: Patient 38. (a) Biopsy of one of these cervical nodules on 
1st May, 1972 showed prolactin and oestradiol dependence. In 
addition to these nodules hepatomegaly was also present. 
(b) After treatment with ICI 46474 the patient was still in 
good health when last seen in March, 1973. The remaining 
nodules in the neck had regressed, as had the hepatomegaly. 
78 
objective remission and remains well with no active disease 7 months 
later (Fig. 20). Patient 47, 71 years of age, presented with a 
Stage IV carcinoma of the left breast in June, 1972. Biopsy and 
testing showed dependence on prolactin only. The primary lesion was 
treated with radiotherapy and the patient was then given !CI 46474 for 
the disseminated disease. There has been good objective regression 
and 11 months later she remains well on the drug. 
The Effect of an Oestrogen-Blocking Drug 
!CI 46474 ('Tamoxifen') is the trans-isomer of l(p-beta-dimethyl-
amino-ethoxy-phenyl)-1,2-diphenylbut-l-ene, a non-steroid preparation 
which is a potent anti-oestrogen in several mammalian species including 
Man. It is believed to act by competitive interference with oestradiol 
uptake at various sites. IC! 46474 has been shown to be useful in the 
management of disseminated breast carcinoma (Cole et al., 1971; Ward, 
1973). Although its main action is that of a peripheral oestrogen 
blocker, the possibility that it will also inhibit oestrogen production 
cannot be excluded on present evidence. Similarly, it is very likely 
that by blocking oestrogen receptors in the pituitary and hypothalamus, 
!CI 46474 may be able to interfere with feedback mechanisms for the 
secretion of prolactin and other pituitary hormones (Walpole, 1973). 
This is therefore another tantalising glimpse of potential hormonal manipu-
lations at a level far more sophisticated than would have seemed possible 
a few years ago. 
Complex Interactions of Prolactin and Oestrogens 
Further difficulties in understanding the precise nature of 
prolactin's and oestrogen's effects on breast tumours need to be 
mentioned. For ill-understood reasons, believed to involve stimulation 
of differential growth of the mammary epithelium induced by prolactin, 
elevation of prolactin levels immediately around the time of administering 
a carcinogen like DMBA to a rat can protect the mammary gland from the 
action of the carcinogen (Meites, 1972). Similarly, administration of 
oestrogen (Huggins, 1965) at this crucial stage also protects the rat 
mammary epithelium against DMBA's carcinogenic action, undoubtedly 
acting at least in part by stimulating prolactin secretion. Each of 
these treatments, perplexingly enough, has been shown to promote growth 
of mammary cancers already present as a result of DMBA induction. 
Hilf et al. (1971) have raised another problem by showing that in 
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the R3230AC mammary tumour in Fischer rats, a different model from 
the DMBA tumour in Sprague-Dawley rats, treatment with fluphenazine, 
(a phenothiazine), which increases prolactin secretion, is accompanied 
by marked growth and secretion in the normal mammary tissue, yet 
regression in the mammary tumours. This effect was enhanced by 
oestrogens. Thus, in this animal model, at least, a hormonal milieu 
which stimulates normal mammary gland growth does not of necessity 
stimulate growth of neoplastic mammary tissue. Huseby and Thomas 
(1954) in fact reported that some women with breast cancer experienced 
secretion responses in the normal breast tissue with administration of 
oestrogens, yet a simultaneous decrease in the size of the breast carcinoma. 
Although in the case of rats the majority of authorities feel that 
the 7,12-DMBA tumour is essentially a prolactin-dependent one, Dao and 
Sinha (1972) stated at the Tenovus Symposium on prolactin and carcino-
genesis that median eminence lesions, which greatly elevate prolactin 
secretion, were nonetheless unable to stimulate tumour growth unless 
ovaries were present, and if they had been previously removed then ovarian 
grafting allowed further progression of the mammary tumours. Dao felt 
that both oestrogen and prolactin are needed for these DMBA tumours in 
rats and that it is difficult to assign primary importance to one or the 
other. In the ensuing discussion Pearson disagreed, since with per-
phenazine administration alone in ovariectomised rats, (i.e. raising 
the prolactin secretion), the tumours did progress, but Meites took a 
middle course stating that they did go on for a while but that after 15-
18 days they stopped growing and at that stage required oestrogen as well. 
Pearson admitted this possibility and it was further agreed that there 
might be some differences in the liability of different strains of 
Sprague-Dawley rats to develop the DMBA-induced tumour. 
The Effects of High Doses of Oestrogen 
There is considerable controversy about the manner in which large 
doses of oestrogens may produce a remission in some cases of breast 
cancer in humans. In 1963 Kim et al. stated that although physiological 
concentrations of oestrogens stimulated prolactin secretion in rats, 
administration of high doses depressed it. He therefore suggested that 
its success in some breast cancer cases was due to a central inhibition 
of prolactin secretion. Meites et al., (1971), however, claim that it 
does not depress prolactin secretion but actually increases it, and feel 
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that the effect is by interference with the direct peripheral action 
of prolactin on the mammary tumour tissue. 
Pearson et al. (1972) supported this hypothesis by ovariectomising 
female rats bearing the DMBA tumour, then re-activating the tumour with 
perphenazine injections, (which produces high prolactin levels by PIF 
suppression), and finally adding high doses of oestradiol benzoate to 
this regime, which produced striking tumour regressions. They felt that 
this was very strong evidence that the action of high doses of oestrogens 
was a peripheral prolactin-blocking one rather than a central effect on 
prolactin secretion. 
One additional new factor needs to be taken into account, namely 
the demonstration by the present study (Flax et al., 1973) that 14 
human breast tumours were dependent on testosterone alone and a further 
10 on testosterone as well as prolactin. This raises the possibility 
that administration of oestrogen to these patients may succeed by 
antagonising testosterone action at tumour cell level. This will be 
discussed in greater detail in the section on testosterone dependence. 
Value of the Present Technique in the Human Situation 
There are thus clearly still many gaps in the understanding of the 
control of prolactin secretion and of the mechanism and site at which 
administration of other hormones or drugs may influence prolactin-
dependent tumours. The dearth of data on factors influencing prolactin 
secretion in humans with breast cancer is not likely to be rapidly 
rectified because the elegant and ingenious controlled situations that 
have been devised in experimental animals cannot be duplicated in patients, 
for obvious reasons. A technique such as the one described in this study 
is therefore all the more valuable because it offers an opportunity to 
study the effects of prolactin on the target tumour itself, at a chosen 
range of concentrations, without grappling with the complexities of 
prolactin secretion in vivo. Furthermore, it indicates which hormone or 
hormones, if any, are directly inhibitory to the tumour itself, without 
involving a debate about central or peripheral sites of action. This 
enabled successful regressions to be achieved by administration of the 
inhibiting hormone, as in patient 46 mentioned previously, without 
attempting to interfere with prolactin secretion. 
The human situation seems to be more complex and more critically 
dependent on concentrations than the DMBA tumour in rats, which is readily 
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stimulated or suppressed by raising or lowering prolactin secretion 
in a simple linear manner. Suppression may certainly be achieved in 
the rat without lowering the levels to anywhere near complete shut-off 
point, which it appears may well be necessary in humans, and which this 
study tends to confirm by demonstrating that prolactin dependence often 
exists at very low concentrations. 
It may be this very factor which has enabled the goal of a 
11 selective medical hypophysectomy 11 for prolactin to elude us up to now, 
whereas in animals this is more easily achieved. It would seem highly 
desirable to pursue vigorously a pharmacological agent that will 
interfere with or block prolactin 1 s action at peripheral tumour cell 
level, rather than influence its secretion via the pituitary or hypo-
thalamus. Here again it is suggested that the present technique 
offers an excellent approach to investigate such agents, which could be 
combined with prolactin in the culture medium in various concentrations and 
compared with cultures in prolactin alone. 
DEPENDENCE ON PROLACTIN AND A STEROID HORMONE 
It will have been noticed in the Results section that a number of 
tumours were dependent on prolactin as well as one or other of the two 
steroid hormones. Interestingly enough, there has not been a single 
tumour over the past 15 months that has exhibited dependence on all 
three hormones tested. This is pertinent in that it suggests that 
those breast cancers which are promoted by a steroid hormone, may 
require an androgen or an oestrogen but not both. The fact that some 
breast tumours may be dependent on more than one hormone goes some way 
to explaining the failure of endocrine therapy in 2 cases out of 3 
selected on the usual clinical guidelines. 
This is a new concept and raises interesting problems in treatment. 
In some patients counter-measures to one of the two hormones may 
produce a good regression, and this can sometimes be rationalised in 
terms of a known feed-back mechanism. For example, patient 38, whom 
I have mentioned earlier, had a tumour which was dependent in vitro 
on oestradiol and prolactin. ICI 46474 alone produced a good regression, 
probably operating as a peripheral oestrogen blocker and possibly also 
by interfering with feed-back stimulation of prolactin secretion 
centrally. In other cases it is more difficult to postulate a mechanism. 
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Although the precise nature of the interaction between prolactin 
and the steroid remains uncertain, it is suggested that when one learns 
from the test that two hormones are capable of enhancing the growth and 
activity of the tumour, one has the option of employing manoeuvres which 
will counter or remove one or both. It may well be that simultaneous 
attack on both hormones will produce a higher regression rate than 
concentrating on only one, which could permit a tumour cell population 
dependent on the other to flourish. Conversely, in the event of the 
third hormone being strikingly inhibitory to the tumour, the test offers 
the chance of administering that to the patient. It is thus hoped that 
a more rational approach to hormonal therapy may result from this type 
of in vitro technique. 
OESTRADIOL DEPENDENCE 
A relatively small proportion of patients were dependent on 
oestradiol alone. This may be to some extent related to the preponderance 
of postmenopausal patients studied. It should also be borne in mind that 
we now know that patients who respond to o·ophorectomy, anti-oestrogen 
drugs or a radiation menopause cannot automatically be considered 
oestrogen-dependent, in that the same treatment may - by lowering 
oestrogens - reduce although probably not abolish prolactin secretion 
by the feedback mechanism. This may affect prolactin-dependent tumours. 
In the oestrogen-dependent group there were again several examples 
of clinical progress bearing out the results of the test. Two will be 
illustrated here. Patient 179, 45 years of age and premenopausal, had 
a left radical mastectomy in 1965 and radiotherapy to a recurrence in 
the scar in 1970. In March, 1973 she presented with a malignant right 
pleural effusion and active left axillary disease. Biopsy on 14th March 
showed oestradiol dependence and a radiation menopause was performed with 
good objective remission. 
Patient 181, 49 years of age and premenopausal, presented in February, 
1973 with a right breast lump and vertebral metastases. Bilateral 
oophorectomy was performed and the breast lump biopsied at the same time. 
Oestradiol dependence was found and it was therefore considered that a 
regression was likely to be achieved, which turned out to be the case. 
At the end of May she was still completely free of pain and with no 
clinical signs of active disease. X-rays show early recalcification of 
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the vertebral metastases. 
VALUE OF THE TEST IN AVOIDING FRUITLESS ABLATIVE SURGERY 
I have made clear in the introductory section that in addition to 
the need to select the patients who will benefit from endocrine-ablative 
surgery, one of the chief aims of a predictive system is to demarcate 
those who are unlikely to respond. It has already been emphasised that 
the present study was concerned with development of a technique rather 
than a clinical trial, and the patients were freely treated by the 
clinicians concerned on the basis of their own conventional practice, 
not on the results of the test. Nevertheless, follow-up of the patients 
showed several situations where the test had very clearly suggested that 
the ablative procedure to be used would fail. 
A typical example was patient number 87, who presented as a pre-
menopausal lady of 47 years with a Stage III carcinoma of the left 
breast in August, 1972 and was treated by radiotherapy. In November, 
1972 a toilet mastectomy was performed. Hormone dependence testing 
on that specimen showed it to be independent, but with poor survival 
in oestradiol and good survival in testosterone, suggesting that 
oophorectomy was contra-indicated and that - if anything - oestrogens 
were inhibiting the tumour. By March, 1973 widespread dissemination 
of the tumour occurred, there having been no other treatment in the 
interim. Since the patient was premenopausal it was decided to perform 
bilateral o'ophorectomy in accordance with the conventional clinical 
guidelines. A skin metastasis was biopsied and re-tested at the same 
time. This confirmed independence with very poor survival in oestradiol 
and good survival in testosterone, i.e. precisely the same result as 
before. As predicted, no remission occurred and indeed the downhill 
course accelerated, with the patient dying of fulminating dissemination 
of the disease a few days after o'ophorectomy. 
This and other examples suggested that clinical guidelines based 
on the menopause were by no means always correct. As indicated in the 
Results, only about two-thirds of premenopausal patients were hormone-
dependent, and not all of those on oestradiol. Conversely, although 
only about a half of the patients over 5 years post-menopausal were 
hormone-dependent, some of those were oestrogen-dependent. The 
potential value of the test, if its early promise is substantiated in 
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forthcoming clinical trials, is obvious. It may suggest a therapeutic 
approach which at times seems to be wholly at variance with the 
convention based on age and menstrual status. For example, in the 
young, premenstrual patient discussed above, oestrogen administration 
rather than removal would have been suggested by the result, and 
certainly the rapid decline after oophorectomy hints that this procedure 
did more harm than good. 
TESTOSTERONE DEPENDENCE IN HUMAN BREAST CANCER 
An interesting facet of these studies has been the demonstration 
that 14 patients in the series had tumours which were dependent on 
testosterone only in vitro in addition to 10 which were dependent on 
testosterone as well as prolactin. This is not a concept that has 
been explored in any depth up to now in humans, though there is a 
well-known Shionogi androgen-dependent rat breast tumour, described 
by Minesita and Yamaguchi, (1965) which was produced by passaging a 
mammary adenocarcinoma, originally from a female, from one male rat 
to another. It was completely suppressed by oestrogens and Minesita 
and Yamaguchi attributed its androgen dependence to adaptation of the 
tumour cell in parallel with modification of the hormonal milieu 
interieur. They suggested that some cases of recurrence in humans 
might arise by a similar sort of mechanism. 
In human breast cancer, it is well-known that oestrogen admini-
stration may produce some clinical remissions. In considering bi-
lateral adrenalectomy, the conventional view has been that it produces 
a remission in the postmenopausal patient by removing adrenocortical 
oestrogen production, but one could also argue that it removes androgens 
and androgen precursors. Nonetheless, androgen-dependence in the human 
situation has hitherto not been seriously evaluated. In 1942 Farrow 
and Adair showed that carcinoma of the human male breast was an androgen-
dependent tumour, and Farrow and Woodard (1942) claimed exacerbation of 
bony metastases in female breast cancer patients by administration of 
large doses of testosterone propionate, (as assessed by the development 
of hypercalcaemia). It is however now well-known that oestrogen as 
well as androgen administration can produce hypercalcaemia in these 
patients, and Jessiman et al. (1963) have clearly shown that it may 
arise spontaneously in the course of the disease without administration 
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of any steroids. Thus development of hypercalcaemia per se cannot 
be taken as evidence that actual tumour growth has been stimulated. 
Although interest in steroid uptake by breast tumours centred 
on oestrogens in the 1960 1 s, Deshpande et al. (1963, 1966) did show 
that certain breast tumours concentrated testosterone, and Braunsberg 
et al. (1967a and b), though they found only l breast tumour in 10 
that concentrated testosterone rather than oestradiol, conceded that 
there might be a small proportion of human breast cancers that did so. 
Adams and Wong (1968) clearly demonstrated the ability of breast cancers 
to metabolise testosterone actively and recently Jenkins and Ash (1973) 
showed that the formation of 5-alpha-dihydrotestosterone was greatest 
in the most undifferentiated breast carcinomas but did not occur in 
normal breast tissue. Even more recently Miller et al. (1973) have 
claimed that this conversion occurs, albeit to a very minute extent, 
in normal breast tissue as well. 
Clinical Examples Supporting A Testosterone Dependence Hypothesis 
It was therefore very interesting to observe that in the present 
study 14 tumours specifically showed dependence on testosterone only 
and not on the other two hormones tested (Flax et al., 1973). It is 
relevant that 13 of the 14 patients were postmenopausal at the time of 
testing, while the fourteenth had been treated with an androgen for 
several months before testing. Six of the 14 had been treated with 
androgens or some other form of anti-oestrogenic therapy, (such as a 
surgical or radiation castration or an anti-oestrogen drug), prior to 
testing their hormonal dependence. This was highly suggestive that the 
tumours had adapted themselves to live in an altered hormonal milieu, much 
like the Shionogi rat tumour model. A further 6 of the 14, all post-
menopausal, had tumours which were testosterone-dependent without any 
previous hormonal treatment, which may indicate that a certain proport-
ion of breast cancers in postmenopausal women may be androgen-dependent 
ab initio, and that the menopause itself, like the administration of 
artificial anti-oestrogenic measures, may bring about precisely the sort 
of modification in the hormonal milieu that we are discussing. 
Strong support for the testosterone-dependence hypothesis also 
came from the clinical progress. Patient 111, 76 years of age, for 
example, had had her menopause at 40. In September, 1970 she under-
went simple mastectomy and post-operative radiotherapy for a right 
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breast carcinoma. In October, 1972 several small nodules recurred 
near the scar. On biopsy these were shown to be testosterone 
dependent with complete death of the tumour in oestradiol. Ethinyl 
oestradiol l mg daily was commenced as anti-androgenic treatment and 
there was excellent objective regression. The patient remains well 
with no signs of recurrence at the time of writing in June, 1973. 
Patient 42, 62 years of age and over 5 years post-menopausal, 
was a similar example. She presented in May, 1972 with a large Stage 
III carcinoma of the left breast. Biopsy revealed the carcinoma to 
be testosterone dependent and also to be markedly inhibited by 
oestradiol. She was treated only with ethinyl oestradiol l mg daily 
as anti-androgenic treatment. No radiotherapy was given. There was 
an excellent objective remission, with the residual lump and the 
axillary nodes shrinking and disappearing completely. She remains 
well with no signs of disease in June, 1973. 
Patient 92, a 62 year old lady who had had the menopause at 
50, illustrated a different form of successful anti-androgenic 
therapy. She had had a simple mastectomy followed by radiotherapy 
for a left breast carcinoma in August, 1969. In October, 1971 a 
mass appeared in the supraclavicular fossa and the anti-oestrogen 
ICI 46474 was administered. In due course the mass disappeared 
completely. In July, 1972 it recurred together with an axillary 
node, which was biopsied and showed testosterone dependence, though 
with fair survival in oestradiol as well. Adrenalectomy was performed 
as an anti-androgenic measure and this brought about excellent 
objective remission which is still maintained. 
Adaptation After Previous Oestrogen Dependence 
The last patient, no. 92, like several others in the group, 
illustrates a further important aspect of testosterone dependence. 
There are good clinical grounds for suspecting that these tumours 
had adapted themselves after having been originally oestrogen-
dependent. Patient 92 1 s tumour had shown an excellent response to 
anti-oestrogenic therapy for many months before recurring and being 
shown to be testosterone-dependent. Similarly, patient 24 was a 
lady whose tumour growth had previously been stimulated by stil-
boestrol and controlled by durabolin administration. When the 
tumour subsequently escaped from control after several months of 
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treatment with durabolin, testing showed testosterone dependence. 
Two more patients, numbers 82 and 31, had had previous excellent 
objective responses to radiation and surgical menopause respectively, 
before the disease later escaped from control and was found to be 
testosterone-dependent. Patient 82 was interesting from another point 
of view as well, in that after her successful radiation menopause 
she had then had a very successful trans-ethmoidal hypophysectomy, 
which gave her 2! years free of active disease. It was only when the 
disease flared up yet again that it was biopsied and shown to be 
testosterone dependent. (A further excellent remission was obtained 
by ethinyl oestradiol, but since local radiotherapy was also given to 
the lesion it cannot be counted as a success of purely hormonal 
treatment.) 
It is interesting and relevant that in this culture system the 
effects of oestradiol and testosterone were not necessarily dia-
metrically opposed, though sometimes they were, as illustrated in 
the first two examples above. Patients 103 and 31 showed testosterone 
dependence of their lesions but they also survived moderately well in 
oestradiol. It was accordingly anticipated that oestradiol administration 
would not benefit either patient. As it transpired, oestradiol was 
among the hormonal treatments tried by the clinicians concerned in both 
patients and neither achieved a remission. 
Most androgen production in the female is derived either directly 
or via precursors from the adrenal cortex, although in the case of 
breast cancer patients there may be some para-endocrine activity and 
androgen synthesis by the tumour itself. Although thus far only one 
patient in this group has undergone adrenalectomy with the deliberate 
intention of reducing androgen production, (followed by a successful 
remission,) the findings lead one to wonder whether this may not be the 
principal underlying mechanism of at least some successful adrena-
lectomies? 
Certain testosterone antagonists such as cyproterone acetate 
are now available and it is intended to test these by our in vitro 
technique to investigate their effects on testosterone-dependent 
breast cancers. 
We are left, then, with the impression that at a given time a 
human breast cancer may well be androgen-dependent, that this is 
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invariably after the menopause, {which naturally diminishes oestrogen 
production,) or at least after anti-oestrogenic treatment, and that it 
may even be a feature of a tumour which earlier in its natural history 
had shown an excellent response to anti-oestrogenic measures. This 
leads persuasively to the concept that these tumours have a dynamic 
capacity for adapting themselves to the prevailing hormonal milieu, 
and that this may explain the common clinical phenomenon of a particular 
hormone producing a good regression, followed by further successful 
control of a recurrence with an opposing hormone. It must obviously 
be remembered that the actions of all hormones are central via intricate 
endocrine feedback pathways as well as peripheral, and we have already 
seen how complex and controversial is the interaction of oestrogens and 
prolactin. Furthermore, testosterone may well be converted to some 
other final active metabolite for use by the cell. However, this in 
vitro technique strongly supports an androgen-dependence hypothesis 
by showing that only testosterone and neither oestradiol nor prolactin 
have enhanced the activity of these tumours, and this has tallied 
fairly closely with the clinical progress. 
HORMONAL TREATMENT IN THE 11 INDEPENDENT 11 CASES 
I have explained earlier that 11 independence 11 of a tumour, i.e. 
failure to show higher activity of the pentose shunt pathway and 
good survival compared with both controls, did not necessarily 
preclude some hormone-responsiveness in vitro nor a clinical response 
to appropriate hormonal treatment. An independent tumour could 
survive very well in all three hormones, very badly in all three, or 
variably. It was in the tumours that had responded variably in vitro 
that there appeared to be the greatest likelihood of applying the 
information usefully, either by attempting to suppress or oppose a 
hormone in which the tumour had fared a good deal better than the 
medium control, or by administering the hormone in which the tumour 
had fared even worse than the medium control. 
Correct Prediction of Unresponsiveness to Hormones 
Typical examples of patients who might have been expected not to 
respond on the basis of the vitro studies and who in fact achieved 
no regression on trials of hormonal therapy were numbers 26, 68, 86 and 
114. In all these the tumours had survived more or less equally in all 
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the hormones tested, and in no case had any particular slice survived 
much better or much worse than the medium control. These patients 
received a variety of hormonal treatments, including oestrogens, 
norethisterone, ICI 46474, oophorectomy and androgens, but none of 
them achieved any remission. All had to be treated with chemotherapy 
and as a matter of fact two of the four were dead of disseminated 
disease within less than a year after biopsy and culture, while the 
remaining two (114 and 68) are poorly-controlled and deteriorating in 
spite of cytotoxic drugs within 6 months of testing. It will only 
emerge from a prospective clinical trial whether those cases that 
fail to respond to hormones in vitro have a much worse prognosis than 
those that do, but these examples suggest it. 
Anticipated Failure of Incorrect Treatment 
As in the case of dependent cases who did not respond clinically 
when given inappropriate treatment, there were several independent 
cases who behaved in the same way. Patient 29 1s tumour was found to 
be independent but inhibited markedly by oestradiol. The selected 
hormonal treatment was norethisterone, which failed to produce a 
remission. The patient died 4 months after testing. Patient 54 
had an independent tumour which was inhibited by testosterone. 
Androgens were not given, however, although norethisterone was. This 
failed to produce a remission and 6 months after testing the patient 
developed a hemiplegia due to a cerebral metastasis. I have already 
referred to patient 87, who was tested twice with an intervening 
interval of 4 months. Although independent on both occasions, both 
tests showed that oestrogens were if anything inhibiting the tumour 
while it survived well in testosterone. Despite this, the patient was 
subjected to oophorectomy because she was pre-menopausal, and 
deteriorated and died remarkably rapidly post-operatively. 
Correct Prediction of Successful Treatment 
Finally, there was a number of examples of patients with independent 
tumours who responded very well indeed to treatment that corresponded to 
the in vitro testing. Patient 59 1 s tumour showed complete death in 
testosterone and good survival in oestradiol. This lady of 76 had 
multiple advancing carcinomata in each breast. She was given nor-
ethisterone and prednisone with complete failure to obtain a remission, 
but on the strength of the test the norethisterone was replaced with the 
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androgen deca-durabolin and the patient achieved an outstanding 
remission. After presenting in Stage IV in May, 1972 and undergoing 
biopsy in July, 1972, at which time her treatment was changed to an 
androgen, she remains well and symptom-free in June, 1973. 
Patient 78, 83 years of age, presented in August, 1972 with an 
ulcerating carcinoma of the right breast. On testing this appeared 
to be independent but completely inhibited by oestradiol. This was 
administered and she had an excellent objective regression lasting 
from August, 1972 to February, 1973, when pain due to a metastasis 
developed in the sacra-iliac area. It is emphasised once again that 
in the clinical examples I have been mentioning, only cases where 
hormonal therapy on its own can be evaluated are included. No 
examples of regression or failure of regression have been used where 
there has been any form of adjuvant therapy like irradiation or 
cytotoxic drugs. 
Patient 30, 79 years of age, had noticed a right breast lump 
in January, 1972 and by the time she presented in April, 1972 there 
was gross fungation. Biopsy and testing showed the tumour to be 
independent but to be inhibited by androgens. A full course of 
radiotherapy between the 8th and 26th May completely failed to control 
the tumour or stop the fungation and durabolin was commenced on 
31st July in view of the result of the test. An outstanding remission 
was obtained and by the beginning of October, 1972 the florid 
ulcerating lesion had completely healed. (Fig.21) This regression 
was maintained on durabolin therapy until the end of April, 1973, 
when satellite lesions began to appear round the original tumour. 
Patient 140, 59 years of age, had received radiotherapy to a 
Stage III right breast carcinoma in August, 1970, followed by a toilet 
mastectomy in October of the same year. By December, 1972 there was 
advancing local disease on the chest wall and radiological evidence of 
pulmonary metastases and a pleural effusion. Biopsy and culture showed 
that although the tumour was independent, it had been inhibited by 
oestradiol while it had survived fairly well in prolactin. She was 
accordingly given stilboestrol and also prednisone, which might 
possibly have lowered prolactin by a pituitary suppressing effect. 
An excellent objective regression of her disease ensued; by May, 1973 




Figure 21: Patient 30 . 
(a) On the 19th May, 1972 this fungating tumour was biopsied 
and shown to be independent, but also to be inhibited by 
testosterone. 
(b) Despite treatment with radiotherapy from 8th to 26th May the 
lesion advanced, as this photograph taken at the end of the 
course shows. More than 2 months later there was still no 
delayed response to radiotherapy. 
(c) In view of the result of the test, treatment with durabolin 
was commenced on 31st July, 1973. An outstanding regression was 
achieved and maintained, as this photograph taken on 26th March, 
1973 shows. 
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pulmonary lesions also appeared to be regressing. 
I feel that the above examples illustrate my earlier statement 
that the Independent group of tumours covers a spectrum ranging from 
those who are very unlikely to benefit from any form of hormonal 
treatment to those who may well achieve outstanding objective regressions. 
Furthermore, the test has seemed to indicate a specific successful line 
of treatment based on a rational experimental method. It may turn out 
to be more convenient to express the results as a "hormonal profile" 
rather than in terms of dependence. At the same time, in spite of 
many examples of success, I cannot emphasise too strongly that the pit-
falls in translating an in vitro test to an in vivo situation are legion, 
and that final proof of the usefulness of the test in clinical practice 
must await the outcome of formal rigorously-controlled prospective 
clinical trials, which are now being undertaken at the Westminster 
Hospital. 
- PATIENTS TESTED TWICE AT DIFFERENT STAGES OF THEIR DISEASE 
Up to the time of writing 6 patients who have been included in the 
series of 150 have had second biopsies and tests, the results of which 
are pertinent in relation to the treatment they had received in the 
interim. For the purposes of the Results Tables, only the first biopsy 
was included, so that they apply to l biopsy each on 150 separate 
patients. The results of the second biopsies are described below. 
Patient 69 has already been mentioned in the section on prolactin 
dependence. After testing in July, 1972 had showed independence of the 
tumour with no useful variation in survival to suggest possible hormonal 
treatment, she was treated for the rest of the year with prednisone and 
5-fluoro-uracil. This failed to control the local and bony disease and 
by January, 1973 the lesions were progressing rapidly. Other combinations 
of chemotherapy also failed to produce a regression and the biopsy was 
repeated in March, 1973. This time the tumour turned out to be dependent 
on testosterone and on prolactin. We have already seen that hypophysectomy 
produced only a transient subjective improvement, followed by further 
inexorable progress of the disease. Prolactin levels, however, showed that 
the hypophysectomy had been incomplete. In this case it is difficult to 
see why the tumour should change from being independent to prolactin and 
testosterone-dependent. It is conceivable that the characteristics of her 
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tumour might have altered as a result of 6 months of cytotoxic 
treatment or that more than one line of cells existed. 
Patient 70 has also been discussed in detail in the section on 
prolactin dependence. In her case there had been no qualitative 
difference in the result of the test, with inhibition by oestradiol 
and good survival in prolactin in both instances. However, there 
was a quantitative difference in that in the second test the survival 
in prolactin had been so good as to have been classified as dependent. 
This enabled a more confident recommendation of hypophysectomy to be 
made. The operation was in due course carried out with an outstanding 
result. 
Patient 24 was discussed in the section on testosterone dependence. 
After having had a right mastectomy in 1955, axillary disease recurred 
in 1963 and a series of hormonal manoeuvres followed, including 
oophorectomy in 1964, stilboestrol in 1971, (which definitely stimulated 
the tumour,) and a year of durabolin up to March. At this stage biopsy 
of the tumour, which was out of control, showed testosterone dependence 
but with fair survival in prolactin as well, though not good enough to 
be deemed dependent. The axillary disease was treated by extensive 
resection and grafting and the durabolin was discontinued. She then 
remained well until March, 1973 when further metastases developed on 
the right arm. At this stage repeat biopsy and testing were carried 
out, confirming that the tumour was again testosterone dependent, but 
this time it was clearly prolactin-dependent as well. A trans-
ethmoidal hypophysectomy was performed in May, 1973 and at the time of 
writing an evaluation of the result is awaited. 
Patient 87 has previously been cited as an example of the use of 
the test in avoiding fruitless ablative surgery. Her first biopsy 
suggested that oestrogens were inhibiting the tumour and testosterone 
permitting it to survive well, despite the fact that she was pre-
menopausal. This would have tended to contra-indicate oophorectomy. 
When her disease spread, however, oophorectomy was nonetheless performed, 
on the usual clinical guidelines, and a repeat biopsy of a skin nodule 
was taken at the same time. (There had been no other treatment in the 
interim 4 months.) The result was identical to the first and seems to 
have been vindicated in that the operation appeared to accelerate the 
patient's downhill course and early demise. 
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Patient 95, a lady of 70 years of age, had had a right radical 
mastectomy in July, 1967. From November, 1970 she was under treatment 
for recurrent chest wall and axillary disease. In April, 1971 she 
was given the anti-oestrogen ICI 46474 with possibly slight diminution 
in the size of the nodules but no sustained regression. In September, 
1972 testing showed dependence on oestradiol and prolactin. Treatment 
was changed to prednisone and durabolin, but after a transient 
improvement more nodules began growing. In January, 1973 repeat biopsy 
showed prolactin dependence only. It is tempting to speculate whether 
several months of treatment with durabolin might have altered the 
hormonal milieu in such a way as to modify the tumour 1 s original 
dependence on both prolactin and oestradiol to prolactin only. Hypo-
physectomy is at present being considered for this patient. 
Patient 106, 57 years of age, was treated by simple mastectomy and 
radiotherapy for a right breast carcinoma in October, 1969. After 
excision of a skin recurrence on the right shoulder in June, 1971 she 
was put on to ICI 46474. In September, 1972 a further recurrence 
appeared on the left shoulder. On excision biopsy and culture this 
showed oestradiol and prolactin dependence. The ICI 46474 was continued 
as anti-oestrogenic treatment (and possibly as anti-prolactin treatment 
as well by the feedback mechanism), but over the next few months a 
further nodule developed in the biopsy scar. Repeat excision biopsy 
and testing were carried out in January, 1973 and this time the tumour 
was dependent on testosterone and prolactin, instead of oestradiol and 
prolactin as it had been 5 months previously. Had the prolonged course 
of anti-oestrogenic treatment caused the tumour to modify its character-
istics? At the time of writing the patient is being considered for 
hypophysectomy. 
In this small group of 6 patients, therefore, only one (no. 87) 
had had no hormonal treatment between the two tests and the result on 
both occasions was identical. In the other patients the results -
while reasonably similar - showed some signs that hormonal treatment 
between the two tests had altered the characteristics of the tumour in 
what would seem a fairly logical manner, although in the case of patient 
69 it is difficult to explain why the tumour changed from being independent 
to prolactin-dependent. As the follow-up period of the whole group of 
150 patient lengthens, there should be further opportunities to perform 
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repeat biopsies and in vitro testing. If the results correlate with 
the response to treatment then this would offer the prospect of 
monitoring the natural history of the disease and changing to the 
appropriate hormone pari passu with any alteration of dependence of 
the tumour. 
LABILE RESPONSE OF THE TUMOUR TO AN ALTERING HORMONAL MILIEU 
Since hormonal treatment was first used in breast cancer patients, 
it has been observed that successive regressions could sometimes be 
obtained with opposing hormones, or even by stopping the administration 
of a particular hormone once the disease had escaped from its control 
after a period of worthwhile regression, (the "rebound" phenomenon). 
This has been observed in several of the 150 patients in the present 
study and the phenomenon is made more interesting by the availability 
of in vitro hormone studies. 
I have already indicated in detail in the discussion on testosterone 
dependence how 4 of the patients described there had in fact had good 
objective regressions on anti-oestrogenic therapy earlier in the natural 
history of their disease. Later, when the disease was again out of 
control and testing was carried out, it was found to be testosterone-
dependent and responded to anti-androgenic measures. It was also 
pointed out that all the patients whose primary tumours were testosterone-
dependent ab initio were in the post-menopausal age-group, suggesting 
that the menopause itself had altered the relationships of the various 
hormones in the milieu interieur. Finally, the preceding section 
indicates that in the few patients whose tumours were tested twice, there 
were signs that a few months of treatment might modify the hormone-
dependence according to the hormone administered. 
In addition to the above observations, the results of the present 
study show that the lowest incidence of hormone-dependence was around 
the menopause, which correlates with clinical experience. The menopause 
is a phase when profound hormonal re-adjustments are taking place before 
there is a stabilisation to a definitive post-menopausal pattern. Five 
years and more after the menopause the incidence of hormone-dependence 
again rises. 
One is thus clearly led towards the conclusion that a given breast 
cancer cannot be assigned a permanent immutable label of dependence on 
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a particular hormone once and for all. It appears instead much more 
likely that the tumour is readily able to adapt itself to changes in 
the hormonal milieu. This lability would explain many of the apparent 
paradoxes that have been observed by clinicians treating these patients 
with hormonal therapy. One of the most interesting aspects of the 
present study is that the in vitro findings seem to correlate well in 
a number of cases with the vagaries of the clinical response. The 
changes in the hormonal milieu could come about through hormonal treat-
ment or through the menopause, and there might in addition be further 
alterations with progressive ageing, related to hypothalamic and 
pituitary function. Furthermore, these changes would operate within a 
physiological range, and not at raised levels. 
One further fascinating speculation that might be mentioned here 
is the effect of cortical influences, stress and emotion on breast 
tumours. Every clinician has come across patients who insist that the 
initial appearance, or the sudden aggravation of their disease, was 
closely related to physical or more especially emotional trauma. We 
have been trained to treat these assertions with a good deal of reserve, 
to say the least, which has been very proper in view of our imperfect 
understanding of the disease. However, there is now indisputable 
evidence that the hypothalamus does affect anterior pituitary function, 
and hence prolactin and other polypeptide hormone release, including the 
gonadotrophins. In view of the equally convincing evidence that cortical 
(i.e. conscious) influences can control hypothalamic function, may there 
not occasionally be a grain of truth in claims of exacerbation of the 
disease by stress? Could cortico-hypothalamic pathways explain the 
heretical claims of apparent tumour regression through faith alone? 
CLINICAL USEFULNESS OF THE TEST 
Monitoring the Natural History of the Disease 
The beauty of the technique described, if forthcoming clinical 
trials unequivocally support its applicability to the in vivo situation, 
is that it will afford us for the first time an opportunity to monitor 
the course of the disease scientifically in the laboratory. Furthermore, 
instead of providing a broad non-specific result like oestrogen receptor 
or urinary discriminant techniques, which aim simply to predict whether 
the tumour is likely to respond to hormonal treatment in general, this 
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test indicates a specific choice of treatment. Being simple to carry 
out and giving a result within about 26 hours, it would be reasonable 
to perform a minor biopsy under local anaesthetic whenever the disease 
escapes from control with a particular hormone. 
Studies on Metastases 
The method also affords us an opportunity of studying metastases 
at different sites. It is well-known that on a particular treatment 
metastases may respond well in one site yet continue growing in 
another. Patient 70 was one such example in this series, where the 
breast disease regressed strikingly on oestradiol therapy, yet the 
bony disease progressed. However, a hypophysectomy to remove prolactin, 
as indicated by the test, resulted in excellent regression of all 
metastases. 
There are certain aspects to this problem of metastases which 
have not yet been investigated in this system. In the first place, 
since the technique depends on the culture of intact slices of tumour, 
no evaluation of in vitro hormone dependence has been made for malignant 
pleural and peritoneal effusions. Secondly, although the technique 
has been successfully applied to primary tumours and metastases in skin, 
soft tissues, lymph nodes and viscera, it has only been used in 3 cases 
(not included in this series) of bone metastases. The technique was 
successful in these 3 cases, where the bone had been largely replaced 
by tumour, but there is a problem in evaluating results for bone in 
that the marrow contains rapidly-proliferating haemopoietic and lymphoid 
system cells which also have a very active pentose shunt pathway. There 
would therefore be difficulty in distinguishing neoplastic and other 
normal bone-marrow cells with the histochemical technique used. This 
difficulty would become proportionately less the more completely an 
area of bone is replaced by tumour. In one such patient, not included 
in the series, culture of a rib segment almost completely replaced by 
tumour showed very good survival in testosterone. The clinician elected 
to perform a bilateral adrenalectomy on the strength of this result and 
an excellent objective regression lasting 7 months up to now was obtained. 
However, at present the use of the technique for bone biopsies still 
needs further evaluation and possibly considerable modification. 
Adjuvant Hormonal Treatment 
A further advantage of an accurate prediction system would be its 
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use in considering appropriate adjuvant hormonal treatment at the 
time of primary surgery or radiotherapy. Although at the present 
time it is thought that adjuvant treatment such as prophylactic 
castration may possibly delay the appearance of metastases, it is 
generally agreed that it is not likely to increase the overall life-
expectancy of the patient. It is conceivable, if an accurate prediction 
were available, that tailoring the hormonal therapy to the individual 
tumour might improve the overall situation. Again, only long-term 
clinical trials will give the answer to this question. Being able to 
pinpoint the exact hormonal therapy might also enable us at some future 
date to lessen the scope of the present mutilating surgery for breast 
cancer, particularly now that there is a better understanding of the 
hypothalamic and pituitary factors involved, which may lead to specific 
pharmacological antagonists. 
CLINICAL CORRELATION 
I have emphasised previously that this project was concerned with 
the development of a technique to study hormone dependence of breast 
cancer in vitro, and that although the progress of the patients 
involved was kept under surveillance, this could under no circumstances 
be considered a clinical trial. There were no protocols of selection 
or treatment and a variety of clinicians employed a wide range of 
therapeutic manoeuvres, including combinations of hormones. If the 
technique is to be proved valuable in predicting response to specific 
hormonal therapy, a long-term prospective evaluation will of course 
be necessary. Before deciding whether to embark on such a formal trial, 
it is therefore relevant to attempt to assess, albeit retrospectively, 
the clinical correlation in these first 150 patients. 
In the first place, all patients in the series who have hitherto 
had no hormonal treatment at all following the test must obviously be 
excluded from the evaluation. The same applies to patients on no 
treatment at all and to those who received other treatment such as 
irradiation or cytotoxic drugs concurrently with hormonal treatment. 
The vast majority of the patients are therefore excluded for these 
reasons. Forty-six patients remain in whom it is possible to assess 
the results of hormonal therapy alone, whatever its nature. 
Since the mode of action of a number of hormones on a tumour and 
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on feedback mechanisms is ill-understood, it is impossible to 
interpret the effects of progestogen and corticosteroid admini-
stration in terms of oestradiol, testosterone or prolactin dep-
endence. The same problem also arises in the case of experimental 
new drugs such as CB154. Finally, since the result of the test was 
available and was often used by the clinician as an additional aid 
to selecting treatment, it is clearly impossible to analyse the 
figures as one would a random trial. 
Results 
Twenty-two of the 46 patients had achieved an objective regression 
on hormonal therapy and 24 had not. In 6 of the 46 it was difficult 
to correlate the clinical response with the test, for example, where 
prednisone had been used alone or in combination with another hormone. 
In the remaining 40 it was possible to evaluate treatment in terms of 
the test. As explained previously, the test could either indicate 
which of the three hormones to remove or counter, or which inhibitory 
hormone to administer. Bilateral oophorectomy, radiation menopause, 
administration of androgens and administration of ICI 46474 were 
accepted as anti-oestrogenic measures; oestrogen administration and 
bilateral adrenalectomy as anti-androgenic measures, and hypophysectomy 
as an anti-prolactin measure. 
"Positive Correlation" 
Nineteen of the 40 patients achieved a good objective regression 
on treatment which corresponded with that indicated by the test. 
"Negative Correlation" 
Seventeen of the 40 patients fared badly and failed to obtain a 
regression on treatment which was contra-indicated by the test. In 5 
of these cases the test result had shown that no hormonal treatment was 
likely to be effective, whereas in the remainder the indicated line of 
treatment was different and often opposite to that chosen by the 
clinician. 
Thus in 36 of this small group of 40 cases there appears to have 
been good correlation with the prediction of the test. In the remaining 
4 patients the prediction of the test turned out to be wrong, 
For the reasons mentioned, this preliminary retrospective evaluation 
of the test is obviously unsuitable for statistical analysis, but the 
extremely high correlation rate (90%) is certainly promising. On the 
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strength of these very encouraging results, a formal prospective 
trial is now commencing at the Westminister Hospital. 
USE OF THE METHOD FOR OTHER TUMOURS 
Benign Breast Lumps 
Before giving some examples of the use of the technique for tumours 
other than in the breast, it is interesting to take note of the results 
in a few benign cases not included in the series, that were studied at 
the beginning of the project. Six benign breast lesions were cultured 
by exactly the same technique, three fibroadenotic lumps and three 
fibroadenomata. The initial controls of all three fibroadenotic lumps 
showed zero activity on histochemistry, confirming that the pentose 
shunt pathway proceeds at a much slower rate in normal or slowly-
proliferating tissues than in malignant, rapidly-proliferating ones. 
One of these fibroadenosis cultures showed considerably enhanced 
activity in the presence of oestradiol. 
Two of the three fibroadenomata showed little and no activity 
respectively in the initial controls, though one of them was again 
enhanced by oestradiol. The third raised a very interesting problem; 
the patient had presented with what was thought to be a Stage III 
carcinoma of the breast and was treated by radiotherapy. She was 
later referred for toilet mastectomy for the residual lump and the 
histology resembled a fibroadenoma more than carcinoma, although 
there was some controversy about the definitive diagnosis. The 
clinicians still thought that this was very likely to have been a 
carcinoma and have kept the patient under regular surveillance. To 
date she has not yet had a recurrence, the mastectomy having been 
performed in February, 1972. The interesting feature of this tumour 
on testing was that it showed very good survival and activity in the 
initial control, no activity in the medium control, and even higher 
activity with oestradiol; in other words, it was oestradiol-dependent 
by the criteria used. The very good survival of the initial control 
suggested that the pentose shunt was operating vigorously in the tumour 
in vivo, and therefore to some extent supported the clinical impression 
that this may have been a malignant tumour after all. 
Male Breast Carcinoma 
One male breast carcinoma has been studied by this technique, 
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(also not included in the 150). This 60 year old man had a right 
radical mastectomy for a Stage II infiltrating papillary carcinoma 
in September, 1972. This was followed by radiotherapy. In vitro 
studies on the specimen showed it to be dependent on both testosterone 
and prolactin, although it also survived fairly well in oestradiol. No 
adjuvant hormonal therapy was added and at present in June, 1973 the 
patient has not developed signs of recurrence. I think that this is 
an extremely important result in that it confirms the finding of Farrow 
and Adair (1942) that the human male breast cancer was an androgen-
dependent tumour, but it also suggests that prolactin may play a role 
as well. Kennedy and Kiang (1972) reported two males with disseminated 
breast cancer who each had a good response to orchidectomy and who then 
each had a further excellent objective regression following trans-
frontal hypophysectomy. The crucial observation they made was that 
oestrogen administration had failed to help both patients. The findings 
in the one male case studied by this technique dovetail remarkably well 
with the two described by Kennedy and Kiang. In view of fair survival 
of this tumour in oestradiol, it would be expected that our patient 
would be unlikely to respond to oestrogen administration either, al-
though he ought to respond to orchidectomy if the need arises. It will 
be recalled that in this section on testosterone dependence two cases 
were described where the tumour had survived fairly well in oestradiol 
and therefore failure to respond to oestrogen therapy had been correctly 
anticipated. The point was made that the in vitro effects of oestradiol 
and testosterone were not necessarily diametrically opposed, though 
they often were, and that knowledge of the precise nature of the hormone 
response in vitro would therefore be very advantageous. 
It would also be expected that our patient would respond well to 
trans-frontal hypophysectomy, in view of the prolactin dependence. 
Kennedy and Kiang found that there were relatively few reports of 
hypophysectomy for disseminated male breast cancer in the literature, but 
in spite of the bad reputation of the disease there was probably a 50% 
objective regression rate. They felt that males stood a better chance 
of regression from ablative procedures than females. 
Malignant Melanoma 
Bodenham (1972) has pointed out various features which suggest 
that malignant melanomas may - in some cases - be influenced by 
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hormonal factors, including the rarity of the disease before 
puberty, alterations in growth pattern at puberty, the menopause, 
pregnancy and menstruation, the significantly longer survivals of 
females with the disseminated disease, and finally the favourable 
response of a small number of patients to alterations of the hormonal 
environment, including hypophysectomy, androgen administration and 
oestrogen administration. He pointed out the need for a widely-
applicable method to detect such patients, although they probably 
comprise only a small proportion of melanomas. His technique was 
based on oral administration of radio-phosphorus and measurement of 
tumour uptake by a Geiger probe inserted into the lesion. After 
several days of baseline readings the effects of oestrogen admini-
stration were then observed (Hale, 1961). This technique involved 
practical problems and is not suitable for screening a large number 
of patients. 
It was decided to test the present technique on melanoma patients 
and to this end melanoma biopsies from 11 patients were collected in 
exactly the same way as the breast biopsies and processed in an 
identical manner, excepting that they were each cultured with 4 
concentrations of ethinyl oestradiol and testosterone respectively, 
,o-5, 10-6, ,o-7 and ,o-8M, but not with prolactin. Four of the 
tumours were also cultured with concentrations of adrenocorticotrophin 
(ACTH) respectively. 
Melanomas proved to be an extremely easy tumour to work with in 
this system. Being relatively firm and homogeneous, they were very 
easy to slice by hand and yielded highly cellular cryostat sections. 
The histochemical reaction worked very satisfactorily in all the 11 
cases and confirmed the impression that total dehydrogenase activity 
of the pentose shunt pathway is an excellent marker of neoplastic 
activity. Three tumours showed increased activity in testosterone 
and few in oestradiol, while there was no significant difference 
between the two hormones in the remaining 4 tumours (Flax, Salih 
and Westbury, 1973). 
Other Tumours 
A selection of other tumours has been tested in this system and 
all of the experiments have worked successfully. All of them showed 
either moderately high or very high activity of the pentose shunt in 
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the initial controls, with variable activities in the different 
hormones tested, confirming the usefulness of this pathway as a 
marker for studying neoplastic activity in vitro. The tumours 
included: l hypernephroma, l ovarian adenocarcinoma, l 
arrhenoblastoma, l endometrial stromal sarcoma, 1 soft tissue 
metastasis of a bronchogenic carcinoma, 1 soft tissue myeloma 
deposit and 1 soft tissue metastasis of a rectal carcinoma. A 
very interesting potential application of the method is to prostatic 
carcinoma; the steroid hormones are known to influence the progress 
of some cases and recent research suggests that prolactin may play 
a role as well. 
USE OF THE TECHNIQUE FOR OTHER HORMONES AND PHARMACOLOGICAL AGENTS 
This study has concentrated on the influence of 17-beta-
oestradiol, testosterone and ovine prolactin in maintenance culture 
systems. However, a few other hormones and drugs have also been 
tested and these preliminary surveys have supported the usefulness 
of the system for investigating pharmacological agents. The use of 
human as well as ovine prolactin in a small number of cases has 
already been described. Six breast tumours were also cultured with 
the anti-oestrogenic agent ICI 46474 by exactly the same technique, 
at concentrations corresponding roughly to the recommended dosage 
of 10 mg twice daily; these tests confirmed that at those concentrations 
the drug did indeed behave as an anti-oestrogen. In the case of 
melanomas 4 tumours were also shown to survive very well in various 
concentrations of ACTH, and the system would also be interesting to 
study the effect of beta-MSH, the circulating fraction of the melano-
cyte-stimulating hormone of the pars intermedia. There is every 
reason to expect that the technique could be useful to study the 
effect of a wide range of hormones, hormone antagonists and other 
drugs on a variety of tumours. The technique also offers the 
opportunity of studying the effects on the tumour of two or more 
hormones or a hormone and its antagonist, in a single culture dish. 
This has not yet been investigated in the present study. 
USE OF THE TECHNIQUE FOR HORMONE UPTAKE STUDIES 
Radioactive studies on tumour uptake of various hormones, 
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especially oestrogens, have hitherto been based on single cell 
suspension systems, in which (as discussed earlier) only a pro-
portion of the cells remain viable. Furthermore, one cannot be 
certain which of the survivors are normal and which are tumour 
cells. It will be of considerable interest to label the hormones 
used, (especially prolactin), with radio-active isotopes, and to 
study the reactions on the intact slices both qualitatively and 
quantitatively. This has just been commenced in the present study, 
using 14c-leucine-labelled prolactin. 
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S U M M A R Y 
(l) It is well-known that certain cases of human breast 
cancer are profoundly modified in their behaviour by various 
hormonal influences. 
(2) The actual initiating agent in human breast cancer is 
probably not a hormone and a virus appears to be the likelier 
carcinogen. However, once the malignant change has been initiated, 
hormonal factors play a predominant role as promoters. 
(3) Following the observation in 1896 that bilateral 
oophorectomy benefited some women with disseminated breast cancer, 
a period of some 30 years elapsed before attention was again 
focussed on the role of hormones in the disease. 
(4) Bilateral orchidectomy was noticed to produce regressions 
in some male patients with breast cancer and bilateral adrenalectomy 
and hypophysectomy were in due course shown to have similar beneficial 
effects in a proportion of women with the disseminated disease. 
(5) At the time, and until very recently, the effects of these 
ablative operations were thought to be produced purely via the 
gonadotrophic, adrenocorticotrophic and steroid hormones, but a 
satisfactory rationale was never produced. Modern work suggests 
that the situation may be more complex and that the role of other 
pituitary and hypothalamic factors, particularly the prolactin 
secretion mechanism, may be important. 
(6) At the same time as regressions were being produced by 
the ablative operations, some successes were being obtained by the 
administration of exogenous steroid hormones, both oestrogenic and 
androgenic. 
(7) Experimental methods of tumour induction in animals were 
also being actively investigated and of these the 7,12-DMBA -
induced breast tumour model in rats was particularly useful. 
(8) Although the understanding of the hormonal mechanisms 
involved was imperfect, and although a prediction system for deciding 
which patients were likely to respond to hormonal therapy was not 
available, a set of clinical guidelines based mainly on the menstrual 
status of the patient evolved. 
(9) The conventional approach relied on ovarian ablation in the 
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premenopausal patient and on either an ablative operation 
(adrenalectomy or hypophysectomy) or a wide range of administered 
hormones (oestrogens, androgens, progestogens, corticosteroids) 
in the postmenopausal patient. The patients in the early post-
menopausal years seemed less likely to respond to hormonal 
treatment. 
(10) Experimental animal work in the 1950 1 s showed that 
prolactin might promote the growth of certain rodent breast tumours 
and a few early observations suggested that this applied to human 
breast tumours as well. 
(11) In 1969 it was demonstrated that the DMBA-induced tumour 
in rats was definitely prolactin dependent and a great deal of 
experimental work was carried out to investigate the role of prolactin 
and the control of its secretion in animals. A hypothalamic substance 
called Prolactin Inhibiting Factor (PIF) appeared to be the most 
important controlling mechanism. 
(12) Attention naturally turned to considering whether a similar 
situation might exist in humans and how prolactin secretion might be 
controlled. Many pharmacological agents were found to influence 
prolactin secretion, mainly via PIF, but also by direct pituitary 
action. Of these the most important groups were the phenothiazines, 
which increased prolactin secretion, and certain ergot alkaloids and 
levodopa, which decreased it. 
(13) In 1972 data from the present study showed that in vitro 
the activity of over 30% of human breast cancers was enhanced by 
prolactin. Ovine prolactin, which behaves very similarly to human 
prolactin, was used for most of the experiments, but later tests with 
a small amount of purified human prolactin that became available 
confirmed the findings. 
(14) The evidence for the separate existence of human prolactin 
is summarised; it was only in 1971 that unanimity was reached that it 
did exist independently of human growth hormone, although it had been 
isolated as a separate hormone in other mammals several decades 
previously. The physiological role of prolactin is discussed. 
(15) Data on human prolactin levels in different conditions 
are still scanty and several different assay systems are in operation. 
From data so far available the levels do not appear to be increased in 
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women with breast cancer. 
(16) Only about 1 in 3 patients shows a favourable response 
to hormonal treatment for advanced breast cancer and there is a 
great need for a prediction system to select these. 
(17) Studies on urinary steroid excretion patterns, and 
particularly the Discriminant Function, have been extensively 
investigated, but these have not proved to be sufficiently accurate 
for use with individual patients. 
(18) Important research indicated that certain breast tumours 
showed selective higher uptake of oestrogen and there was some 
evidence that this might correlate with the clinical response. 
However, these studies do not as yet take into account other hormones 
that may be involved and have so far not proved effective as a 
prediction system. 
(19) In spite of attempts to predict response, management of 
hormonal therapy of the patient at present still relies mainly on 
clinical guidelines such as the menstrual status, distribution of 
metastases and disease-free interval. 
(20) The development of cell and organ culture techniques 
permitted in vitro studies of the action of hormones and drugs on 
various tissues, including breast tumours. This approach continues 
to be extensively investigated but as yet no method has been shown 
to have reliable clinical applicability. In general, cell suspension 
techniques have certain major disadvantages in this approach as 
compared with organ culture techniques. 
(21) A technique was developed which utilised short-term 
maintenance cultures of intact breast cancer slices in a fully-
defined synthetic culture medium. Evaluation of survival of the 
tumours was both by histology and by a histochemical technique which 
measured the total dehydrogenase activity of the pentose shunt path-
way. 
(22) It was decided to test the tumours against two experi-
mentally-selected concentrations each of 17-beta-oestradiol, testo-
sterone and prolactin. The concentrations selected, after appropriate 
standardisation experiments, were similar to those used by other 
investigators. 
(23) The techniques of handling the biopsies, setting up the 
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cultures and carrying out the histological and histochemical 
examination are described in detail. 
(24) The system of scoring the survival and activity of the 
tumours is described. It was found convenient to classify a tumour 
as 11 dependent 11 on a particular hormone if it had shown higher activity 
in that hormone than both a medium control and a fresh-frozen un-
cultured control of the tumour immediately after removal from the 
patient. The 11 independent 11 cases covered a spectrum ranging from those 
that had shown no differential responses in the hormones tested to 
those that had either survived very well or been strikingly inhibited by 
a particular hormone. 
(25) No attempt at a clinical trial was made at the start of the 
project, but the progress of all the patients was carefully followed 
and documented in order to evaluate whether there was any useful corre-
lation with the result of the test. 
(26) Seventy nine of the 150 tumours tested satisfied the criteria 
for dependence on one or two of the hormones tested. The most dramatic 
feature was the finding of prolactin dependence in 50 (33%) of the tumours. 
(27) Analysis of the results in relation to menstrual status shows 
that there is a significant change in dependence around the menopause. 
Prolactin and oestradiol dependence are markedly commoner before the 
menopause and testosterone dependence afterwards. 
(28) Hormone dependence is least common in the five years immediately 
following the menopause, which supports the clinical observation that 
hormonal therapy is least effective in this period. 
(29) In the patients whose tumours were tested subsequent to an 
endocrine-ablative procedure, the dependence seemed to be related to the 
nature of the ablation. 
(30) The site of the biopsy and the clinical stage of the tumour 
did not appear to influence the distribution of dependence. 
(31) The advantages of the technique used are enumerated. In 
particular it avoids drastic changes of the tumour from its physiological 
conditions, and it also measures the effect of a given hormone on the 
tumour cell specifically. It offers the opportunity to study a particular 
hormone's action at target cell level without involving other variables 
such as feedback mechanisms and interactions with other circulating 
hormones. 
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(32) The only two serious technical problems were contamination 
of the culture and an inadequate biopsy. The method has built-in 
safeguards to detect and eliminate these. 
(33) A small number of tumours fared better in the medium control 
than in the initial control. This is almost certainly due to the 
stimulating effect of insulin in the medium. 
(34) The remarkably high incidence of prolactin dependence is 
discussed. There is much controversy about the factors controlling 
prolactin secretion and it appears as if many forms of other hormonal 
treatment may influence it by a feedback mechanism. It does seem, 
however, as if prolactin-dependence of human breast cancers operates 
as physiological and not excessive levels of circulating prolactin. 
(35) Investigations are in progress to find a specific prolactin-
suppressing pharmacological agent. Bromergocryptine and levodopa have 
attracted the most attention so far, although no striking results have 
hitherto been obtained from their use in women with breast cancer. 
(36) It is demonstrated that hypophysectomy may well operate, 
at least in some cases, by removing prolactin secretion, and that 
inadequate hypophysectomy may fail to bring about a regression because 
of continued prolactin secretion. 
(37) A number of other hormonal and anti-hormonal treatments may 
well work via a prolactin-suppressing effect, and several possible 
examples are cited, but it is clear that the situation in humans is a 
good deal more complex than in the rat, where the relationship between 
prolactin secretion and breast tumour growth is a relatively simple and 
direct one. 
(38) Examples are also given of correlation of the clinical progress 
with in vitro dependence of the tumours on oestradiol. 
(39) The concept of testosterone dependence is introduced. Although 
well-known in rats, this concept has never been explored in depth in humans. 
Clinical examples are given which support the in vitro findings. There is 
some evidence to suggest that at least some adrenalectomies may produce 
regressions by removing testosterone. 
(40) The test also appears to be of potential use in avoiding fruit-
less endocrine-ablative surgery. 
(41) Many of the dependent and independent cases were also amenable 
to successful hormonal therapy by administering a hormone that was inhibitory 
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to the tumour in vitro, as an alternative to countering one in which 
the tumour had survived well. 
(42) Evidence from this study, including from several patients 
whose tumours have been tested at different stages of their disease, 
strongly opposes any suggestion that a breast cancer can be assigned 
one unchanging hormone dependence which applies throughout its natural 
history. The tumour appears to be very labile and to be able to adapt 
itself dynamically to changes in the hormonal milieu, for example 
those occurring at the menopause or as a result of treatment. 
(43) The potential uses of this technique as a prediction system 
and for monitoring the course of the disease are discussed, but it is 
emphasised that there are many difficulties in translating in vitro 
results to an in vivo situation, and that only long-term, prospective, 
controlled trials will determine its validity. 
(44) In a group of 40 patients in whom it was possible to make a 
comparison between the results of the test and the response to hormonal 
therapy there was good correlation in 36 (90%). This highly-encouraging 
finding has resulted in the establishment of a formal trial of the 
technique at the Westminister Hospital. 
(45) In addition to its use in breast cancer, the technique has 
been tried for a variety of other tumours, notably malignant melanoma, 
and with a number of other hormones and drugs. It appears to be a good 
research tool for tumour studies of this nature. 
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CaC1 2 22 
MgS04.7H 20 25 
NaHl04. 2H 20 45 
NaHC0 3 282 
Glucose 400 
L-arginine HCl 2. l 
L-cysteine HCl 4.7 
L-histidine HCl 1.0 
L-isoleucine 2.6 
L-leucine 2.6 
L-lysine HCl 3.6 
DL-methionine 1. 5 
DL-phenylalanine 3.3 
DL-threonine 4.8 
L-tryptopha n 0.4 
L-tyrosi ne 1.8 
L-valine 2.3 
Thiamine HCl 1. 7 
P-aminobenzoic acid 3.5 
Insulin 5.0 
Chloramphenicol 3.0 
Phenol Red 1.0 
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Slee "Pearse" Cold Retracting Microtome Cryostat (Type HR), 
Slee Block Holders, Simple Tubular Pattern, No. 4035/S and Slee 
Laminar Flow Bench, HLF/H, with ultra-violet attachment, from 
South London Medical Equipment Ltd., London S.E.13. 
Instanton Electric Balance Unimatic CL4D, from Stanton In-
struments Ltd., London S.W.17. 
PHM28 pH Meter, Radiometer Copenhagen, from V. and A. Howe 
and Co. Ltd., London S.W.6. 
Griffin Incubator, operating at 37°C. 
"Little Sister" Autoclave, operating at 30 lb. per square 
inch at 135°c. 
G.V. Planer Cooling Unit Type R200, cooling at 2°c per 
minute. 
Chance Propper Pre-Cleaned Select Microscope Slides, 
76 x 25 mm., from Solmedia Ltd., London E. 17. 
Steel Slide Racks, Staining Troughs and Chance Coverslips 
22 x 32 mm., from A.R. Harwell Ltd., London N.W.6. 
Ampoule Racks from Arnold's Veterinary Products, Reading, 
Berkshire. 
Screw-Cap Specimen Ampoules for liquid nitrogen storage 
and Sterile Plastic Universal Containers (Pl28/A) from Sterilin 
Ltd., Richmond, Surrey. 
Plastic Sterile Disposable Culture Dishes, 60 x 15 mm., 
from Falcon Plastics, London W.C. 1. 
Stainless-Steel Sharp-Point Dissecting Forceps (MA2478, 
6 inches) and Stainless-Steel Spatulas (MC2332, Nuffield 
pattern), from C.E. Payne and Sons Ltd., London S.W.4. 
Stainless-Steel Grids cut from "expanded meta 1," (mesh 
1.3 mm., 0.0005 inches thick), from The Expanded Metal Co., 
London S.W.l. 
Green's Lens Tissue Cl05, from J. Barcham Green Ltd., 
Maids tone, Kent. 
Gillette Scimitar Sterile Disposable Needles No. 1 (21g) 
and Sterile Disposable Scalpels No. 22 from Gillette Industries 
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Ltd., Isleworth, Middlesex. 
B & D Plastipak Sterile Disposable Polypropylene Syringes, 
from Becton, Dickinson and Co. Ltd., Republic of Ireland. 
Liquid Nitrogen, from Nitrochill Ltd., Wembley, Middlesex. 
Liquid Nitrogen Refrigerator and Dewar Flasks of liquid 
nitrogen, from Union Carbide, Darlington, Durham. 
Decon 90 Detergent, from Decon Laboratories, Brighton, Sussex. 
Trowell 's TS Culture Medium, from Difeo Laboratories, East 
Molesey, Surrey. 
17-beta-oestradiol, testosterone and L-glutathione (reduced), 
from Koch-Light Laboratories, Colnbrook, Buckinghamshire. 
Sheep Prolactin, 22 I.U. per mg., in 10 mg. ampoules, from the 
Medical Research Council Division of Biological Standards, London N.W.7. 
Human Prolactin (90% pure), from Dr. H. Friesen, McGill 
University, Montreal, Canada. 
Ethyl Alcohol 99.8% v/v, from James Burroughs Ltd., London S.E.11. 
Neotetrazolium Chloride, from SERVA, Heidelberg, West Germany. 
Phenazine Methosulphate, from Sigma Chemical Company, St. Louis, 
U.S.A. 
Glucose-6-Phosphate (di-sodium salt) and NADP, from Boehringer, 
Mannheim, West Germany. 
Polyvinyl Alcohol, from Bush, Beach and Segner, London W. 1. 
Glycylglycine, Ascorbic Acid and Xylene from B.D.H. Chemicals 
Ltd., Poole, Dorset. 
Ehrlich's Haematoxylin, Eosin, Canada Balsam and Farrant's Medium, from 
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The photographs show total dehydrogenase activity of the pentose-shunt pathway deposited as coloured formazan aftei reduction of 
ncotetrazolium chloride when phenazine methosulphate is used as the first hydrogen acceptor (reduced to about half of x 375). 
(E.) Tissue taken at operation. 
(F.) After maintenance in TI medium alone for 24 hours; the few whorls of cancer cells show very little activity. 
(G.) Aftei maintenance in TI medium containing 10-•M 1713-a:stradiol for 24 hours; very high activity of the pentose-shunt pathway 
which ultimately produces reducing power for biosynthetic purposes essential for survival of cancei tissue. 
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technique applied to the angiograms accentuated the 
appearance of the vasospasm and of the vasodilatation as a 
result of treatment (Rickham, 1964). 
The experimental model permits long-term survival and 
repeated production of subarachnoid haemorrhage. The 
tolerance to drug modification of vascular tone suggests 
that this may have clinical application in the control of 
cerebral vasospasm, and in the prevention of ischaemic 
sequelae following subarachnoid haemorrhage. 
RICKHAM, P . P. (1964), Br. med. J., 2, 173. 
51. The Effect of Ovariectomy on Experi-
mental Mammary Carcinoma in the Rat with 
P ortacaval Shunt: J. F. O'GRADY, MARGOT 
GRUENSTEIN, and F . A. REICHLE (P. Fitzgerald ), 
Department of Surgery, University College, Dublin , 
and Temple University Hospital, Philadelphia, 
U nited States. 
End-to-side portacaval shunt (P.C.S.) significantly 
reduces the incidence of experimental mammary carcinoma 
in the rat (Reichle et al., 1969). The mechanism of this 
inhibition is unknown. The major circulatory, metabolic, 
and hormonal changes which occur after portasystemic 
by-pass may be related to this tumour inhibition (Reichle 
et al., 1972). 
Ten mg. of 7,12-dimethylbenz-(cx)-anthracene (DMBA) 
were given in a single intragastric instillation to 105 
Holtzman rats (150 g. ). After 2 weeks P.C.S. (77 rats) and 
sham operations (28 rats) were performed. When palpable 
mammary tumours had developed bilateral ovariectomy 
was performed. A total of 19 rats ( IO with shunts, 9 
having had sham operations) with breast tumours under-
went bilateral ovariectomy and survived long enough for 
adequate follow-up. Average increase in tumour size at 
death or I year after DMBA was 2"48 ± 0·57 cm. in 
sham-operated rats and 0·82 ± 0 ·39 cm. in rats with 
shunts (P < 0·05). The average time of death after 
ovariectomy was 85·7 ± II ·8 days in sham-operated rats 
and 92 ·7 ± 18·2 days in rats with shunts (not significant). 
Approximately equal weight-gain following the sham or 
shunt operation was observed in both groups. 
Following bilateral ovariectomy the suppression of 
DMBA-produced carcinoma growth is significantly 
greater in animals with a portasystemic by-pass. This may 
be due either to an altered hormonal response of the 
tumours in the shunted animals or to an effect of the P.C.S. 
on the hormonal changes associated with ovariectomy. 
REICHLE, F. A., GRUENSTEIN, M ., MERANZE, D. R ., 
ROSEMOND, G. P. , and SHIMKIN, M. B. (1969),J. surg. 
R es., 9, 559. 
- - - - REICHLE, R . M ., MERANZE, D. R. , 
ROSEMOND, G. P. , and SHIMKIN, M . B. (1972), Archs 
Surg., Chicago, 104, 206. 
52. In vivo Binding of Tritiated Oestradiol in 
Benign and Malignant Lesions of the Human 
Breast: N. O'HIGGINS, N . DESHPANDE, and J. I. 
BURN, Breast Unit, D epartment of Su rgery, R oyal 
Postgraduate Medical School, London, and the 
Imperial Cancer Research Fund. 
Previous workers have examined the uptake of tritium-
labelled hormones by mammary cancers (Braunsberg 
et al. , 1967). The capacity to bind tritiated oestradiol-17 
in vivo was determined in 8 benign and 13 malignant 
mammary cancers. Uptake was measured in whole-
tissue slices and nuclear preparations. 
A loading dose of 9 µc . of tritiated oestradiol was given 
intravenously. This was followed by a continuous slow 
infusion of 64fLc. of tritiated oestradiol, which was started 
at least 3 hours before operation and continued until the 
lesion had been removed. Serial venous blood samples 
were examined to confirm that a steady state of oestradiol 
had been achieved. Radioactivity levels in the excised 
specimens were measured in a well counter. 
The uptake in the benign lesions ranged between 808 
and 2530 disintegrations per minute (d.p.m.) per mg. of 
wet tissue (mean 1229 d .p.m.). Levels in the malignant 
cancers ranged between 1456 and 12,563 d.p.m. (mean 
2196 d.p.m.). There was a complete separation between 
postmenopausal patients with benign and malignant 
disease. 
BRAUNSBERG, H., IRVINE, W. T., and JAMES, V. H . T . 
(1967), Br.J. Cancer, 21 ,714. 
53. Macrophage Activity and Hormonal 
Responsiveness in Mammary Cancer: W. D . 
GEORGE, WENDY P ARTRIDGE, and J. I. BURN, Breast 
Unit, Department of Surgery, R oyal Postgraduate 
Medical School, London. 
Changes in reticulo-endothelial macrophage activity 
occur in patients with cancer and may rettect the host's 
resistance to the disease (Old et al., 1961). Hormone 
therapy in advanced breast cancer should theoretically 
stimulate macrophage activity. Hepatic macrophage 
activity was studied serially in 14 patients with advanced 
mammary cancers before and after endocrine therapy. 
Activity was measured by the rate of clearance of radio-
iodine labelled micro-aggregates of albumin given intra-
venously (Ilio and Wagner, 1963). 
Seven patients received oestrogen therapy. Four 
responded successfully to treatment and all showed an 
increase in macrophage activity as therapy continued. Of 
3 patients who failed to respond to oestrogens, 2 showed a 
decrease in macrophage activity whilst the third showed no 
change. 
Seven patients underwent major endocrine ablations. 
Two responded successfully and both showed increase in 
macrophage activity. Of the 5 non-responders, macrophage 
activity decreased in 4 and remained unchanged in the 
other patient. 
These results suggest that in patients with advanced 
mammary cancer successful endocrine therapy is related 
to the stimulation of reticulo-endothelial macrophage 
activity. 
!LIO, M., and WAGNER, H. N. (1963), J. clin. Invest. , 42, 
417. 
OLD, L. J ., BENACERRAF, B., CLARKE, D. A., CARSWELL, 
E. A., and STOCKERT, E. (1961), Cancer R es., 21 , 128 I. 
54. A New Method of determining the 
Hormone Dependence of Human B reast Cancer: 
H. FLAX (H. Ellis), Tumour Biology Group, 
Westminster Hospital, Lon don. 
A new technique has been developed to determine the 
hormone dependence of individual breast cancers (Salih et 
al., 1972) involving the 24-hour maintenance at 37° C. of 
tumour slices in Trowell's T8 medium with two near-
physiological concentrations each of 17-,8-oestradiol, 
testosterone, and prolactin. The technique has been 
successful for soft-tissue metastases as well as for the pri-
mary tumour. Results are determined by a histochemical 
reaction demonstrating the total dehydrogenase activity of 
the pentose shunt (Chayen et al., 1970) as well as by 
conventional haematoxylin and eosin staining (which 
showed 96 per cent correlation on independent histo-
pathological assessment). The tumour is classed as 
dependent if it appears more active with a particular 
hormone or hormones than both the initial untreated 
biopsy and the medium control. 
In the 100 patients studied so far, dependences have 
been as follows: prolactin only, 14 per cent; prolactin and 
oestradiol, 10 per cent; testosterone only, 12 per cent; 
prolactin and testosterone, 8 per cent; oestradiol only, 
8 per cent. Where appropriate, endocrine-ablative surgery 
318 BRIT. J. SURG., 1973, Vol. 60, No. 4, APRIL 
was advised for the dependent cases. In the 48 per cent of 
cases that were independent the results, by indicating 
whether any particular hormone was strikingly inhibitory 
to the tumour, were helpful for selecting hormones for 
administration. Correlation with the clinical progress 
of these patients (only at 9 months so far) has been 
encouraging. 
CHAYEN, J. , ALTMANN, F. P., BITENSKY, L., and DALY, 
J. R. (1970), Lancet, I , 868. 
SALrH, H., FLAX, H ., and HOBBS, J. R. (1972), Ibid., I , 
II98, 
55. The Effect of Vagotomy on the Exocrine 
Pancreatic Secretory Response to Pentagastrin 
and to a 400-g. Meat Meal in Dogs: M. DAVIS, 
SAROJ GUPTA, and J. B. ELDER, University Depart-
ment of Surgery, Royal Infirmary, Manchester. 
It has been stated that the pancreas becomes more 
sensitive to humeral stimulation after truncal vagotomy 
but the evidence is controversial (Konturek et al., 1971; 
Moreland and Johnson, 1971). The effect of truncal 
vagotomy on the exocrine secretory response to a 400-g. 
meat meal and to intravenous pentagastrin infusion at a 
dose maximal for acid secretion before and after vagotomy 
in 2 dogs with chronic pancreatic and gastric fistula (G.F.) 
has been studied. 
With the G.F. closed the mean bicarbonate output after 
pentagastrin (8 µg. per kg. per hour) increased from 
22·98±1·1mEq. to 33·1±4·6mEq. (P<o·o5) after 
vagotomy; protein output to pentagastrin increased 
from 1898 ± 422 mg. to 3520 ± 342 mg. (P < 0·01) after 
vagotomy. Bicarbonate output to the meat meal decreased 
significantly (P < 0·001) after vagotomy but protein output 
was not significantly altered (P < 0'4). 
These results may be explained on the basis of an 
increased sensitivity of the pancreas to hormonal stimula-
tion after vagotomy. 
KoNTUREK, s. J., POPIELA, T., and THOR, P. (1971), 
J. dig. Dis., 16, 1087. 
MORELAND, H. J., and JOHNSON, L. R. (1971), Gastro-
enterology, 60, 425. 
56. Does the Vagal Nerve-supply to the 
Pancreas matter in Man? R. B. SMITH, J. P. 
EDWARDS, and D . JOHNSTON, University Department 
of Surgery, The General Infirmary, Leeds. 
Reports on the function of the pancreas after severance 
of its parasympathetic nerve-supply in man (as in truncal 
vagotomy (T.V.)) are conflicting. These nerves are 
preserved in highly selective vagotomy (H.S.V.). The 
pancreatic response to insulin (0 ·2 U. per kg.) has been 
studied in 9 preoperative patients with duodenal ulcer 
(D.U.), and in patients more than 1 year after T.V. (6 
patients) or H.S.V. (12 patients). The three groups of 
patients were matched for age and weight. Gastric _acid 
was aspirated continuously and the duodenal pH remamed 
greater than 7. 
Outputs of amylase were found to increase significantly 
after insulin in D.U. and H.S.V. patients (from a mean of 
9·1 to 20·5 kilo units in D.U. patients and fro:111 ~-o to 
16·5 kilo units in H.S .V. patients), whereas no s1gruficant 
increase was found in patients after T.V. (3·8 to 4·5 kilo 
units). Similarly, outputs of trypsin increased si~nifi~ntly 
in D.U. patients (from 16·0 to 31·1 I.U.) and m patients 
after H.S.V. (from 14·1 to 27·6 I.U.), whereas no such 
increase was observed after truncal vagotomy. 
These results are in agreement with previous reports of 
impaired (Pfeffer et al., 1952) or absent (Dreiling et al., 
1952) pancreatic response to insulin after T.V. in ma~. 
After H.S.V. significant increases in enzyme output still 
occurred in response to vagal stimulation. 
DREILING, D. A., DRUCKERMAN, L. J., and HOLLANDER, F. 
(1952), Gastroenterology, 20, 578. 
PFEFFER, R. B., STEPHENSON, H. E., and HINTON, J. w. 
(1952), Ann. Surg., 136, 585. 
57. Disappearance of Acid from the 
Duodenum: N. J. DORRICOTT and W . SILEN (G. 
Slaney), Department of Surgery, Queen Elizabeth 
Hospital, Birmingham, and Harvard Medical School, 
Beth Israel Hospital, Boston , United States. 
Experiments were carried out to investigate the poorly 
understood mechanism by which the duodenal mucosa 
contributes to the disappearance of hydrogen ions in the 
duodenum in the absence of pancreatic juice and bile. 
In 7 standing awake dogs distal duodenal pouches were 
perfused by a constant-circulation technique with isotonic 
solutions ranging from 60 to 120 mM HCl (Dorricott and 
Silen, 1972). Fluxes of H +, Na+, K +, and Cl- were 
related to the initial concentration ofH+ and Na+ and load 
of H + exposed to the duodenal mucosa per unit of time. 
In all the experiments there was a loss of H + from the 
perfusate and a gain of Na+, K +, and Cl- . A higher initial 
concentration of H + was associated with a greater rate of 
disappearance of H +, e.g., 667 ± 70 µEq. per 30 minutes 
from 120 mM HCl and 312 ± 30 µEq. per 30 minutes 
from 60 mM HCl (P < 0·001). Alteration of load of H + 
and initial concentration of Na+ did not produce significant 
change in the rate of disappearance of H +. An excess of 
cations over measurable anions, closely related to H + loss, 
entered the pouch, which can best be explained by a 
process of bicarbonate neutralization. 
These experiments show a relationship between disposal 
of H + by the duodenal mucosa and intraluminal H + concen-
tration, and not load of H + as found by Meyer et al. (1970). 
DoRRICOTT, N. J., and SILEN, W. (1972), Surg. Forum, 
23, 391. 
MEYER, J. H., WONG, L. w., and GROSSMAN, M. I. (1970), 
Am.J. Physiol., 219,971. 
58. Human Duodenal Electrical Activity: 
w. WATERFALL, B. BROWN, and H. L. DUTHIE, 
University Department of Surgery, Royal Infirmary, 
Sheffield. 
Stainless-steel electrodes (0·25 mm. in diameter) were 
mounted on a gastric tube and attached to the mucosa of 
the second part of the duodenum by suction in 16 subjects. 
Unipolar records of the electrical activity of the duodenum 
were obtained with the subjects in the resting state and also 
during intravenous infusion of pentagastrin (1·0 and 
6·o µg. per kg. per hour in 8 tests) and of secretin (0·25 and 
2·0 U. per kg. per hour in 6 tests). 
In the fasting subject a regular waveform of u-12 cycles 
per minute was present all the time (pacesetter potential; 
basal electrical activity) with an amplitude of 0·2-1·6 mV. 
When motor waves were present (16 per cent of the time) 
they were accompanied by bursts of action potentials 
superimposed on the pacesetter potentials which then had 
their maximal amplitude. The frequency of the pacesetter 
potential was not affected by the infusion of pentagastrin 
or secretin. Action potentials and motor activity were 
increased significantly with pentagastrin and decreased 
with secretin. The contrasting actions of these hormones 
on the motor action of the duodenum have been confirmed 
and their effects on the electrical activity displayed. 
59. Ex vivo Perfusion of Canine Jejunal Loop: 
Electrical and Mechanical Activities: C. MENDEL, 
D. JAEcK, J. C. ScHANG, J. KAcHELHOFFER, M. R. 
ELOY, and J. F . GRENIER (H. L. Duthie), Service 
d ' Investigations Chirurgicales et Unite de Recherches 
de Biophysiopathologie Digestive de l'I.N.S.E.R.M. 
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Letters to the Editor 
HORMONE THERAPY IN 
MAUGNANT MELANOMA 
SIR,-The evidence that some cases of malignant 
melanoma may be hormonally influenced has been re-
viewed by Bodenham, 1 who cites excellent regression in a 
small number of patients on hormonal therapy. 2 were 
treated by hypophysectomy, 1 by androgen administration, 
and 1 by a:strogen administration. He emphasised the need 
for a more widely applicable system to select these patients, 
in that the assessment in his cases depended on the use 
of an intralesional Geiger probe 2 which remained in situ 
for several days and involved a number of practical prob-
lems. -
We have described 3 the use of a short-term main-
tenance culture system to study hormonal influences in 
human breast cancers and have found that the histochemical 
assessment of survival by measurement of the total de-
hydrogenase activity of the pentose-shunt pathway is a 
sensitive marker of tumour-cell activity. In a short project 
to test the same technique for malignant melanoma, 
biopsies from 11 patients with recurrent disease were 
treated in the way we have described for breast-cancer 
biopsies. After removal of the specimen, an uncultured 
fresh-frozen initial control slice was stored in liquid nitrogen, 
while a medium control (Trowell's TS Medium) and cul-
tures in 3 concentrations each (10-5, 10-6, and 10-1M) of 
testosterone and 17~-a:stradiol were incubated for 24 hours 
in an oxygen and 5% carbon-dioxide mixture. The results 
are shown in the following table (comparisons between 
a:stradiol and testosterone are in each case between identi-
cal concentrations-namely, those which demonstrated the 
difference in survival optimally) : 
Initial M edium Testo-
Ca,, Sex control control CF.stradiol sterone 
I F + + ++ +-'- + + + + Relatively more 
2 F ++++ ++ + ++ active in tcsto-
3 M ++++ + + +++ sterone than in 
a,stradiol 
4 F + + +++ +++ +++ No significant 
s F ++ + + ++ ++ difference in activity 
6 F + ++ + -L +++ +++ between the two 
7 F +++ -L + + ++ hormones 
8 F .J.. ..L .J.. 4- +T+ ++++ -L Relatively more 
9 F + + + +++ ++ active in a,stradiol 
10 M +++ + +++ +++ T than in testo-
11 F + + + + ++ + stcronc 
In only 1 (case 9) of the 11 cases was the enzyme activity 
in one of the hormones actually higher than that of both 
controls. 
Four of these tumours were also cultured in 3 con-
centrations of corticotrophin (0·75, 0·075, and 0·0075 
ml.ti. per ml.), and they all survived well in these, although 
in no case better than both controls. 
The technique is simple, and melanoma is easier to work 
with than breast cancers, in that it is more cellular and 
homogeneous. It may well be that modification of the 
concentrations or the time scale of the experiment may 
accentuate the differences in survival. The method also 
offers an opportunity of studying other hormones in rela-
tion to melanoma-for example, corticotrophin and ~-
M.S.H. Although we would agree that only a small pro-
portion of patients may benefit from hormonal therapy in 
I. Bodenham, D . C. in Endocrine Therapy in Malignant Disease 
(edited by B. A. Stoll) ; p . 377. London, 1972. 
2. Hale, B. T . Lancet, 1961, ii, 345. 
3. Salih, H ., Flax, H ., Hobbs, J . R. ibid. 1972, i, 1198. 
147 
this disease, this in-vitro approach may merit further ex-
ploration. 






HORMONE THERAPY FOR 
MAUGNANT MYELOMA 
SIR,-Because they reduce the negative calcium balance 1 
and stimulate erythropoiesis, 2 androgens are useful in the 
management of the hypercalca:mia and ana:mia of multiple 
myeloma. We have used androgens to treat patients with 
multiple myeloma. 
34 patients with multiple myeloma were initially and 
adequately treated with alkylating agents (cyclophospha-
mide or melphalan) and prednisone. 18 of the 34 patients 
TABLE I-EFFECTS OF ANDROGENS IN MULTIPLE MYELOMA DURING 
CHEMOTHERAPY 
Increase Decrease Correction Correction 
- ofHb of M• of hyper- of Tumour ;,, 2 g./ protein calcaemia azota:mia response 
100 ml. ;,, 50% 
Androgens 9/16 (56 ) 10/12 6/6 4/8 8/16 (50) 
Non-
I 
androgens 4/18 (22) 5/12 3/5 2/6 2/18 (11) 
P value < 0·05 <0·05 < 0·05 N.S. <0·01 
N.s. = Not significant. 
Percentages are shown in parentheses. 
TABLE II-DURATION AND DOSAGE OF CYCLOPHOSPHAMIDE IN 
PATIENTS WITH OR WITHOUT ANDROGEN 
I I Cyclophosphamide t I Initial 
Group I No. of W.B.C. t 
patients • ( x !O') Total dose Duration mg. /day (g.) (days) --! 
Androgen I 
N on- I 
androgen 
12 6 (6·8) 10·7 (31 ·7) 450 (453) 
11 7 (6·5) 6·0 (10·4) 44 (159) 
I 
• Remaining patients received melphalan. 
t Median (mean). 
w .s .c . = White-blood-cell count. 
75 (70) 
60 (65) 
did not receive androgenic hormones, and 16 had adjuvant 
androgen therapy for at least one month in the form of 
either fluoxymesterone (10 mg. twice a day orally) or testo-
·sterone a:nanthate ( 400 mg. intramuscularly twice a week 
for two to four weeks, then once fortnightly or monthly). 
The pretreatment mean ha:moglobin level (10 g. per 
100 ml.) was identical in both groups. There was an 
increase in ha:moglobin of 2 g. per 100 ml. or more in 56% 
of the patients in the androgen group and in 22 % of the 
non-androgen group (P < 0·05) (table 1). More patients in 
the androgen group had their M-protein reduced and/or 
hypercalca:mia corrected during therapy than in the non-
androgen group (both P < 0·05). The tumour-response rate, 
as judged by subjective and objective measurements other 
than ha:moglobin,8 was 50% in the androgen group and 
11 % in the non-androgen group (P < 0·01). In the non-
androgen group, of the 3 patients who did not respond, 2 
achieved a good tumour response when androgen was sub-
sequently added. 
The total dose and the duration of cyclophosphamide 
therapy were greater in the androgen-treated group (table 
11). The higher dose and the longer duration of chemo-
therapy probably contributed to the better response-rate 
I. Lafferty, F. W ., Spencer, G . E., Jr., Pearson, 0 . H . Am. J. Med. 
1964, 36, 514. 
2. Kennedy, B. J ., Gilbertsen, A. S. New Eng/.J. Med. 1957, 256,719. 
3. Committee of Chronic Leukemia/M yeloma Task Force. Cancn 
Chemother. Rep. 1968, 1, 13.· 
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in the androgen group. Adjuvant androgen therapy seems 
to enhance the patient's tolerance of chemotherapy and 
thus improves the therapeutic potential of cytotoxic agents. 
The report ' that androgens stimulate the proliferation of 
granulocyte precursor in mouse bone-marrow accords with 
our clinical observations. 
Department of Medicine, 
Univenity of Minnesota 
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B.C.G. PLUS PROTEASE I IN MALIGNANT 
MELANOMA 
SIR,-The findings of Professor Thornes and his 
colleagues (June 16, p. 1386) corroborate work I have been 
doing with transfer factor combined with B.C.G. vaccine. 
In my technique, transfer factor replaces brinase with its 
toxic effects. 
In 2 severely immunosuppressed patients with seronegative 
late-stage systemic lupus, B.C.G. vaccine was given in an attempt 
to improve cellular immunity. In both cases all 4 screening skin 
tests were negative. A series of six to eight B.C.G. injections was 
poorly tolerated and produced virtual abscess formation. The 
purified-protein-derivative skin tests remained negative. These 
patients then received transfer factor from an ABO compatible 
donor. Neither of the donors had a positive tuberculin skin test, 
although both had skin tests positive to either one or all of Candida 
albicans, trichophyton, and mumps. Four days after receiving 
transfer factor the recipients were retested. Both had strongly 
positive tuberculin reactions with vesiculation. One was strongly 
positive seven weeks after transfer factor. The other remained 
so up to five weeks after transfer factor. Follow-up was lost. 
The third patient with stage-m malignant melanoma was 
totally anergic. This patient had received a series of B.C.G. 
vaccine, both intradermally and by the grid-scratch method of 
Mathe. Intratumour injections were given weekly. The patient 
evidenced no inflammatory reaction at any B.C.G. site. This was 
carried out over a period of three months. Repeated skin tests 
showed total anergy to the four antigens. The patient then 
received transfer factor from his mother, who carried a negative 
tuberculin skin test, a 3 cm. flare, and induration to mumps, 
although negative to monilia and trichophyton. 
Four days later this patient developed positive P.P.D. skin tests 
with 12 mm. induration. Seven weeks later it was still positive. 
The mumps skin test also became positive. B.c.G. vaccinations 
now produced, for the first time in three months, active inflam-
matory reactions. The palm-sized group of chronic B.C.G. 
abscesses in the s.L.E. patient was 75 % healed in two weeks. 
From my observations, B.C.G. vaccinations at weekly 
intervals for at least one month, followed by transfer 
factor, will result in positive P.P.D. cellular immune response. 
The toxicity of brinase is avoided. 
Rockwood Clinic, 
312 West 8th Avenue, 
Spokane, Washington 99204, 
U .S.A. S. K. MclLVANIE, 
POPULATION AND THE N.H.S. BILL 
SIR,-How interesting to see in your issue of July 7 an 
editorial (p. 29) on population problems and an account 
(p. 37) of the fate of the Lords' amendment to the N.H.S. 
Reorganisation Bill. 
The restraints on population growth in the world are 
the ultimately limited amounts of food and natural resources 
which can be made available. Since Britain already con-
sumes much more of these than Bangladesh, and Britain's 
population continues to grow, it ill becomes us to urge 
population control there, whilst taking no action at home. 
UNROD recommends a Ministry of Population Affairs: 
4. Canelloa, G. P., Hess, S. M. C/in. Res. 1973, 21, 643. 
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a similar recommendation has been made for a Miniater in 
Britain, but no action is forthcoming from the Govern-
ment. One can only feel dismay that the Commons have 
finally succeeded in overcoming their more enlightened 
colleagues in the Lords and rejected a free family-planning 
service. 
Royal Infirmary, 
Edinburgh EH3 9YW. D. M. PARICIN. 
FLUOROCARBON PROPELLANTS IN 
AEROSOLS 
S1R,-Dr Silverglade (June 9, p. 1325) mentions some 
18 articles on the subject of the cardiotoxicity of fluoro-
carbon compounds used as aerosol propellants. He con-
cluded that the weight of evidence attests to both the safety 
and efficacy of the pressurised bronchodilator aerosols 
when properly used. 
Some of the articles, however, emphasise that the 
aerosol propellant compounds such as dibromotetra-
fluoroethane or trichlorofluoromethane are closely related 
in structure to halogenated hydrocarbons used in anzs-
thesia, such as halothane or chloroform. A degree of 
concern 1 has been expressed about the inhalation of trace 
levels of halogenated ana:sthetics by theatre workers, as 
this chronic exposure might be implicated in explaining 
the various abnormalities revealed in statistical surveys. 
If the halothane which is absorbed by theatre worken to 
blood-levels 1 , 3 of around 100 µg. per 100 ml. can be 
suspected of producing spontaneous abortions ' or liver 
damage, surely aerosol propellants with a very similar 
chemical structure and absorbed to equal or higher blood-
levels 6 , 6 must also be suspect? 
Department of Clinical Physics 
and Bio-engineering, 
Western Regional Hospital 
Board, 
11 West Graham Street, 
Glasgow G4 9LF. IAN B. MONK. 
DISPOSABLE SYRINGES FOR DIABETICS 
SIR,-Regarding this correspondence (May 19, p. 1130; 
July 7, p. 41; and June 16, p. 1381) I should like to point 
out that, although disposable syringes are not generally 
available to diabetics on the National Health Service, in 
exceptional cases, where the general practitioner considers 
that disposable syringes and needles are needed on medical 
grounds, they can be obtained through hospitals, with the 
agreement of the consultant concerned. This applies 
chiefly to diabetic children, who often find the disposable 
syringes easier to manipulate. 
The British Diabetic Association has made several pleas 
to the Department of Health and Social Security for the 
provision of disposable syringes for diabetics generally on 
the National Health Service, but the decision of the 
Department remains that the expenditure involved cannot 
be justified. 
In answer to Professor Dundee (June 16, p. 1381), I 
should like to point out that a plastic spirit-proof container 
for the glass insulin syringe is now available on the National 
Health Service, which obviates the need for frequent 
l. Lancet, 1972, ii, 519. 
2. Hallcn, B., Ehmer-Samuel, H., Thomason, M . Acta ana1th. 
scand. 1970, 14, 17. 
3. Nikki, P., Pfiiffli, P., Ahlman, K. Lancet, 1972, ii, 490. 
4. Gotell, P., Sundell, L. ibid. p. 424. 
5. Dollery, C. T., Draffan, G. H., Davies, D. S., Williams, F . M., 
Conally, M. E . ibid. 1970, ii, 1164. 
6. Paterson, J. W., Sudlow, M. F., Walker, S. R. ibid. 1971, ii, 565. 
